id	sid	tid	token	lemma	pos
dpc-5196	1	1	dermatology	dermatology	NOUN
dpc-5196	1	2	:	:	PUNCT
dpc-5196	1	3	practical	practical	ADJ
dpc-5196	1	4	and	and	CCONJ
dpc-5196	1	5	conceptual	conceptual	ADJ
dpc-5196	1	6	original	original	ADJ
dpc-5196	1	7	article	article	NOUN
dpc-5196	1	8	|	|	ADV
dpc-5196	1	9	dermatol	dermatol	ADJ
dpc-5196	1	10	pract	pract	NOUN
dpc-5196	1	11	concept	concept	NOUN
dpc-5196	1	12	.	.	PUNCT
dpc-5196	2	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	2	2	1	1	NUM
dpc-5196	2	3	factors	factor	NOUN
dpc-5196	2	4	influencing	influence	VERB
dpc-5196	2	5	relapse	relapse	NOUN
dpc-5196	2	6	after	after	ADP
dpc-5196	2	7	omalizumab	omalizumab	NOUN
dpc-5196	2	8	in	in	ADP
dpc-5196	2	9	chronic	chronic	ADJ
dpc-5196	2	10	urticaria	urticaria	NOUN
dpc-5196	2	11	.	.	PUNCT
dpc-5196	3	1	does	do	VERB
dpc-5196	3	2	the	the	DET
dpc-5196	3	3	method	method	NOUN
dpc-5196	3	4	of	of	ADP
dpc-5196	3	5	discontinuation	discontinuation	NOUN
dpc-5196	3	6	influence	influence	NOUN
dpc-5196	3	7	relapse	relapse	NOUN
dpc-5196	3	8	?	?	PUNCT
dpc-5196	4	1	petek	petek	NOUN
dpc-5196	4	2	üstün1	üstün1	NOUN
dpc-5196	4	3	,	,	PUNCT
dpc-5196	4	4	esra	esra	PROPN
dpc-5196	4	5	adışen2	adışen2	PROPN
dpc-5196	5	1	1	1	NUM
dpc-5196	5	2	deparment	deparment	NOUN
dpc-5196	5	3	of	of	ADP
dpc-5196	5	4	dermatology	dermatology	NOUN
dpc-5196	5	5	,	,	PUNCT
dpc-5196	5	6	aksaray	aksaray	VERB
dpc-5196	5	7	training	training	NOUN
dpc-5196	5	8	and	and	CCONJ
dpc-5196	5	9	research	research	NOUN
dpc-5196	5	10	hospital	hospital	NOUN
dpc-5196	5	11	,	,	PUNCT
dpc-5196	5	12	aksaray	aksaray	VERB
dpc-5196	5	13	,	,	PUNCT
dpc-5196	5	14	turkey	turkey	PROPN
dpc-5196	5	15	2	2	NUM
dpc-5196	5	16	deparment	deparment	NOUN
dpc-5196	5	17	of	of	ADP
dpc-5196	5	18	dermatology	dermatology	NOUN
dpc-5196	5	19	,	,	PUNCT
dpc-5196	5	20	gazi	gazi	PROPN
dpc-5196	5	21	university	university	PROPN
dpc-5196	5	22	faculty	faculty	NOUN
dpc-5196	5	23	of	of	ADP
dpc-5196	5	24	medicine	medicine	NOUN
dpc-5196	5	25	,	,	PUNCT
dpc-5196	5	26	ankara	ankara	PROPN
dpc-5196	5	27	,	,	PUNCT
dpc-5196	5	28	turkey	turkey	PROPN
dpc-5196	5	29	key	key	ADJ
dpc-5196	5	30	words	word	NOUN
dpc-5196	5	31	:	:	PUNCT
dpc-5196	5	32	urticaria	urticaria	NOUN
dpc-5196	5	33	,	,	PUNCT
dpc-5196	5	34	omalizumab	omalizumab	NOUN
dpc-5196	5	35	,	,	PUNCT
dpc-5196	5	36	relapse	relapse	NOUN
dpc-5196	5	37	citation	citation	NOUN
dpc-5196	5	38	:	:	PUNCT
dpc-5196	5	39	üstün	üstün	PROPN
dpc-5196	5	40	p	p	X
dpc-5196	5	41	,	,	PUNCT
dpc-5196	5	42	adışen	adışen	PROPN
dpc-5196	5	43	e.	e.	PROPN
dpc-5196	5	44	factors	factor	NOUN
dpc-5196	5	45	influencing	influence	VERB
dpc-5196	5	46	relapse	relapse	NOUN
dpc-5196	5	47	after	after	ADP
dpc-5196	5	48	omalizumab	omalizumab	NOUN
dpc-5196	5	49	in	in	ADP
dpc-5196	5	50	chronic	chronic	ADJ
dpc-5196	5	51	urticaria	urticaria	NOUN
dpc-5196	5	52	.	.	PUNCT
dpc-5196	6	1	does	do	VERB
dpc-5196	6	2	the	the	DET
dpc-5196	6	3	method	method	NOUN
dpc-5196	6	4	of	of	ADP
dpc-5196	6	5	discontinuation	discontinuation	NOUN
dpc-5196	6	6	influence	influence	NOUN
dpc-5196	6	7	relapse	relapse	NOUN
dpc-5196	6	8	?	?	PUNCT
dpc-5196	7	1	dermatol	dermatol	NOUN
dpc-5196	7	2	pract	pract	PROPN
dpc-5196	7	3	concept	concept	NOUN
dpc-5196	7	4	.	.	PUNCT
dpc-5196	8	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	8	2	.	.	PUNCT
dpc-5196	9	1	doi	doi	NOUN
dpc-5196	9	2	:	:	PUNCT
dpc-5196	9	3	https://doi.org/10.5826/dpc.1503a5196	https://doi.org/10.5826/dpc.1503a5196	PROPN
dpc-5196	9	4	accepted	accept	VERB
dpc-5196	9	5	:	:	PUNCT
dpc-5196	9	6	february	february	NOUN
dpc-5196	9	7	4	4	NUM
dpc-5196	9	8	,	,	PUNCT
dpc-5196	9	9	2025	2025	NUM
dpc-5196	9	10	;	;	PUNCT
dpc-5196	9	11	published	publish	VERB
dpc-5196	9	12	:	:	PUNCT
dpc-5196	9	13	july	july	PROPN
dpc-5196	9	14	2025	2025	NUM
dpc-5196	9	15	copyright	copyright	NOUN
dpc-5196	9	16	:	:	PUNCT
dpc-5196	10	1	©	©	PROPN
dpc-5196	10	2	2025	2025	NUM
dpc-5196	10	3	üstün	üstün	NOUN
dpc-5196	10	4	et	et	PROPN
dpc-5196	10	5	al	al	PROPN
dpc-5196	10	6	.	.	PUNCT
dpc-5196	11	1	this	this	PRON
dpc-5196	11	2	is	be	AUX
dpc-5196	11	3	an	an	DET
dpc-5196	11	4	open	open	ADJ
dpc-5196	11	5	-	-	PUNCT
dpc-5196	11	6	access	access	NOUN
dpc-5196	11	7	article	article	NOUN
dpc-5196	11	8	distributed	distribute	VERB
dpc-5196	11	9	under	under	ADP
dpc-5196	11	10	the	the	DET
dpc-5196	11	11	terms	term	NOUN
dpc-5196	11	12	of	of	ADP
dpc-5196	11	13	the	the	DET
dpc-5196	11	14	creative	creative	ADJ
dpc-5196	11	15	commons	common	NOUN
dpc-5196	11	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5196	11	17	license	license	NOUN
dpc-5196	11	18	(	(	PUNCT
dpc-5196	11	19	by	by	ADP
dpc-5196	11	20	-	-	PUNCT
dpc-5196	11	21	nc-4.0	nc-4.0	NOUN
dpc-5196	11	22	)	)	PUNCT
dpc-5196	11	23	,	,	PUNCT
dpc-5196	11	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5196	11	25	,	,	PUNCT
dpc-5196	11	26	which	which	PRON
dpc-5196	11	27	permits	permit	VERB
dpc-5196	11	28	unrestricted	unrestricted	ADJ
dpc-5196	11	29	noncommercial	noncommercial	ADJ
dpc-5196	11	30	use	use	NOUN
dpc-5196	11	31	,	,	PUNCT
dpc-5196	11	32	distribution	distribution	NOUN
dpc-5196	11	33	,	,	PUNCT
dpc-5196	11	34	and	and	CCONJ
dpc-5196	11	35	reproduction	reproduction	NOUN
dpc-5196	11	36	in	in	ADP
dpc-5196	11	37	any	any	DET
dpc-5196	11	38	medium	medium	NOUN
dpc-5196	11	39	,	,	PUNCT
dpc-5196	11	40	provided	provide	VERB
dpc-5196	11	41	the	the	DET
dpc-5196	11	42	original	original	ADJ
dpc-5196	11	43	authors	author	NOUN
dpc-5196	11	44	and	and	CCONJ
dpc-5196	11	45	source	source	NOUN
dpc-5196	11	46	are	be	AUX
dpc-5196	11	47	credited	credit	VERB
dpc-5196	11	48	.	.	PUNCT
dpc-5196	12	1	funding	funding	NOUN
dpc-5196	12	2	:	:	PUNCT
dpc-5196	12	3	none	none	NOUN
dpc-5196	12	4	.	.	PUNCT
dpc-5196	13	1	competing	compete	VERB
dpc-5196	13	2	interests	interest	NOUN
dpc-5196	13	3	:	:	PUNCT
dpc-5196	13	4	none	none	NOUN
dpc-5196	13	5	.	.	PUNCT
dpc-5196	14	1	authorship	authorship	NOUN
dpc-5196	14	2	:	:	PUNCT
dpc-5196	14	3	all	all	DET
dpc-5196	14	4	authors	author	NOUN
dpc-5196	14	5	have	have	AUX
dpc-5196	14	6	contributed	contribute	VERB
dpc-5196	14	7	significantly	significantly	ADV
dpc-5196	14	8	to	to	ADP
dpc-5196	14	9	this	this	DET
dpc-5196	14	10	publication	publication	NOUN
dpc-5196	14	11	.	.	PUNCT
dpc-5196	15	1	corresponding	correspond	VERB
dpc-5196	15	2	author	author	NOUN
dpc-5196	15	3	:	:	PUNCT
dpc-5196	15	4	petek	petek	NOUN
dpc-5196	15	5	üstün	üstün	PROPN
dpc-5196	15	6	,	,	PUNCT
dpc-5196	15	7	md	md	PROPN
dpc-5196	15	8	,	,	PUNCT
dpc-5196	15	9	department	department	PROPN
dpc-5196	15	10	of	of	ADP
dpc-5196	15	11	dermatology	dermatology	NOUN
dpc-5196	15	12	,	,	PUNCT
dpc-5196	15	13	aksaray	aksaray	VERB
dpc-5196	15	14	training	training	NOUN
dpc-5196	15	15	and	and	CCONJ
dpc-5196	15	16	research	research	NOUN
dpc-5196	15	17	hospital	hospital	NOUN
dpc-5196	15	18	,	,	PUNCT
dpc-5196	15	19	tacin	tacin	PROPN
dpc-5196	15	20	street	street	NOUN
dpc-5196	15	21	,	,	PUNCT
dpc-5196	15	22	68200	68200	NUM
dpc-5196	15	23	aksaray	aksaray	VERB
dpc-5196	15	24	,	,	PUNCT
dpc-5196	15	25	türkiye	türkiye	PROPN
dpc-5196	15	26	.	.	PUNCT
dpc-5196	16	1	orcid	orcid	PROPN
dpc-5196	17	1	i	i	PRON
dpc-5196	17	2	d	d	NOUN
dpc-5196	17	3	:	:	PUNCT
dpc-5196	17	4	0000	0000	NUM
dpc-5196	17	5	-	-	PUNCT
dpc-5196	17	6	0001	0001	NUM
dpc-5196	17	7	-	-	PUNCT
dpc-5196	17	8	9051	9051	NUM
dpc-5196	17	9	-	-	PUNCT
dpc-5196	17	10	8580	8580	NUM
dpc-5196	17	11	.	.	PUNCT
dpc-5196	18	1	e	e	X
dpc-5196	18	2	-	-	NOUN
dpc-5196	18	3	mail	mail	NOUN
dpc-5196	18	4	:	:	PUNCT
dpc-5196	18	5	pustun8@gmail.com	pustun8@gmail.com	X
dpc-5196	18	6	introduction	introduction	NOUN
dpc-5196	18	7	:	:	PUNCT
dpc-5196	18	8	omalizumab	omalizumab	NOUN
dpc-5196	18	9	is	be	AUX
dpc-5196	18	10	recommended	recommend	VERB
dpc-5196	18	11	for	for	ADP
dpc-5196	18	12	chronic	chronic	ADJ
dpc-5196	18	13	urticaria	urticaria	NOUN
dpc-5196	18	14	(	(	PUNCT
dpc-5196	18	15	cu	cu	PROPN
dpc-5196	18	16	)	)	PUNCT
dpc-5196	18	17	until	until	SCONJ
dpc-5196	18	18	spontaneous	spontaneous	ADJ
dpc-5196	18	19	remission	remission	NOUN
dpc-5196	18	20	occurs	occur	VERB
dpc-5196	18	21	rather	rather	ADV
dpc-5196	18	22	than	than	ADP
dpc-5196	18	23	for	for	ADP
dpc-5196	18	24	a	a	DET
dpc-5196	18	25	specific	specific	ADJ
dpc-5196	18	26	period	period	NOUN
dpc-5196	18	27	of	of	ADP
dpc-5196	18	28	time	time	NOUN
dpc-5196	18	29	.	.	PUNCT
dpc-5196	19	1	the	the	DET
dpc-5196	19	2	rate	rate	NOUN
dpc-5196	19	3	of	of	ADP
dpc-5196	19	4	relapse	relapse	NOUN
dpc-5196	19	5	after	after	SCONJ
dpc-5196	19	6	treatment	treatment	NOUN
dpc-5196	19	7	varies	vary	VERB
dpc-5196	19	8	depending	depend	VERB
dpc-5196	19	9	on	on	ADP
dpc-5196	19	10	the	the	DET
dpc-5196	19	11	method	method	NOUN
dpc-5196	19	12	of	of	ADP
dpc-5196	19	13	discontinuation	discontinuation	NOUN
dpc-5196	19	14	.	.	PUNCT
dpc-5196	20	1	objectives	objective	NOUN
dpc-5196	20	2	:	:	PUNCT
dpc-5196	20	3	our	our	PRON
dpc-5196	20	4	study	study	NOUN
dpc-5196	20	5	aimed	aim	VERB
dpc-5196	20	6	to	to	PART
dpc-5196	20	7	investigate	investigate	VERB
dpc-5196	20	8	how	how	SCONJ
dpc-5196	20	9	the	the	DET
dpc-5196	20	10	method	method	NOUN
dpc-5196	20	11	of	of	ADP
dpc-5196	20	12	omalizumab	omalizumab	NOUN
dpc-5196	20	13	discontinuation	discontinuation	NOUN
dpc-5196	20	14	and	and	CCONJ
dpc-5196	20	15	other	other	ADJ
dpc-5196	20	16	factors	factor	NOUN
dpc-5196	20	17	affect	affect	VERB
dpc-5196	20	18	the	the	DET
dpc-5196	20	19	rate	rate	NOUN
dpc-5196	20	20	of	of	ADP
dpc-5196	20	21	post	post	ADJ
dpc-5196	20	22	-	-	ADJ
dpc-5196	20	23	treatment	treatment	NOUN
dpc-5196	20	24	relapses	relapse	NOUN
dpc-5196	20	25	.	.	PUNCT
dpc-5196	21	1	methods	method	NOUN
dpc-5196	21	2	:	:	PUNCT
dpc-5196	21	3	patients	patient	NOUN
dpc-5196	21	4	with	with	ADP
dpc-5196	21	5	cu	cu	PROPN
dpc-5196	21	6	were	be	AUX
dpc-5196	21	7	divided	divide	VERB
dpc-5196	21	8	into	into	ADP
dpc-5196	21	9	three	three	NUM
dpc-5196	21	10	groups	group	NOUN
dpc-5196	21	11	based	base	VERB
dpc-5196	21	12	on	on	ADP
dpc-5196	21	13	their	their	PRON
dpc-5196	21	14	method	method	NOUN
dpc-5196	21	15	of	of	ADP
dpc-5196	21	16	discontinuing	discontinue	VERB
dpc-5196	21	17	omalizumab	omalizumab	NOUN
dpc-5196	21	18	treatment	treatment	NOUN
dpc-5196	21	19	:	:	PUNCT
dpc-5196	21	20	direct	direct	ADJ
dpc-5196	21	21	discontinuation	discontinuation	NOUN
dpc-5196	21	22	,	,	PUNCT
dpc-5196	21	23	extending	extend	VERB
dpc-5196	21	24	treatment	treatment	NOUN
dpc-5196	21	25	intervals	interval	NOUN
dpc-5196	21	26	to	to	ADP
dpc-5196	21	27	eight	eight	NUM
dpc-5196	21	28	weeks	week	NOUN
dpc-5196	21	29	,	,	PUNCT
dpc-5196	21	30	and	and	CCONJ
dpc-5196	21	31	reducing	reduce	VERB
dpc-5196	21	32	the	the	DET
dpc-5196	21	33	treatment	treatment	NOUN
dpc-5196	21	34	dose	dose	VERB
dpc-5196	21	35	to	to	ADP
dpc-5196	21	36	150	150	NUM
dpc-5196	21	37	mg/4	mg/4	NOUN
dpc-5196	21	38	weeks	week	NOUN
dpc-5196	21	39	.	.	PUNCT
dpc-5196	22	1	these	these	DET
dpc-5196	22	2	groups	group	NOUN
dpc-5196	22	3	were	be	AUX
dpc-5196	22	4	then	then	ADV
dpc-5196	22	5	compared	compare	VERB
dpc-5196	22	6	for	for	ADP
dpc-5196	22	7	relapse	relapse	NOUN
dpc-5196	22	8	rates	rate	NOUN
dpc-5196	22	9	.	.	PUNCT
dpc-5196	23	1	results	result	NOUN
dpc-5196	23	2	:	:	PUNCT
dpc-5196	23	3	a	a	DET
dpc-5196	23	4	total	total	NOUN
dpc-5196	23	5	of	of	ADP
dpc-5196	23	6	200	200	NUM
dpc-5196	23	7	patients	patient	NOUN
dpc-5196	23	8	were	be	AUX
dpc-5196	23	9	included	include	VERB
dpc-5196	23	10	in	in	ADP
dpc-5196	23	11	this	this	DET
dpc-5196	23	12	study	study	NOUN
dpc-5196	23	13	.	.	PUNCT
dpc-5196	24	1	among	among	ADP
dpc-5196	24	2	the	the	DET
dpc-5196	24	3	109	109	NUM
dpc-5196	24	4	patients	patient	NOUN
dpc-5196	24	5	who	who	PRON
dpc-5196	24	6	discontinued	discontinue	VERB
dpc-5196	24	7	omalizumab	omalizumab	NOUN
dpc-5196	24	8	directly	directly	ADV
dpc-5196	24	9	,	,	PUNCT
dpc-5196	24	10	65.1	65.1	NUM
dpc-5196	24	11	%	%	NOUN
dpc-5196	24	12	experienced	experience	VERB
dpc-5196	24	13	a	a	DET
dpc-5196	24	14	relapse	relapse	NOUN
dpc-5196	24	15	.	.	PUNCT
dpc-5196	25	1	the	the	DET
dpc-5196	25	2	relapse	relapse	NOUN
dpc-5196	25	3	rate	rate	NOUN
dpc-5196	25	4	was	be	AUX
dpc-5196	25	5	40.7	40.7	NUM
dpc-5196	25	6	%	%	NOUN
dpc-5196	25	7	in	in	ADP
dpc-5196	25	8	those	those	PRON
dpc-5196	25	9	who	who	PRON
dpc-5196	25	10	extended	extend	VERB
dpc-5196	25	11	the	the	DET
dpc-5196	25	12	treatment	treatment	NOUN
dpc-5196	25	13	intervals	interval	NOUN
dpc-5196	25	14	to	to	ADP
dpc-5196	25	15	eight	eight	NUM
dpc-5196	25	16	weeks	week	NOUN
dpc-5196	25	17	and	and	CCONJ
dpc-5196	25	18	15.6	15.6	NUM
dpc-5196	25	19	%	%	NOUN
dpc-5196	25	20	in	in	ADP
dpc-5196	25	21	those	those	PRON
dpc-5196	25	22	who	who	PRON
dpc-5196	25	23	reduced	reduce	VERB
dpc-5196	25	24	the	the	DET
dpc-5196	25	25	dose	dose	NOUN
dpc-5196	25	26	to	to	ADP
dpc-5196	25	27	150	150	NUM
dpc-5196	25	28	mg/4	mg/4	PROPN
dpc-5196	25	29	weeks	week	NOUN
dpc-5196	25	30	.	.	PUNCT
dpc-5196	26	1	there	there	PRON
dpc-5196	26	2	was	be	VERB
dpc-5196	26	3	a	a	DET
dpc-5196	26	4	statistically	statistically	ADV
dpc-5196	26	5	significant	significant	ADJ
dpc-5196	26	6	difference	difference	NOUN
dpc-5196	26	7	in	in	ADP
dpc-5196	26	8	post	post	ADJ
dpc-5196	26	9	-	-	ADJ
dpc-5196	26	10	treatment	treatment	ADJ
dpc-5196	26	11	relapse	relapse	NOUN
dpc-5196	26	12	rates	rate	NOUN
dpc-5196	26	13	according	accord	VERB
dpc-5196	26	14	to	to	ADP
dpc-5196	26	15	the	the	DET
dpc-5196	26	16	method	method	NOUN
dpc-5196	26	17	of	of	ADP
dpc-5196	26	18	discontinuation	discontinuation	NOUN
dpc-5196	26	19	(	(	PUNCT
dpc-5196	26	20	p	p	X
dpc-5196	26	21	<	<	X
dpc-5196	26	22	0.001	0.001	NUM
dpc-5196	26	23	)	)	PUNCT
dpc-5196	26	24	.	.	PUNCT
dpc-5196	27	1	conclusions	conclusion	NOUN
dpc-5196	27	2	:	:	PUNCT
dpc-5196	27	3	gradual	gradual	ADJ
dpc-5196	27	4	tapering	tapering	NOUN
dpc-5196	27	5	of	of	ADP
dpc-5196	27	6	treatment	treatment	NOUN
dpc-5196	27	7	rather	rather	ADV
dpc-5196	27	8	than	than	ADP
dpc-5196	27	9	direct	direct	ADJ
dpc-5196	27	10	discontinuation	discontinuation	NOUN
dpc-5196	27	11	has	have	AUX
dpc-5196	27	12	been	be	AUX
dpc-5196	27	13	shown	show	VERB
dpc-5196	27	14	to	to	PART
dpc-5196	27	15	prolong	prolong	VERB
dpc-5196	27	16	remission	remission	NOUN
dpc-5196	27	17	.	.	PUNCT
dpc-5196	28	1	achieving	achieve	VERB
dpc-5196	28	2	the	the	DET
dpc-5196	28	3	lowest	low	ADJ
dpc-5196	28	4	relapse	relapse	NOUN
dpc-5196	28	5	rate	rate	NOUN
dpc-5196	28	6	with	with	ADP
dpc-5196	28	7	a	a	DET
dpc-5196	28	8	reduction	reduction	NOUN
dpc-5196	28	9	in	in	ADP
dpc-5196	28	10	the	the	DET
dpc-5196	28	11	treatment	treatment	NOUN
dpc-5196	28	12	dose	dose	VERB
dpc-5196	28	13	to	to	ADP
dpc-5196	28	14	150	150	NUM
dpc-5196	28	15	mg/4	mg/4	PROPN
dpc-5196	28	16	weeks	week	NOUN
dpc-5196	28	17	is	be	AUX
dpc-5196	28	18	significant	significant	ADJ
dpc-5196	28	19	for	for	ADP
dpc-5196	28	20	the	the	DET
dpc-5196	28	21	design	design	NOUN
dpc-5196	28	22	of	of	ADP
dpc-5196	28	23	omalizumab	omalizumab	NOUN
dpc-5196	28	24	discontinuation	discontinuation	NOUN
dpc-5196	28	25	protocol	protocol	NOUN
dpc-5196	28	26	and	and	CCONJ
dpc-5196	28	27	provides	provide	VERB
dpc-5196	28	28	insights	insight	NOUN
dpc-5196	28	29	for	for	ADP
dpc-5196	28	30	future	future	ADJ
dpc-5196	28	31	studies	study	NOUN
dpc-5196	28	32	.	.	PUNCT
dpc-5196	29	1	abstract	abstract	ADJ
dpc-5196	29	2	2	2	NUM
dpc-5196	29	3	original	original	ADJ
dpc-5196	29	4	article	article	NOUN
dpc-5196	29	5	|	|	ADV
dpc-5196	29	6	dermatol	dermatol	ADJ
dpc-5196	29	7	pract	pract	NOUN
dpc-5196	29	8	concept	concept	NOUN
dpc-5196	29	9	.	.	PUNCT
dpc-5196	30	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	30	2	introduction	introduction	NOUN
dpc-5196	30	3	chronic	chronic	ADJ
dpc-5196	30	4	urticaria	urticaria	NOUN
dpc-5196	30	5	(	(	PUNCT
dpc-5196	30	6	cu	cu	PROPN
dpc-5196	30	7	)	)	PUNCT
dpc-5196	30	8	is	be	AUX
dpc-5196	30	9	characterized	characterize	VERB
dpc-5196	30	10	by	by	ADP
dpc-5196	30	11	wheals	wheal	NOUN
dpc-5196	30	12	and	and	CCONJ
dpc-5196	30	13	angioedema	angioedema	NOUN
dpc-5196	30	14	that	that	PRON
dpc-5196	30	15	persist	persist	VERB
dpc-5196	30	16	for	for	ADP
dpc-5196	30	17	more	more	ADJ
dpc-5196	30	18	than	than	ADP
dpc-5196	30	19	six	six	NUM
dpc-5196	30	20	weeks	week	NOUN
dpc-5196	30	21	and	and	CCONJ
dpc-5196	30	22	significantly	significantly	ADV
dpc-5196	30	23	impair	impair	VERB
dpc-5196	30	24	the	the	DET
dpc-5196	30	25	quality	quality	NOUN
dpc-5196	30	26	of	of	ADP
dpc-5196	30	27	life	life	NOUN
dpc-5196	30	28	of	of	ADP
dpc-5196	30	29	patients	patient	NOUN
dpc-5196	30	30	due	due	ADP
dpc-5196	30	31	to	to	ADP
dpc-5196	30	32	its	its	PRON
dpc-5196	30	33	pruritic	pruritic	ADJ
dpc-5196	30	34	nature	nature	NOUN
dpc-5196	30	35	.	.	PUNCT
dpc-5196	31	1	the	the	DET
dpc-5196	31	2	prevalence	prevalence	NOUN
dpc-5196	31	3	of	of	ADP
dpc-5196	31	4	cu	cu	PROPN
dpc-5196	31	5	is	be	AUX
dpc-5196	31	6	estimated	estimate	VERB
dpc-5196	31	7	to	to	PART
dpc-5196	31	8	be	be	AUX
dpc-5196	31	9	between	between	ADP
dpc-5196	31	10	0.5	0.5	NUM
dpc-5196	31	11	%	%	NOUN
dpc-5196	31	12	and	and	CCONJ
dpc-5196	31	13	1	1	NUM
dpc-5196	31	14	%	%	NOUN
dpc-5196	31	15	of	of	ADP
dpc-5196	31	16	the	the	DET
dpc-5196	31	17	population	population	NOUN
dpc-5196	32	1	[	[	X
dpc-5196	32	2	1	1	NUM
dpc-5196	32	3	]	]	PUNCT
dpc-5196	32	4	.	.	PUNCT
dpc-5196	33	1	omalizumab	omalizumab	NOUN
dpc-5196	33	2	is	be	AUX
dpc-5196	33	3	a	a	DET
dpc-5196	33	4	monoclonal	monoclonal	NOUN
dpc-5196	33	5	antibody	antibody	NOUN
dpc-5196	33	6	that	that	PRON
dpc-5196	33	7	targets	target	VERB
dpc-5196	33	8	ige	ige	PROPN
dpc-5196	33	9	and	and	CCONJ
dpc-5196	33	10	is	be	AUX
dpc-5196	33	11	the	the	DET
dpc-5196	33	12	preferred	preferred	ADJ
dpc-5196	33	13	thirdline	thirdline	ADJ
dpc-5196	33	14	treatment	treatment	NOUN
dpc-5196	33	15	for	for	ADP
dpc-5196	33	16	cu	cu	NOUN
dpc-5196	33	17	patients	patient	NOUN
dpc-5196	33	18	who	who	PRON
dpc-5196	33	19	have	have	AUX
dpc-5196	33	20	not	not	PART
dpc-5196	33	21	responded	respond	VERB
dpc-5196	33	22	to	to	ADP
dpc-5196	33	23	a	a	DET
dpc-5196	33	24	fourfold	fourfold	ADJ
dpc-5196	33	25	dose	dose	NOUN
dpc-5196	33	26	of	of	ADP
dpc-5196	33	27	antihistamines	antihistamine	NOUN
dpc-5196	33	28	(	(	PUNCT
dpc-5196	33	29	ahs	ahs	INTJ
dpc-5196	33	30	)	)	PUNCT
dpc-5196	33	31	.	.	PUNCT
dpc-5196	34	1	the	the	DET
dpc-5196	34	2	efficacy	efficacy	NOUN
dpc-5196	34	3	and	and	CCONJ
dpc-5196	34	4	safety	safety	NOUN
dpc-5196	34	5	of	of	ADP
dpc-5196	34	6	omalizumab	omalizumab	NOUN
dpc-5196	34	7	300	300	NUM
dpc-5196	34	8	mg	mg	NOUN
dpc-5196	34	9	in	in	ADP
dpc-5196	34	10	patients	patient	NOUN
dpc-5196	34	11	with	with	ADP
dpc-5196	34	12	cu	cu	PROPN
dpc-5196	34	13	refractory	refractory	NOUN
dpc-5196	34	14	to	to	ADP
dpc-5196	34	15	ahs	ahs	PROPN
dpc-5196	34	16	have	have	AUX
dpc-5196	34	17	been	be	AUX
dpc-5196	34	18	demonstrated	demonstrate	VERB
dpc-5196	34	19	in	in	ADP
dpc-5196	34	20	three	three	NUM
dpc-5196	34	21	pivotal	pivotal	ADJ
dpc-5196	34	22	phase	phase	NOUN
dpc-5196	34	23	iii	iii	NUM
dpc-5196	34	24	randomized	randomize	VERB
dpc-5196	34	25	controlled	control	VERB
dpc-5196	34	26	trials	trial	NOUN
dpc-5196	34	27	in	in	ADP
dpc-5196	34	28	which	which	PRON
dpc-5196	34	29	52.4	52.4	NUM
dpc-5196	34	30	%	%	NOUN
dpc-5196	34	31	to	to	ADP
dpc-5196	34	32	58.8	58.8	NUM
dpc-5196	34	33	%	%	NOUN
dpc-5196	34	34	of	of	ADP
dpc-5196	34	35	patients	patient	NOUN
dpc-5196	34	36	achieved	achieve	VERB
dpc-5196	34	37	well	well	ADV
dpc-5196	34	38	-	-	PUNCT
dpc-5196	34	39	controlled	control	VERB
dpc-5196	34	40	urticaria	urticaria	NOUN
dpc-5196	34	41	[	[	X
dpc-5196	34	42	2	2	NUM
dpc-5196	34	43	]	]	PUNCT
dpc-5196	34	44	.	.	PUNCT
dpc-5196	35	1	in	in	ADP
dpc-5196	35	2	patients	patient	NOUN
dpc-5196	35	3	with	with	ADP
dpc-5196	35	4	a	a	DET
dpc-5196	35	5	complete	complete	ADJ
dpc-5196	35	6	response	response	NOUN
dpc-5196	35	7	to	to	ADP
dpc-5196	35	8	omalizumab	omalizumab	NOUN
dpc-5196	35	9	,	,	PUNCT
dpc-5196	35	10	there	there	PRON
dpc-5196	35	11	is	be	VERB
dpc-5196	35	12	currently	currently	ADV
dpc-5196	35	13	no	no	DET
dpc-5196	35	14	consensus	consensus	NOUN
dpc-5196	35	15	on	on	ADP
dpc-5196	35	16	the	the	DET
dpc-5196	35	17	optimal	optimal	ADJ
dpc-5196	35	18	method	method	NOUN
dpc-5196	35	19	and	and	CCONJ
dpc-5196	35	20	timing	timing	NOUN
dpc-5196	35	21	for	for	ADP
dpc-5196	35	22	cessation	cessation	NOUN
dpc-5196	35	23	of	of	ADP
dpc-5196	35	24	treatment	treatment	NOUN
dpc-5196	35	25	.	.	PUNCT
dpc-5196	36	1	to	to	PART
dpc-5196	36	2	determine	determine	VERB
dpc-5196	36	3	whether	whether	SCONJ
dpc-5196	36	4	the	the	DET
dpc-5196	36	5	disease	disease	NOUN
dpc-5196	36	6	is	be	AUX
dpc-5196	36	7	in	in	ADP
dpc-5196	36	8	remission	remission	NOUN
dpc-5196	36	9	,	,	PUNCT
dpc-5196	36	10	periodic	periodic	ADJ
dpc-5196	36	11	attempts	attempt	NOUN
dpc-5196	36	12	to	to	PART
dpc-5196	36	13	discontinue	discontinue	VERB
dpc-5196	36	14	omalizumab	omalizumab	NOUN
dpc-5196	36	15	in	in	ADP
dpc-5196	36	16	patients	patient	NOUN
dpc-5196	36	17	with	with	ADP
dpc-5196	36	18	completely	completely	ADV
dpc-5196	36	19	controlled	control	VERB
dpc-5196	36	20	disease	disease	NOUN
dpc-5196	36	21	may	may	AUX
dpc-5196	36	22	be	be	AUX
dpc-5196	36	23	beneficial	beneficial	ADJ
dpc-5196	36	24	.	.	PUNCT
dpc-5196	37	1	this	this	PRON
dpc-5196	37	2	is	be	AUX
dpc-5196	37	3	frequently	frequently	ADV
dpc-5196	37	4	achieved	achieve	VERB
dpc-5196	37	5	by	by	ADP
dpc-5196	37	6	discontinuing	discontinue	VERB
dpc-5196	37	7	omalizumab	omalizumab	NOUN
dpc-5196	37	8	treatment	treatment	NOUN
dpc-5196	37	9	within	within	ADP
dpc-5196	37	10	six	six	NUM
dpc-5196	37	11	months	month	NOUN
dpc-5196	37	12	to	to	ADP
dpc-5196	37	13	one	one	NUM
dpc-5196	37	14	year	year	NOUN
dpc-5196	37	15	in	in	ADP
dpc-5196	37	16	a	a	DET
dpc-5196	37	17	significant	significant	ADJ
dpc-5196	37	18	proportion	proportion	NOUN
dpc-5196	37	19	of	of	ADP
dpc-5196	37	20	patients	patient	NOUN
dpc-5196	37	21	[	[	X
dpc-5196	37	22	3	3	NUM
dpc-5196	37	23	]	]	PUNCT
dpc-5196	37	24	.	.	PUNCT
dpc-5196	38	1	to	to	ADP
dpc-5196	38	2	date	date	NOUN
dpc-5196	38	3	,	,	PUNCT
dpc-5196	38	4	three	three	NUM
dpc-5196	38	5	distinct	distinct	ADJ
dpc-5196	38	6	methods	method	NOUN
dpc-5196	38	7	of	of	ADP
dpc-5196	38	8	discontinuation	discontinuation	NOUN
dpc-5196	38	9	have	have	AUX
dpc-5196	38	10	been	be	AUX
dpc-5196	38	11	described	describe	VERB
dpc-5196	38	12	in	in	ADP
dpc-5196	38	13	the	the	DET
dpc-5196	38	14	literature	literature	NOUN
dpc-5196	38	15	:	:	PUNCT
dpc-5196	38	16	direct	direct	ADJ
dpc-5196	38	17	discontinuation	discontinuation	NOUN
dpc-5196	38	18	,	,	PUNCT
dpc-5196	38	19	gradual	gradual	ADJ
dpc-5196	38	20	extension	extension	NOUN
dpc-5196	38	21	of	of	ADP
dpc-5196	38	22	the	the	DET
dpc-5196	38	23	dose	dose	NOUN
dpc-5196	38	24	intervals	interval	NOUN
dpc-5196	38	25	to	to	ADP
dpc-5196	38	26	eight	eight	NUM
dpc-5196	38	27	weeks	week	NOUN
dpc-5196	38	28	while	while	SCONJ
dpc-5196	38	29	maintaining	maintain	VERB
dpc-5196	38	30	a	a	DET
dpc-5196	38	31	response	response	NOUN
dpc-5196	38	32	for	for	ADP
dpc-5196	38	33	at	at	ADV
dpc-5196	38	34	least	least	ADV
dpc-5196	38	35	two	two	NUM
dpc-5196	38	36	doses	dose	NOUN
dpc-5196	38	37	within	within	ADP
dpc-5196	38	38	this	this	DET
dpc-5196	38	39	period	period	NOUN
dpc-5196	38	40	,	,	PUNCT
dpc-5196	38	41	and	and	CCONJ
dpc-5196	38	42	dose	dose	NOUN
dpc-5196	38	43	reduction	reduction	NOUN
dpc-5196	38	44	to	to	ADP
dpc-5196	38	45	150	150	NUM
dpc-5196	38	46	mg	mg	NOUN
dpc-5196	38	47	every	every	DET
dpc-5196	38	48	four	four	NUM
dpc-5196	38	49	weeks	week	NOUN
dpc-5196	38	50	while	while	SCONJ
dpc-5196	38	51	maintaining	maintain	VERB
dpc-5196	38	52	a	a	DET
dpc-5196	38	53	response	response	NOUN
dpc-5196	38	54	for	for	ADP
dpc-5196	38	55	at	at	ADV
dpc-5196	38	56	least	least	ADV
dpc-5196	38	57	two	two	NUM
dpc-5196	38	58	doses	dose	NOUN
dpc-5196	38	59	at	at	ADP
dpc-5196	38	60	this	this	DET
dpc-5196	38	61	level	level	NOUN
dpc-5196	38	62	.	.	PUNCT
dpc-5196	39	1	stepwise	stepwise	PROPN
dpc-5196	39	2	tapering	tapering	NOUN
dpc-5196	39	3	has	have	AUX
dpc-5196	39	4	been	be	AUX
dpc-5196	39	5	linked	link	VERB
dpc-5196	39	6	to	to	ADP
dpc-5196	39	7	both	both	DET
dpc-5196	39	8	improved	improve	VERB
dpc-5196	39	9	disease	disease	NOUN
dpc-5196	39	10	control	control	NOUN
dpc-5196	39	11	and	and	CCONJ
dpc-5196	39	12	a	a	DET
dpc-5196	39	13	longer	long	ADJ
dpc-5196	39	14	remission	remission	NOUN
dpc-5196	39	15	period	period	NOUN
dpc-5196	39	16	.	.	PUNCT
dpc-5196	40	1	patients	patient	NOUN
dpc-5196	40	2	who	who	PRON
dpc-5196	40	3	discontinued	discontinue	VERB
dpc-5196	40	4	omalizumab	omalizumab	NOUN
dpc-5196	40	5	directly	directly	ADV
dpc-5196	40	6	were	be	AUX
dpc-5196	40	7	compared	compare	VERB
dpc-5196	40	8	with	with	ADP
dpc-5196	40	9	those	those	PRON
dpc-5196	40	10	who	who	PRON
dpc-5196	40	11	gradually	gradually	ADV
dpc-5196	40	12	extended	extend	VERB
dpc-5196	40	13	the	the	DET
dpc-5196	40	14	dose	dose	NOUN
dpc-5196	40	15	intervals	interval	NOUN
dpc-5196	40	16	before	before	ADP
dpc-5196	40	17	discontinuation	discontinuation	NOUN
dpc-5196	40	18	[	[	X
dpc-5196	40	19	4,5	4,5	NUM
dpc-5196	40	20	]	]	PUNCT
dpc-5196	40	21	.	.	PUNCT
dpc-5196	41	1	objective	objective	NOUN
dpc-5196	41	2	given	give	VERB
dpc-5196	41	3	the	the	DET
dpc-5196	41	4	limited	limited	ADJ
dpc-5196	41	5	literature	literature	NOUN
dpc-5196	41	6	available	available	ADJ
dpc-5196	41	7	on	on	ADP
dpc-5196	41	8	this	this	DET
dpc-5196	41	9	topic	topic	NOUN
dpc-5196	41	10	,	,	PUNCT
dpc-5196	41	11	the	the	DET
dpc-5196	41	12	aim	aim	NOUN
dpc-5196	41	13	of	of	ADP
dpc-5196	41	14	our	our	PRON
dpc-5196	41	15	study	study	NOUN
dpc-5196	41	16	was	be	AUX
dpc-5196	41	17	to	to	PART
dpc-5196	41	18	investigate	investigate	VERB
dpc-5196	41	19	how	how	SCONJ
dpc-5196	41	20	the	the	DET
dpc-5196	41	21	method	method	NOUN
dpc-5196	41	22	of	of	ADP
dpc-5196	41	23	omalizumab	omalizumab	NOUN
dpc-5196	41	24	discontinuation	discontinuation	NOUN
dpc-5196	41	25	,	,	PUNCT
dpc-5196	41	26	as	as	ADV
dpc-5196	41	27	well	well	ADV
dpc-5196	41	28	as	as	ADP
dpc-5196	41	29	other	other	ADJ
dpc-5196	41	30	factors	factor	NOUN
dpc-5196	41	31	,	,	PUNCT
dpc-5196	41	32	affects	affect	VERB
dpc-5196	41	33	the	the	DET
dpc-5196	41	34	rate	rate	NOUN
dpc-5196	41	35	of	of	ADP
dpc-5196	41	36	post	post	ADJ
dpc-5196	41	37	-	-	ADJ
dpc-5196	41	38	treatment	treatment	ADJ
dpc-5196	41	39	relapses	relapse	NOUN
dpc-5196	41	40	.	.	PUNCT
dpc-5196	42	1	methods	method	NOUN
dpc-5196	42	2	ethics	ethic	NOUN
dpc-5196	42	3	approval	approval	NOUN
dpc-5196	42	4	this	this	DET
dpc-5196	42	5	study	study	NOUN
dpc-5196	42	6	was	be	AUX
dpc-5196	42	7	approved	approve	VERB
dpc-5196	42	8	by	by	ADP
dpc-5196	42	9	the	the	DET
dpc-5196	42	10	local	local	ADJ
dpc-5196	42	11	ethics	ethic	NOUN
dpc-5196	42	12	committee	committee	NOUN
dpc-5196	42	13	and	and	CCONJ
dpc-5196	42	14	conducted	conduct	VERB
dpc-5196	42	15	in	in	ADP
dpc-5196	42	16	accordance	accordance	NOUN
dpc-5196	42	17	with	with	ADP
dpc-5196	42	18	the	the	DET
dpc-5196	42	19	tenets	tenet	NOUN
dpc-5196	42	20	of	of	ADP
dpc-5196	42	21	the	the	DET
dpc-5196	42	22	declaration	declaration	NOUN
dpc-5196	42	23	of	of	ADP
dpc-5196	42	24	helsinki	helsinki	PROPN
dpc-5196	42	25	(	(	PUNCT
dpc-5196	42	26	05.2023.499	05.2023.499	PROPN
dpc-5196	42	27	.	.	PUNCT
dpc-5196	42	28	)	)	PUNCT
dpc-5196	42	29	.	.	PUNCT
dpc-5196	43	1	informed	informed	ADJ
dpc-5196	43	2	consent	consent	NOUN
dpc-5196	43	3	was	be	AUX
dpc-5196	43	4	obtained	obtain	VERB
dpc-5196	43	5	from	from	ADP
dpc-5196	43	6	all	all	DET
dpc-5196	43	7	participants	participant	NOUN
dpc-5196	43	8	.	.	PUNCT
dpc-5196	44	1	study	study	NOUN
dpc-5196	44	2	population	population	NOUN
dpc-5196	44	3	this	this	DET
dpc-5196	44	4	study	study	NOUN
dpc-5196	44	5	included	include	VERB
dpc-5196	44	6	patients	patient	NOUN
dpc-5196	44	7	aged	age	VERB
dpc-5196	44	8	12	12	NUM
dpc-5196	44	9	years	year	NOUN
dpc-5196	44	10	or	or	CCONJ
dpc-5196	44	11	older	old	ADJ
dpc-5196	44	12	who	who	PRON
dpc-5196	44	13	were	be	AUX
dpc-5196	44	14	diagnosed	diagnose	VERB
dpc-5196	44	15	with	with	ADP
dpc-5196	44	16	cu	cu	PROPN
dpc-5196	44	17	and	and	CCONJ
dpc-5196	44	18	treated	treat	VERB
dpc-5196	44	19	with	with	ADP
dpc-5196	44	20	omalizumab	omalizumab	NOUN
dpc-5196	44	21	at	at	ADP
dpc-5196	44	22	a	a	DET
dpc-5196	44	23	dose	dose	NOUN
dpc-5196	44	24	of	of	ADP
dpc-5196	44	25	300	300	NUM
dpc-5196	44	26	mg	mg	NOUN
dpc-5196	44	27	every	every	DET
dpc-5196	44	28	four	four	NUM
dpc-5196	44	29	weeks	week	NOUN
dpc-5196	44	30	for	for	ADP
dpc-5196	44	31	at	at	ADV
dpc-5196	44	32	least	least	ADV
dpc-5196	44	33	three	three	NUM
dpc-5196	44	34	months	month	NOUN
dpc-5196	44	35	between	between	ADP
dpc-5196	44	36	january	january	PROPN
dpc-5196	44	37	2009	2009	NUM
dpc-5196	44	38	and	and	CCONJ
dpc-5196	44	39	may	may	PROPN
dpc-5196	44	40	2022	2022	NUM
dpc-5196	44	41	.	.	PUNCT
dpc-5196	45	1	each	each	DET
dpc-5196	45	2	patient	patient	NOUN
dpc-5196	45	3	was	be	AUX
dpc-5196	45	4	followed	follow	VERB
dpc-5196	45	5	for	for	ADP
dpc-5196	45	6	at	at	ADV
dpc-5196	45	7	least	least	ADV
dpc-5196	45	8	15	15	NUM
dpc-5196	45	9	months	month	NOUN
dpc-5196	45	10	after	after	ADP
dpc-5196	45	11	discontinuing	discontinue	VERB
dpc-5196	45	12	omalizumab	omalizumab	NOUN
dpc-5196	45	13	.	.	PUNCT
dpc-5196	46	1	patients	patient	NOUN
dpc-5196	46	2	who	who	PRON
dpc-5196	46	3	were	be	AUX
dpc-5196	46	4	resistant	resistant	ADJ
dpc-5196	46	5	to	to	ADP
dpc-5196	46	6	standard	standard	ADJ
dpc-5196	46	7	omalizumab	omalizumab	NOUN
dpc-5196	46	8	treatment	treatment	NOUN
dpc-5196	46	9	and	and	CCONJ
dpc-5196	46	10	required	require	VERB
dpc-5196	46	11	higher	high	ADJ
dpc-5196	46	12	doses	dose	NOUN
dpc-5196	46	13	or	or	CCONJ
dpc-5196	46	14	intervals	interval	NOUN
dpc-5196	46	15	shorter	short	ADJ
dpc-5196	46	16	than	than	ADP
dpc-5196	46	17	four	four	NUM
dpc-5196	46	18	weeks	week	NOUN
dpc-5196	46	19	were	be	AUX
dpc-5196	46	20	excluded	exclude	VERB
dpc-5196	46	21	.	.	PUNCT
dpc-5196	47	1	additionally	additionally	ADV
dpc-5196	47	2	,	,	PUNCT
dpc-5196	47	3	patients	patient	NOUN
dpc-5196	47	4	lost	lose	VERB
dpc-5196	47	5	to	to	PART
dpc-5196	47	6	follow	follow	VERB
dpc-5196	47	7	-	-	PUNCT
dpc-5196	47	8	up	up	NOUN
dpc-5196	47	9	after	after	ADP
dpc-5196	47	10	completing	complete	VERB
dpc-5196	47	11	omalizumab	omalizumab	NOUN
dpc-5196	47	12	treatment	treatment	NOUN
dpc-5196	47	13	were	be	AUX
dpc-5196	47	14	also	also	ADV
dpc-5196	47	15	excluded	exclude	VERB
dpc-5196	47	16	.	.	PUNCT
dpc-5196	48	1	data	datum	NOUN
dpc-5196	48	2	collection	collection	NOUN
dpc-5196	48	3	and	and	CCONJ
dpc-5196	48	4	analysis	analysis	NOUN
dpc-5196	48	5	patients	patient	NOUN
dpc-5196	48	6	with	with	ADP
dpc-5196	48	7	cu	cu	PROPN
dpc-5196	48	8	are	be	AUX
dpc-5196	48	9	followed	follow	VERB
dpc-5196	48	10	at	at	ADP
dpc-5196	48	11	intervals	interval	NOUN
dpc-5196	48	12	of	of	ADP
dpc-5196	48	13	4	4	NUM
dpc-5196	48	14	-	-	SYM
dpc-5196	48	15	8	8	NUM
dpc-5196	48	16	weeks	week	NOUN
dpc-5196	48	17	.	.	PUNCT
dpc-5196	49	1	at	at	ADP
dpc-5196	49	2	each	each	DET
dpc-5196	49	3	visit	visit	NOUN
dpc-5196	49	4	,	,	PUNCT
dpc-5196	49	5	symptom	symptom	NOUN
dpc-5196	49	6	severity	severity	NOUN
dpc-5196	49	7	and	and	CCONJ
dpc-5196	49	8	disease	disease	NOUN
dpc-5196	49	9	control	control	NOUN
dpc-5196	49	10	are	be	AUX
dpc-5196	49	11	assessed	assess	VERB
dpc-5196	49	12	using	use	VERB
dpc-5196	49	13	the	the	DET
dpc-5196	49	14	7	7	NUM
dpc-5196	49	15	-	-	PUNCT
dpc-5196	49	16	day	day	NOUN
dpc-5196	49	17	urticaria	urticaria	NOUN
dpc-5196	49	18	activity	activity	NOUN
dpc-5196	49	19	score	score	NOUN
dpc-5196	49	20	(	(	PUNCT
dpc-5196	49	21	uas7	uas7	PROPN
dpc-5196	49	22	)	)	PUNCT
dpc-5196	49	23	and	and	CCONJ
dpc-5196	49	24	the	the	DET
dpc-5196	49	25	urticaria	urticaria	PROPN
dpc-5196	49	26	control	control	PROPN
dpc-5196	49	27	test	test	PROPN
dpc-5196	49	28	(	(	PUNCT
dpc-5196	49	29	uct	uct	PROPN
dpc-5196	49	30	)	)	PUNCT
dpc-5196	49	31	.	.	PUNCT
dpc-5196	50	1	moreover	moreover	ADV
dpc-5196	50	2	,	,	PUNCT
dpc-5196	50	3	serum	serum	PROPN
dpc-5196	50	4	ige	ige	PROPN
dpc-5196	50	5	and	and	CCONJ
dpc-5196	50	6	blood	blood	NOUN
dpc-5196	50	7	basophil	basophil	NOUN
dpc-5196	50	8	levels	level	NOUN
dpc-5196	50	9	are	be	AUX
dpc-5196	50	10	measured	measure	VERB
dpc-5196	50	11	and	and	CCONJ
dpc-5196	50	12	documented	document	VERB
dpc-5196	50	13	at	at	ADP
dpc-5196	50	14	weeks	week	NOUN
dpc-5196	50	15	0	0	NUM
dpc-5196	50	16	and	and	CCONJ
dpc-5196	50	17	4	4	NUM
dpc-5196	50	18	of	of	ADP
dpc-5196	50	19	treatment	treatment	NOUN
dpc-5196	50	20	.	.	PUNCT
dpc-5196	51	1	the	the	DET
dpc-5196	51	2	demographic	demographic	ADJ
dpc-5196	51	3	and	and	CCONJ
dpc-5196	51	4	clinical	clinical	ADJ
dpc-5196	51	5	characteristics	characteristic	NOUN
dpc-5196	51	6	of	of	ADP
dpc-5196	51	7	the	the	DET
dpc-5196	51	8	patients	patient	NOUN
dpc-5196	51	9	,	,	PUNCT
dpc-5196	51	10	including	include	VERB
dpc-5196	51	11	age	age	NOUN
dpc-5196	51	12	,	,	PUNCT
dpc-5196	51	13	sex	sex	NOUN
dpc-5196	51	14	,	,	PUNCT
dpc-5196	51	15	comorbidities	comorbiditie	NOUN
dpc-5196	51	16	,	,	PUNCT
dpc-5196	51	17	disease	disease	NOUN
dpc-5196	51	18	duration	duration	NOUN
dpc-5196	51	19	,	,	PUNCT
dpc-5196	51	20	presence	presence	NOUN
dpc-5196	51	21	of	of	ADP
dpc-5196	51	22	angioedema	angioedema	ADJ
dpc-5196	51	23	,	,	PUNCT
dpc-5196	51	24	concomitant	concomitant	ADJ
dpc-5196	51	25	treatments	treatment	NOUN
dpc-5196	51	26	,	,	PUNCT
dpc-5196	51	27	method	method	NOUN
dpc-5196	51	28	of	of	ADP
dpc-5196	51	29	omalizumab	omalizumab	NOUN
dpc-5196	51	30	discontinuation	discontinuation	NOUN
dpc-5196	51	31	,	,	PUNCT
dpc-5196	51	32	and	and	CCONJ
dpc-5196	51	33	time	time	NOUN
dpc-5196	51	34	to	to	PART
dpc-5196	51	35	relapse	relapse	VERB
dpc-5196	51	36	after	after	ADP
dpc-5196	51	37	treatment	treatment	NOUN
dpc-5196	51	38	,	,	PUNCT
dpc-5196	51	39	were	be	AUX
dpc-5196	51	40	obtained	obtain	VERB
dpc-5196	51	41	from	from	ADP
dpc-5196	51	42	electronic	electronic	ADJ
dpc-5196	51	43	medical	medical	ADJ
dpc-5196	51	44	records	record	NOUN
dpc-5196	51	45	.	.	PUNCT
dpc-5196	52	1	a	a	DET
dpc-5196	52	2	uas7	uas7	ADJ
dpc-5196	52	3	score	score	NOUN
dpc-5196	52	4	of	of	ADP
dpc-5196	52	5	less	less	ADJ
dpc-5196	52	6	than	than	ADP
dpc-5196	52	7	6	6	NUM
dpc-5196	52	8	is	be	AUX
dpc-5196	52	9	defined	define	VERB
dpc-5196	52	10	as	as	ADP
dpc-5196	52	11	a	a	DET
dpc-5196	52	12	good	good	ADJ
dpc-5196	52	13	response	response	NOUN
dpc-5196	52	14	to	to	AUX
dpc-5196	52	15	omalizumab	omalizumab	NOUN
dpc-5196	52	16	treatment	treatment	NOUN
dpc-5196	52	17	[	[	X
dpc-5196	52	18	6	6	NUM
dpc-5196	52	19	]	]	PUNCT
dpc-5196	52	20	.	.	PUNCT
dpc-5196	53	1	in	in	ADP
dpc-5196	53	2	our	our	PRON
dpc-5196	53	3	study	study	NOUN
dpc-5196	53	4	,	,	PUNCT
dpc-5196	53	5	we	we	PRON
dpc-5196	53	6	attempted	attempt	VERB
dpc-5196	53	7	to	to	PART
dpc-5196	53	8	discontinue	discontinue	VERB
dpc-5196	53	9	treatment	treatment	NOUN
dpc-5196	53	10	in	in	ADP
dpc-5196	53	11	patients	patient	NOUN
dpc-5196	53	12	with	with	ADP
dpc-5196	53	13	a	a	DET
dpc-5196	53	14	uas7	uas7	ADJ
dpc-5196	53	15	score	score	NOUN
dpc-5196	53	16	of	of	ADP
dpc-5196	53	17	less	less	ADJ
dpc-5196	53	18	than	than	ADP
dpc-5196	53	19	6	6	NUM
dpc-5196	53	20	following	follow	VERB
dpc-5196	53	21	omalizumab	omalizumab	NOUN
dpc-5196	53	22	therapy	therapy	NOUN
dpc-5196	53	23	.	.	PUNCT
dpc-5196	54	1	patients	patient	NOUN
dpc-5196	54	2	were	be	AUX
dpc-5196	54	3	divided	divide	VERB
dpc-5196	54	4	into	into	ADP
dpc-5196	54	5	three	three	NUM
dpc-5196	54	6	groups	group	NOUN
dpc-5196	54	7	based	base	VERB
dpc-5196	54	8	on	on	ADP
dpc-5196	54	9	the	the	DET
dpc-5196	54	10	method	method	NOUN
dpc-5196	54	11	of	of	ADP
dpc-5196	54	12	discontinuing	discontinue	VERB
dpc-5196	54	13	omalizumab	omalizumab	NOUN
dpc-5196	54	14	treatment	treatment	NOUN
dpc-5196	54	15	:	:	PUNCT
dpc-5196	54	16	direct	direct	ADJ
dpc-5196	54	17	discontinuation	discontinuation	NOUN
dpc-5196	54	18	,	,	PUNCT
dpc-5196	54	19	extending	extend	VERB
dpc-5196	54	20	the	the	DET
dpc-5196	54	21	treatment	treatment	NOUN
dpc-5196	54	22	intervals	interval	NOUN
dpc-5196	54	23	to	to	ADP
dpc-5196	54	24	eight	eight	NUM
dpc-5196	54	25	weeks	week	NOUN
dpc-5196	54	26	,	,	PUNCT
dpc-5196	54	27	and	and	CCONJ
dpc-5196	54	28	reducing	reduce	VERB
dpc-5196	54	29	the	the	DET
dpc-5196	54	30	treatment	treatment	NOUN
dpc-5196	54	31	dose	dose	VERB
dpc-5196	54	32	to	to	ADP
dpc-5196	54	33	150	150	NUM
dpc-5196	54	34	mg	mg	NOUN
dpc-5196	54	35	every	every	DET
dpc-5196	54	36	four	four	NUM
dpc-5196	54	37	weeks	week	NOUN
dpc-5196	54	38	.	.	PUNCT
dpc-5196	55	1	relapse	relapse	NOUN
dpc-5196	55	2	in	in	ADP
dpc-5196	55	3	patients	patient	NOUN
dpc-5196	55	4	with	with	ADP
dpc-5196	55	5	cu	cu	PROPN
dpc-5196	55	6	was	be	AUX
dpc-5196	55	7	defined	define	VERB
dpc-5196	55	8	as	as	ADP
dpc-5196	55	9	the	the	DET
dpc-5196	55	10	recurrence	recurrence	NOUN
dpc-5196	55	11	of	of	ADP
dpc-5196	55	12	symptoms	symptom	NOUN
dpc-5196	55	13	after	after	ADP
dpc-5196	55	14	discontinuation	discontinuation	NOUN
dpc-5196	55	15	of	of	ADP
dpc-5196	55	16	omalizumab	omalizumab	NOUN
dpc-5196	55	17	treatment	treatment	NOUN
dpc-5196	55	18	,	,	PUNCT
dpc-5196	55	19	determined	determine	VERB
dpc-5196	55	20	by	by	ADP
dpc-5196	55	21	a	a	DET
dpc-5196	55	22	uct	uct	PROPN
dpc-5196	55	23	<	<	X
dpc-5196	55	24	12	12	NUM
dpc-5196	55	25	or	or	CCONJ
dpc-5196	55	26	a	a	DET
dpc-5196	55	27	uas7	uas7	ADJ
dpc-5196	55	28	score	score	NOUN
dpc-5196	55	29	>	>	PUNCT
dpc-5196	55	30	16	16	NUM
dpc-5196	56	1	[	[	X
dpc-5196	56	2	7,8	7,8	NUM
dpc-5196	56	3	]	]	PUNCT
dpc-5196	56	4	.	.	PUNCT
dpc-5196	57	1	these	these	DET
dpc-5196	57	2	groups	group	NOUN
dpc-5196	57	3	were	be	AUX
dpc-5196	57	4	then	then	ADV
dpc-5196	57	5	compared	compare	VERB
dpc-5196	57	6	for	for	ADP
dpc-5196	57	7	relapse	relapse	NOUN
dpc-5196	57	8	rates	rate	NOUN
dpc-5196	57	9	.	.	PUNCT
dpc-5196	58	1	statistical	statistical	ADJ
dpc-5196	58	2	analysis	analysis	NOUN
dpc-5196	58	3	statistical	statistical	ADJ
dpc-5196	58	4	analysis	analysis	NOUN
dpc-5196	58	5	of	of	ADP
dpc-5196	58	6	the	the	DET
dpc-5196	58	7	data	datum	NOUN
dpc-5196	58	8	was	be	AUX
dpc-5196	58	9	performed	perform	VERB
dpc-5196	58	10	using	use	VERB
dpc-5196	58	11	ibm	ibm	PROPN
dpc-5196	58	12	spss	spss	PROPN
dpc-5196	58	13	24.0	24.0	NUM
dpc-5196	58	14	.	.	PUNCT
dpc-5196	59	1	descriptive	descriptive	ADJ
dpc-5196	59	2	statistics	statistic	NOUN
dpc-5196	59	3	were	be	AUX
dpc-5196	59	4	calculated	calculate	VERB
dpc-5196	59	5	as	as	ADP
dpc-5196	59	6	mean	mean	NOUN
dpc-5196	59	7	(	(	PUNCT
dpc-5196	59	8	±	±	NOUN
dpc-5196	59	9	standard	standard	ADJ
dpc-5196	59	10	deviation	deviation	NOUN
dpc-5196	59	11	)	)	PUNCT
dpc-5196	59	12	,	,	PUNCT
dpc-5196	59	13	median	median	NOUN
dpc-5196	59	14	and	and	CCONJ
dpc-5196	59	15	range	range	VERB
dpc-5196	59	16	for	for	ADP
dpc-5196	59	17	continuous	continuous	ADJ
dpc-5196	59	18	variables	variable	NOUN
dpc-5196	59	19	,	,	PUNCT
dpc-5196	59	20	and	and	CCONJ
dpc-5196	59	21	percentages	percentage	NOUN
dpc-5196	59	22	for	for	ADP
dpc-5196	59	23	categorical	categorical	ADJ
dpc-5196	59	24	variables	variable	NOUN
dpc-5196	59	25	.	.	PUNCT
dpc-5196	60	1	for	for	ADP
dpc-5196	60	2	categorical	categorical	ADJ
dpc-5196	60	3	variables	variable	NOUN
dpc-5196	60	4	,	,	PUNCT
dpc-5196	60	5	the	the	DET
dpc-5196	60	6	chi	chi	NOUN
dpc-5196	60	7	-	-	PUNCT
dpc-5196	60	8	squared	square	VERB
dpc-5196	60	9	test	test	NOUN
dpc-5196	60	10	was	be	AUX
dpc-5196	60	11	used	use	VERB
dpc-5196	60	12	to	to	PART
dpc-5196	60	13	compare	compare	VERB
dpc-5196	60	14	independent	independent	ADJ
dpc-5196	60	15	groups	group	NOUN
dpc-5196	60	16	.	.	PUNCT
dpc-5196	61	1	continuous	continuous	ADJ
dpc-5196	61	2	variables	variable	NOUN
dpc-5196	61	3	with	with	ADP
dpc-5196	61	4	a	a	DET
dpc-5196	61	5	normal	normal	ADJ
dpc-5196	61	6	distribution	distribution	NOUN
dpc-5196	61	7	were	be	AUX
dpc-5196	61	8	analyzed	analyze	VERB
dpc-5196	61	9	using	use	VERB
dpc-5196	61	10	an	an	DET
dpc-5196	61	11	independent	independent	ADJ
dpc-5196	61	12	samples	sample	NOUN
dpc-5196	61	13	t	t	NOUN
dpc-5196	61	14	-	-	PUNCT
dpc-5196	61	15	test	test	NOUN
dpc-5196	61	16	for	for	ADP
dpc-5196	61	17	independent	independent	ADJ
dpc-5196	61	18	groups	group	NOUN
dpc-5196	61	19	and	and	CCONJ
dpc-5196	61	20	a	a	DET
dpc-5196	61	21	paired	pair	VERB
dpc-5196	61	22	samples	sample	NOUN
dpc-5196	61	23	t	t	NOUN
dpc-5196	61	24	-	-	PUNCT
dpc-5196	61	25	test	test	NOUN
dpc-5196	61	26	for	for	ADP
dpc-5196	61	27	dependent	dependent	ADJ
dpc-5196	61	28	groups	group	NOUN
dpc-5196	61	29	.	.	PUNCT
dpc-5196	62	1	for	for	ADP
dpc-5196	62	2	non	non	ADJ
dpc-5196	62	3	-	-	ADJ
dpc-5196	62	4	normally	normally	ADV
dpc-5196	62	5	distributed	distribute	VERB
dpc-5196	62	6	variables	variable	NOUN
dpc-5196	62	7	,	,	PUNCT
dpc-5196	62	8	the	the	DET
dpc-5196	62	9	mann	mann	PROPN
dpc-5196	62	10	-	-	PUNCT
dpc-5196	62	11	whitney	whitney	PROPN
dpc-5196	62	12	u	u	PROPN
dpc-5196	62	13	test	test	NOUN
dpc-5196	62	14	was	be	AUX
dpc-5196	62	15	used	use	VERB
dpc-5196	62	16	to	to	PART
dpc-5196	62	17	analyze	analyze	VERB
dpc-5196	62	18	data	datum	NOUN
dpc-5196	62	19	between	between	ADP
dpc-5196	62	20	independent	independent	ADJ
dpc-5196	62	21	groups	group	NOUN
dpc-5196	62	22	.	.	PUNCT
dpc-5196	63	1	a	a	DET
dpc-5196	63	2	p	p	NOUN
dpc-5196	63	3	-	-	PUNCT
dpc-5196	63	4	value	value	NOUN
dpc-5196	63	5	of	of	ADP
dpc-5196	63	6	less	less	ADJ
dpc-5196	63	7	than	than	ADP
dpc-5196	63	8	0.05	0.05	NUM
dpc-5196	63	9	was	be	AUX
dpc-5196	63	10	considered	consider	VERB
dpc-5196	63	11	statistically	statistically	ADV
dpc-5196	63	12	significant	significant	ADJ
dpc-5196	63	13	.	.	PUNCT
dpc-5196	64	1	results	result	VERB
dpc-5196	64	2	demographic	demographic	ADJ
dpc-5196	64	3	and	and	CCONJ
dpc-5196	64	4	clinical	clinical	ADJ
dpc-5196	64	5	characteristics	characteristic	NOUN
dpc-5196	64	6	the	the	DET
dpc-5196	64	7	study	study	NOUN
dpc-5196	64	8	included	include	VERB
dpc-5196	64	9	200	200	NUM
dpc-5196	64	10	patients	patient	NOUN
dpc-5196	64	11	with	with	ADP
dpc-5196	64	12	cu	cu	PROPN
dpc-5196	64	13	.	.	PUNCT
dpc-5196	65	1	the	the	DET
dpc-5196	65	2	mean	mean	ADJ
dpc-5196	65	3	age	age	NOUN
dpc-5196	65	4	of	of	ADP
dpc-5196	65	5	the	the	DET
dpc-5196	65	6	patients	patient	NOUN
dpc-5196	65	7	was	be	AUX
dpc-5196	65	8	45.86	45.86	NUM
dpc-5196	65	9	years	year	NOUN
dpc-5196	65	10	,	,	PUNCT
dpc-5196	65	11	and	and	CCONJ
dpc-5196	65	12	66	66	NUM
dpc-5196	65	13	%	%	NOUN
dpc-5196	65	14	(	(	PUNCT
dpc-5196	65	15	n	n	NOUN
dpc-5196	65	16	=	=	SYM
dpc-5196	65	17	132	132	NUM
dpc-5196	65	18	)	)	PUNCT
dpc-5196	65	19	of	of	ADP
dpc-5196	65	20	the	the	DET
dpc-5196	65	21	original	original	ADJ
dpc-5196	65	22	article	article	NOUN
dpc-5196	65	23	|	|	ADV
dpc-5196	65	24	dermatol	dermatol	ADJ
dpc-5196	65	25	pract	pract	NOUN
dpc-5196	65	26	concept	concept	NOUN
dpc-5196	65	27	.	.	PUNCT
dpc-5196	66	1	2025;15(3):5196	2025;15(3):5196	NOUN
dpc-5196	66	2	3	3	NUM
dpc-5196	66	3	patients	patient	NOUN
dpc-5196	66	4	were	be	AUX
dpc-5196	66	5	female	female	ADJ
dpc-5196	66	6	.	.	PUNCT
dpc-5196	67	1	the	the	DET
dpc-5196	67	2	demographic	demographic	ADJ
dpc-5196	67	3	,	,	PUNCT
dpc-5196	67	4	clinical	clinical	ADJ
dpc-5196	67	5	,	,	PUNCT
dpc-5196	67	6	and	and	CCONJ
dpc-5196	67	7	laboratory	laboratory	NOUN
dpc-5196	67	8	characteristics	characteristic	NOUN
dpc-5196	67	9	of	of	ADP
dpc-5196	67	10	the	the	DET
dpc-5196	67	11	patients	patient	NOUN
dpc-5196	67	12	are	be	AUX
dpc-5196	67	13	shown	show	VERB
dpc-5196	67	14	in	in	ADP
dpc-5196	67	15	table	table	NOUN
dpc-5196	67	16	1	1	NUM
dpc-5196	67	17	.	.	PUNCT
dpc-5196	68	1	the	the	DET
dpc-5196	68	2	duration	duration	NOUN
dpc-5196	68	3	of	of	ADP
dpc-5196	68	4	cu	cu	PROPN
dpc-5196	68	5	prior	prior	ADV
dpc-5196	68	6	to	to	ADP
dpc-5196	68	7	omalizumab	omalizumab	NOUN
dpc-5196	68	8	treatment	treatment	NOUN
dpc-5196	68	9	ranged	range	VERB
dpc-5196	68	10	from	from	ADP
dpc-5196	68	11	1	1	NUM
dpc-5196	68	12	to	to	ADP
dpc-5196	68	13	39	39	NUM
dpc-5196	68	14	months	month	NOUN
dpc-5196	68	15	,	,	PUNCT
dpc-5196	68	16	with	with	ADP
dpc-5196	68	17	a	a	DET
dpc-5196	68	18	median	median	NOUN
dpc-5196	68	19	of	of	ADP
dpc-5196	68	20	6.09	6.09	NUM
dpc-5196	68	21	months	month	NOUN
dpc-5196	68	22	.	.	PUNCT
dpc-5196	69	1	a	a	DET
dpc-5196	69	2	history	history	NOUN
dpc-5196	69	3	of	of	ADP
dpc-5196	69	4	angioedema	angioedema	NOUN
dpc-5196	69	5	was	be	AUX
dpc-5196	69	6	present	present	ADJ
dpc-5196	69	7	in	in	ADP
dpc-5196	69	8	49.5	49.5	NUM
dpc-5196	69	9	%	%	NOUN
dpc-5196	69	10	(	(	PUNCT
dpc-5196	69	11	n=99	n=99	ADJ
dpc-5196	69	12	)	)	PUNCT
dpc-5196	69	13	of	of	ADP
dpc-5196	69	14	the	the	DET
dpc-5196	69	15	patients	patient	NOUN
dpc-5196	69	16	.	.	PUNCT
dpc-5196	70	1	at	at	ADP
dpc-5196	70	2	baseline	baseline	NOUN
dpc-5196	70	3	and	and	CCONJ
dpc-5196	70	4	week	week	NOUN
dpc-5196	70	5	4	4	NUM
dpc-5196	70	6	uas7	uas7	PROPN
dpc-5196	70	7	scores	score	NOUN
dpc-5196	70	8	of	of	ADP
dpc-5196	70	9	the	the	DET
dpc-5196	70	10	patients	patient	NOUN
dpc-5196	70	11	were	be	AUX
dpc-5196	70	12	available	available	ADJ
dpc-5196	70	13	for	for	ADP
dpc-5196	70	14	154	154	NUM
dpc-5196	70	15	and	and	CCONJ
dpc-5196	70	16	151	151	NUM
dpc-5196	70	17	patients	patient	NOUN
dpc-5196	70	18	,	,	PUNCT
dpc-5196	70	19	respectively	respectively	ADV
dpc-5196	70	20	.	.	PUNCT
dpc-5196	71	1	the	the	DET
dpc-5196	71	2	mean	mean	ADJ
dpc-5196	71	3	baseline	baseline	PROPN
dpc-5196	71	4	uas7	uas7	PROPN
dpc-5196	71	5	score	score	NOUN
dpc-5196	71	6	was	be	AUX
dpc-5196	71	7	37.45	37.45	NUM
dpc-5196	71	8	,	,	PUNCT
dpc-5196	71	9	and	and	CCONJ
dpc-5196	71	10	the	the	DET
dpc-5196	71	11	mean	mean	ADJ
dpc-5196	71	12	week	week	NOUN
dpc-5196	71	13	4	4	NUM
dpc-5196	71	14	uas7	uas7	NOUN
dpc-5196	71	15	score	score	NOUN
dpc-5196	71	16	was	be	AUX
dpc-5196	71	17	7.79	7.79	NUM
dpc-5196	71	18	.	.	PUNCT
dpc-5196	72	1	there	there	PRON
dpc-5196	72	2	was	be	VERB
dpc-5196	72	3	a	a	DET
dpc-5196	72	4	statistically	statistically	ADV
dpc-5196	72	5	significant	significant	ADJ
dpc-5196	72	6	decrease	decrease	NOUN
dpc-5196	72	7	in	in	ADP
dpc-5196	72	8	uas7	uas7	PROPN
dpc-5196	72	9	scores	score	NOUN
dpc-5196	72	10	at	at	ADP
dpc-5196	72	11	week	week	NOUN
dpc-5196	72	12	4	4	NUM
dpc-5196	72	13	compared	compare	VERB
dpc-5196	72	14	to	to	PART
dpc-5196	72	15	baseline	baseline	VERB
dpc-5196	72	16	(	(	PUNCT
dpc-5196	72	17	p<0.001	p<0.001	PROPN
dpc-5196	72	18	)	)	PUNCT
dpc-5196	72	19	.	.	PUNCT
dpc-5196	73	1	laboratory	laboratory	NOUN
dpc-5196	73	2	characteristics	characteristic	NOUN
dpc-5196	73	3	serum	serum	PROPN
dpc-5196	73	4	ige	ige	PROPN
dpc-5196	73	5	levels	level	NOUN
dpc-5196	73	6	at	at	ADP
dpc-5196	73	7	baseline	baseline	NOUN
dpc-5196	73	8	and	and	CCONJ
dpc-5196	73	9	week	week	NOUN
dpc-5196	73	10	4	4	NUM
dpc-5196	73	11	were	be	AUX
dpc-5196	73	12	available	available	ADJ
dpc-5196	73	13	for	for	ADP
dpc-5196	73	14	106	106	NUM
dpc-5196	73	15	and	and	CCONJ
dpc-5196	73	16	65	65	NUM
dpc-5196	73	17	patients	patient	NOUN
dpc-5196	73	18	,	,	PUNCT
dpc-5196	73	19	respectively	respectively	ADV
dpc-5196	73	20	.	.	PUNCT
dpc-5196	74	1	the	the	DET
dpc-5196	74	2	median	median	PROPN
dpc-5196	74	3	ige	ige	PROPN
dpc-5196	74	4	level	level	NOUN
dpc-5196	74	5	was	be	AUX
dpc-5196	74	6	101.50	101.50	NUM
dpc-5196	74	7	iu	iu	NOUN
dpc-5196	74	8	/	/	SYM
dpc-5196	74	9	ml	ml	X
dpc-5196	74	10	at	at	ADP
dpc-5196	74	11	baseline	baseline	NOUN
dpc-5196	74	12	and	and	CCONJ
dpc-5196	74	13	275	275	NUM
dpc-5196	74	14	iu	iu	ADV
dpc-5196	74	15	/	/	SYM
dpc-5196	74	16	ml	ml	NOUN
dpc-5196	74	17	at	at	ADP
dpc-5196	74	18	week	week	NOUN
dpc-5196	74	19	4	4	NUM
dpc-5196	74	20	.	.	PUNCT
dpc-5196	75	1	forty	forty	NUM
dpc-5196	75	2	-	-	PUNCT
dpc-5196	75	3	seven	seven	NUM
dpc-5196	75	4	patients	patient	NOUN
dpc-5196	75	5	(	(	PUNCT
dpc-5196	75	6	90.4	90.4	NUM
dpc-5196	75	7	%	%	NOUN
dpc-5196	75	8	)	)	PUNCT
dpc-5196	75	9	demonstrated	demonstrate	VERB
dpc-5196	75	10	an	an	DET
dpc-5196	75	11	increase	increase	NOUN
dpc-5196	75	12	in	in	ADP
dpc-5196	75	13	ige	ige	PROPN
dpc-5196	75	14	levels	level	NOUN
dpc-5196	75	15	at	at	ADP
dpc-5196	75	16	week	week	NOUN
dpc-5196	75	17	4	4	NUM
dpc-5196	75	18	,	,	PUNCT
dpc-5196	75	19	while	while	SCONJ
dpc-5196	75	20	five	five	NUM
dpc-5196	75	21	(	(	PUNCT
dpc-5196	75	22	9.6	9.6	NUM
dpc-5196	75	23	%	%	NOUN
dpc-5196	75	24	)	)	PUNCT
dpc-5196	75	25	showed	show	VERB
dpc-5196	75	26	a	a	DET
dpc-5196	75	27	decrease	decrease	NOUN
dpc-5196	75	28	.	.	PUNCT
dpc-5196	76	1	a	a	DET
dpc-5196	76	2	statistically	statistically	ADV
dpc-5196	76	3	significant	significant	ADJ
dpc-5196	76	4	increase	increase	NOUN
dpc-5196	76	5	in	in	ADP
dpc-5196	76	6	serum	serum	PROPN
dpc-5196	76	7	ige	ige	PROPN
dpc-5196	76	8	levels	level	NOUN
dpc-5196	76	9	was	be	AUX
dpc-5196	76	10	observed	observe	VERB
dpc-5196	76	11	from	from	ADP
dpc-5196	76	12	baseline	baseline	NOUN
dpc-5196	76	13	to	to	ADP
dpc-5196	76	14	week	week	NOUN
dpc-5196	76	15	4	4	NUM
dpc-5196	76	16	(	(	PUNCT
dpc-5196	76	17	p<0.001	p<0.001	PROPN
dpc-5196	76	18	)	)	PUNCT
dpc-5196	76	19	.	.	PUNCT
dpc-5196	77	1	blood	blood	NOUN
dpc-5196	77	2	basophil	basophil	NOUN
dpc-5196	77	3	levels	level	NOUN
dpc-5196	77	4	were	be	AUX
dpc-5196	77	5	measured	measure	VERB
dpc-5196	77	6	in	in	ADP
dpc-5196	77	7	143	143	NUM
dpc-5196	77	8	patients	patient	NOUN
dpc-5196	77	9	at	at	ADP
dpc-5196	77	10	baseline	baseline	NOUN
dpc-5196	77	11	and	and	CCONJ
dpc-5196	77	12	in	in	ADP
dpc-5196	77	13	52	52	NUM
dpc-5196	77	14	patients	patient	NOUN
dpc-5196	77	15	at	at	ADP
dpc-5196	77	16	week	week	NOUN
dpc-5196	77	17	4	4	NUM
dpc-5196	77	18	.	.	PUNCT
dpc-5196	78	1	the	the	DET
dpc-5196	78	2	mean	mean	ADJ
dpc-5196	78	3	basophil	basophil	NOUN
dpc-5196	78	4	level	level	NOUN
dpc-5196	78	5	remained	remain	VERB
dpc-5196	78	6	at	at	ADP
dpc-5196	78	7	0.03	0.03	NUM
dpc-5196	78	8	(	(	PUNCT
dpc-5196	78	9	1000/µl	1000/µl	NUM
dpc-5196	78	10	)	)	PUNCT
dpc-5196	78	11	from	from	ADP
dpc-5196	78	12	baseline	baseline	NOUN
dpc-5196	78	13	to	to	ADP
dpc-5196	78	14	week	week	NOUN
dpc-5196	78	15	4	4	NUM
dpc-5196	78	16	.	.	PUNCT
dpc-5196	78	17	basopenia	basopenia	NOUN
dpc-5196	78	18	was	be	AUX
dpc-5196	78	19	present	present	ADJ
dpc-5196	78	20	in	in	ADP
dpc-5196	78	21	20	20	NUM
dpc-5196	78	22	patients	patient	NOUN
dpc-5196	78	23	(	(	PUNCT
dpc-5196	78	24	13.9	13.9	NUM
dpc-5196	78	25	%	%	NOUN
dpc-5196	78	26	)	)	PUNCT
dpc-5196	78	27	at	at	ADP
dpc-5196	78	28	baseline	baseline	NOUN
dpc-5196	78	29	.	.	PUNCT
dpc-5196	79	1	omalizumab	omalizumab	NOUN
dpc-5196	79	2	treatment	treatment	NOUN
dpc-5196	79	3	all	all	DET
dpc-5196	79	4	patients	patient	NOUN
dpc-5196	79	5	had	have	AUX
dpc-5196	79	6	used	use	VERB
dpc-5196	79	7	ahs	ahs	NOUN
dpc-5196	79	8	prior	prior	ADV
dpc-5196	79	9	to	to	ADP
dpc-5196	79	10	starting	start	VERB
dpc-5196	79	11	omalizumab	omalizumab	NOUN
dpc-5196	79	12	.	.	PUNCT
dpc-5196	80	1	while	while	SCONJ
dpc-5196	80	2	27	27	NUM
dpc-5196	80	3	patients	patient	NOUN
dpc-5196	80	4	(	(	PUNCT
dpc-5196	80	5	13.5	13.5	NUM
dpc-5196	80	6	%	%	NOUN
dpc-5196	80	7	)	)	PUNCT
dpc-5196	80	8	had	have	AUX
dpc-5196	80	9	not	not	PART
dpc-5196	80	10	received	receive	VERB
dpc-5196	80	11	any	any	DET
dpc-5196	80	12	additional	additional	ADJ
dpc-5196	80	13	treatment	treatment	NOUN
dpc-5196	80	14	,	,	PUNCT
dpc-5196	80	15	173	173	NUM
dpc-5196	80	16	patients	patient	NOUN
dpc-5196	80	17	(	(	PUNCT
dpc-5196	80	18	86.5	86.5	NUM
dpc-5196	80	19	%	%	NOUN
dpc-5196	80	20	)	)	PUNCT
dpc-5196	80	21	continued	continue	VERB
dpc-5196	80	22	to	to	PART
dpc-5196	80	23	use	use	VERB
dpc-5196	80	24	ahs	ah	NOUN
dpc-5196	80	25	alongside	alongside	ADP
dpc-5196	80	26	omalizumab	omalizumab	NOUN
dpc-5196	80	27	treatment	treatment	NOUN
dpc-5196	80	28	.	.	PUNCT
dpc-5196	81	1	of	of	ADP
dpc-5196	81	2	these	these	PRON
dpc-5196	81	3	,	,	PUNCT
dpc-5196	81	4	125	125	NUM
dpc-5196	81	5	(	(	PUNCT
dpc-5196	81	6	62.5	62.5	NUM
dpc-5196	81	7	%	%	NOUN
dpc-5196	81	8	)	)	PUNCT
dpc-5196	81	9	adhered	adhere	VERB
dpc-5196	81	10	to	to	ADP
dpc-5196	81	11	the	the	DET
dpc-5196	81	12	treatment	treatment	NOUN
dpc-5196	81	13	regularly	regularly	ADV
dpc-5196	81	14	,	,	PUNCT
dpc-5196	81	15	with	with	ADP
dpc-5196	81	16	a	a	DET
dpc-5196	81	17	mean	mean	ADJ
dpc-5196	81	18	duration	duration	NOUN
dpc-5196	81	19	of	of	ADP
dpc-5196	81	20	4.90	4.90	NUM
dpc-5196	81	21	months	month	NOUN
dpc-5196	81	22	,	,	PUNCT
dpc-5196	81	23	while	while	SCONJ
dpc-5196	81	24	48	48	NUM
dpc-5196	81	25	patients	patient	NOUN
dpc-5196	81	26	(	(	PUNCT
dpc-5196	81	27	24	24	NUM
dpc-5196	81	28	%	%	NOUN
dpc-5196	81	29	)	)	PUNCT
dpc-5196	81	30	used	use	VERB
dpc-5196	81	31	ahs	ahs	NOUN
dpc-5196	81	32	only	only	ADV
dpc-5196	81	33	as	as	ADP
dpc-5196	81	34	needed	need	VERB
dpc-5196	81	35	(	(	PUNCT
dpc-5196	81	36	table	table	NOUN
dpc-5196	81	37	2	2	NUM
dpc-5196	81	38	)	)	PUNCT
dpc-5196	81	39	.	.	PUNCT
dpc-5196	82	1	the	the	DET
dpc-5196	82	2	total	total	ADJ
dpc-5196	82	3	duration	duration	NOUN
dpc-5196	82	4	of	of	ADP
dpc-5196	82	5	omalizumab	omalizumab	NOUN
dpc-5196	82	6	use	use	NOUN
dpc-5196	82	7	ranged	range	VERB
dpc-5196	82	8	from	from	ADP
dpc-5196	82	9	3	3	NUM
dpc-5196	82	10	to	to	ADP
dpc-5196	82	11	39	39	NUM
dpc-5196	82	12	months	month	NOUN
dpc-5196	82	13	,	,	PUNCT
dpc-5196	82	14	with	with	ADP
dpc-5196	82	15	a	a	DET
dpc-5196	82	16	mean	mean	ADJ
dpc-5196	82	17	duration	duration	NOUN
dpc-5196	82	18	of	of	ADP
dpc-5196	82	19	19.47	19.47	NUM
dpc-5196	82	20	months	month	NOUN
dpc-5196	82	21	.	.	PUNCT
dpc-5196	83	1	post	post	ADJ
dpc-5196	83	2	-	-	ADJ
dpc-5196	83	3	treatment	treatment	ADJ
dpc-5196	83	4	relapse	relapse	NOUN
dpc-5196	83	5	status	status	NOUN
dpc-5196	83	6	after	after	ADP
dpc-5196	83	7	at	at	ADV
dpc-5196	83	8	least	least	ADV
dpc-5196	83	9	three	three	NUM
dpc-5196	83	10	months	month	NOUN
dpc-5196	83	11	of	of	ADP
dpc-5196	83	12	standard	standard	ADJ
dpc-5196	83	13	omalizumab	omalizumab	NOUN
dpc-5196	83	14	treatment	treatment	NOUN
dpc-5196	83	15	,	,	PUNCT
dpc-5196	83	16	109	109	NUM
dpc-5196	83	17	patients	patient	NOUN
dpc-5196	83	18	(	(	PUNCT
dpc-5196	83	19	54.5	54.5	NUM
dpc-5196	83	20	%	%	NOUN
dpc-5196	83	21	)	)	PUNCT
dpc-5196	83	22	discontinued	discontinue	VERB
dpc-5196	83	23	omalizumab	omalizumab	NOUN
dpc-5196	83	24	treatment	treatment	NOUN
dpc-5196	83	25	directly	directly	ADV
dpc-5196	83	26	,	,	PUNCT
dpc-5196	83	27	59	59	NUM
dpc-5196	83	28	patients	patient	NOUN
dpc-5196	83	29	(	(	PUNCT
dpc-5196	83	30	29.5	29.5	NUM
dpc-5196	83	31	%	%	NOUN
dpc-5196	83	32	)	)	PUNCT
dpc-5196	83	33	extended	extend	VERB
dpc-5196	83	34	the	the	DET
dpc-5196	83	35	dose	dose	NOUN
dpc-5196	83	36	intervals	interval	NOUN
dpc-5196	83	37	to	to	ADP
dpc-5196	83	38	eight	eight	NUM
dpc-5196	83	39	weeks	week	NOUN
dpc-5196	83	40	,	,	PUNCT
dpc-5196	83	41	and	and	CCONJ
dpc-5196	83	42	32	32	NUM
dpc-5196	83	43	patients	patient	NOUN
dpc-5196	83	44	(	(	PUNCT
dpc-5196	83	45	16	16	NUM
dpc-5196	83	46	%	%	NOUN
dpc-5196	83	47	)	)	PUNCT
dpc-5196	83	48	reduced	reduce	VERB
dpc-5196	83	49	the	the	DET
dpc-5196	83	50	dose	dose	NOUN
dpc-5196	83	51	to	to	ADP
dpc-5196	83	52	150	150	NUM
dpc-5196	83	53	mg/4	mg/4	NOUN
dpc-5196	83	54	weeks	week	NOUN
dpc-5196	83	55	before	before	ADP
dpc-5196	83	56	discontinuation	discontinuation	NOUN
dpc-5196	83	57	.	.	PUNCT
dpc-5196	84	1	among	among	ADP
dpc-5196	84	2	patients	patient	NOUN
dpc-5196	84	3	who	who	PRON
dpc-5196	84	4	completed	complete	VERB
dpc-5196	84	5	treatment	treatment	NOUN
dpc-5196	84	6	,	,	PUNCT
dpc-5196	84	7	relapse	relapse	NOUN
dpc-5196	84	8	was	be	AUX
dpc-5196	84	9	observed	observe	VERB
dpc-5196	84	10	in	in	ADP
dpc-5196	84	11	100	100	NUM
dpc-5196	84	12	patients	patient	NOUN
dpc-5196	84	13	(	(	PUNCT
dpc-5196	84	14	50	50	NUM
dpc-5196	84	15	%	%	NOUN
dpc-5196	84	16	)	)	PUNCT
dpc-5196	84	17	,	,	PUNCT
dpc-5196	84	18	with	with	ADP
dpc-5196	84	19	a	a	DET
dpc-5196	84	20	median	median	ADJ
dpc-5196	84	21	time	time	NOUN
dpc-5196	84	22	to	to	PART
dpc-5196	84	23	relapse	relapse	VERB
dpc-5196	84	24	of	of	ADP
dpc-5196	84	25	four	four	NUM
dpc-5196	84	26	months	month	NOUN
dpc-5196	84	27	(	(	PUNCT
dpc-5196	84	28	range	range	NOUN
dpc-5196	84	29	:	:	PUNCT
dpc-5196	84	30	1–40	1–40	NUM
dpc-5196	84	31	)	)	PUNCT
dpc-5196	84	32	.	.	PUNCT
dpc-5196	85	1	the	the	DET
dpc-5196	85	2	most	most	ADV
dpc-5196	85	3	common	common	ADJ
dpc-5196	85	4	relapse	relapse	NOUN
dpc-5196	85	5	occurred	occur	VERB
dpc-5196	85	6	in	in	ADP
dpc-5196	85	7	the	the	DET
dpc-5196	85	8	third	third	ADJ
dpc-5196	85	9	month	month	NOUN
dpc-5196	85	10	,	,	PUNCT
dpc-5196	85	11	affecting	affect	VERB
dpc-5196	85	12	27	27	NUM
dpc-5196	85	13	%	%	NOUN
dpc-5196	85	14	(	(	PUNCT
dpc-5196	85	15	n=	n=	ADJ
dpc-5196	85	16	7	7	NUM
dpc-5196	85	17	)	)	PUNCT
dpc-5196	85	18	of	of	ADP
dpc-5196	85	19	the	the	DET
dpc-5196	85	20	patients	patient	NOUN
dpc-5196	85	21	,	,	PUNCT
dpc-5196	85	22	and	and	CCONJ
dpc-5196	85	23	49	49	NUM
dpc-5196	85	24	%	%	NOUN
dpc-5196	85	25	(	(	PUNCT
dpc-5196	85	26	n=49	n=49	NUM
dpc-5196	85	27	)	)	PUNCT
dpc-5196	85	28	of	of	ADP
dpc-5196	85	29	patients	patient	NOUN
dpc-5196	85	30	experienced	experience	VERB
dpc-5196	85	31	a	a	DET
dpc-5196	85	32	relapse	relapse	NOUN
dpc-5196	85	33	within	within	ADP
dpc-5196	85	34	the	the	DET
dpc-5196	85	35	first	first	ADJ
dpc-5196	85	36	three	three	NUM
dpc-5196	85	37	months	month	NOUN
dpc-5196	85	38	of	of	ADP
dpc-5196	85	39	treatment	treatment	NOUN
dpc-5196	85	40	(	(	PUNCT
dpc-5196	85	41	table	table	NOUN
dpc-5196	85	42	2	2	NUM
dpc-5196	85	43	)	)	PUNCT
dpc-5196	85	44	.	.	PUNCT
dpc-5196	86	1	among	among	ADP
dpc-5196	86	2	those	those	PRON
dpc-5196	86	3	who	who	PRON
dpc-5196	86	4	discontinued	discontinue	VERB
dpc-5196	86	5	omalizumab	omalizumab	NOUN
dpc-5196	86	6	directly	directly	ADV
dpc-5196	86	7	,	,	PUNCT
dpc-5196	86	8	relapse	relapse	NOUN
dpc-5196	86	9	was	be	AUX
dpc-5196	86	10	observed	observe	VERB
dpc-5196	86	11	in	in	ADP
dpc-5196	86	12	65.1	65.1	NUM
dpc-5196	86	13	%	%	NOUN
dpc-5196	86	14	(	(	PUNCT
dpc-5196	86	15	n=71	n=71	NOUN
dpc-5196	86	16	)	)	PUNCT
dpc-5196	86	17	of	of	ADP
dpc-5196	86	18	cases	case	NOUN
dpc-5196	86	19	,	,	PUNCT
dpc-5196	86	20	while	while	SCONJ
dpc-5196	86	21	among	among	ADP
dpc-5196	86	22	those	those	PRON
dpc-5196	86	23	who	who	PRON
dpc-5196	86	24	extended	extend	VERB
dpc-5196	86	25	the	the	DET
dpc-5196	86	26	dose	dose	NOUN
dpc-5196	86	27	intervals	interval	NOUN
dpc-5196	86	28	,	,	PUNCT
dpc-5196	86	29	relapse	relapse	NOUN
dpc-5196	86	30	was	be	AUX
dpc-5196	86	31	observed	observe	VERB
dpc-5196	86	32	in	in	ADP
dpc-5196	86	33	40.7	40.7	NUM
dpc-5196	86	34	%	%	NOUN
dpc-5196	86	35	(	(	PUNCT
dpc-5196	86	36	n=24	n=24	PROPN
dpc-5196	86	37	)	)	PUNCT
dpc-5196	86	38	of	of	ADP
dpc-5196	86	39	cases	case	NOUN
dpc-5196	86	40	.	.	PUNCT
dpc-5196	87	1	among	among	ADP
dpc-5196	87	2	those	those	PRON
dpc-5196	87	3	who	who	PRON
dpc-5196	87	4	reduced	reduce	VERB
dpc-5196	87	5	the	the	DET
dpc-5196	87	6	dose	dose	NOUN
dpc-5196	87	7	prior	prior	ADV
dpc-5196	87	8	to	to	ADP
dpc-5196	87	9	discontinuation	discontinuation	NOUN
dpc-5196	87	10	,	,	PUNCT
dpc-5196	87	11	relapse	relapse	NOUN
dpc-5196	87	12	was	be	AUX
dpc-5196	87	13	observed	observe	VERB
dpc-5196	87	14	in	in	ADP
dpc-5196	87	15	15.6	15.6	NUM
dpc-5196	87	16	%	%	NOUN
dpc-5196	87	17	(	(	PUNCT
dpc-5196	87	18	n=5	n=5	PROPN
dpc-5196	87	19	)	)	PUNCT
dpc-5196	87	20	of	of	ADP
dpc-5196	87	21	cases	case	NOUN
dpc-5196	87	22	.	.	PUNCT
dpc-5196	88	1	there	there	PRON
dpc-5196	88	2	was	be	VERB
dpc-5196	88	3	a	a	DET
dpc-5196	88	4	statistically	statistically	ADV
dpc-5196	88	5	significant	significant	ADJ
dpc-5196	88	6	difference	difference	NOUN
dpc-5196	88	7	in	in	ADP
dpc-5196	88	8	post	post	ADJ
dpc-5196	88	9	-	-	ADJ
dpc-5196	88	10	treatment	treatment	ADJ
dpc-5196	88	11	relapse	relapse	NOUN
dpc-5196	88	12	rates	rate	NOUN
dpc-5196	88	13	according	accord	VERB
dpc-5196	88	14	to	to	ADP
dpc-5196	88	15	the	the	DET
dpc-5196	88	16	method	method	NOUN
dpc-5196	88	17	of	of	ADP
dpc-5196	88	18	treatment	treatment	NOUN
dpc-5196	88	19	discontinuation	discontinuation	NOUN
dpc-5196	88	20	(	(	PUNCT
dpc-5196	88	21	p<0.001	p<0.001	X
dpc-5196	88	22	)	)	PUNCT
dpc-5196	88	23	(	(	PUNCT
dpc-5196	88	24	table	table	NOUN
dpc-5196	88	25	3	3	NUM
dpc-5196	88	26	,	,	PUNCT
dpc-5196	88	27	figure	figure	NOUN
dpc-5196	88	28	1	1	NUM
dpc-5196	88	29	)	)	PUNCT
dpc-5196	88	30	.	.	PUNCT
dpc-5196	89	1	in	in	ADP
dpc-5196	89	2	patients	patient	NOUN
dpc-5196	89	3	who	who	PRON
dpc-5196	89	4	discontinued	discontinue	VERB
dpc-5196	89	5	omalizumab	omalizumab	NOUN
dpc-5196	89	6	directly	directly	ADV
dpc-5196	89	7	,	,	PUNCT
dpc-5196	89	8	relapse	relapse	NOUN
dpc-5196	89	9	occurred	occur	VERB
dpc-5196	89	10	after	after	ADP
dpc-5196	89	11	an	an	DET
dpc-5196	89	12	average	average	NOUN
dpc-5196	89	13	of	of	ADP
dpc-5196	89	14	6.77	6.77	NUM
dpc-5196	89	15	months	month	NOUN
dpc-5196	89	16	.	.	PUNCT
dpc-5196	90	1	for	for	ADP
dpc-5196	90	2	those	those	PRON
dpc-5196	90	3	who	who	PRON
dpc-5196	90	4	discontinued	discontinue	VERB
dpc-5196	90	5	treatment	treatment	NOUN
dpc-5196	90	6	by	by	ADP
dpc-5196	90	7	extending	extend	VERB
dpc-5196	90	8	the	the	DET
dpc-5196	90	9	dose	dose	NOUN
dpc-5196	90	10	intervals	interval	NOUN
dpc-5196	90	11	,	,	PUNCT
dpc-5196	90	12	the	the	DET
dpc-5196	90	13	mean	mean	ADJ
dpc-5196	90	14	time	time	NOUN
dpc-5196	90	15	to	to	PART
dpc-5196	90	16	relapse	relapse	VERB
dpc-5196	90	17	was	be	AUX
dpc-5196	90	18	6.71	6.71	NUM
dpc-5196	90	19	months	month	NOUN
dpc-5196	90	20	,	,	PUNCT
dpc-5196	90	21	while	while	SCONJ
dpc-5196	90	22	in	in	ADP
dpc-5196	90	23	patients	patient	NOUN
dpc-5196	90	24	who	who	PRON
dpc-5196	90	25	reduced	reduce	VERB
dpc-5196	90	26	the	the	DET
dpc-5196	90	27	dose	dose	NOUN
dpc-5196	90	28	before	before	ADP
dpc-5196	90	29	discontinuation	discontinuation	NOUN
dpc-5196	90	30	,	,	PUNCT
dpc-5196	90	31	it	it	PRON
dpc-5196	90	32	was	be	AUX
dpc-5196	90	33	4.8	4.8	NUM
dpc-5196	90	34	months	month	NOUN
dpc-5196	90	35	.	.	PUNCT
dpc-5196	91	1	no	no	DET
dpc-5196	91	2	statistically	statistically	ADV
dpc-5196	91	3	significant	significant	ADJ
dpc-5196	91	4	difference	difference	NOUN
dpc-5196	91	5	was	be	AUX
dpc-5196	91	6	observed	observe	VERB
dpc-5196	91	7	between	between	ADP
dpc-5196	91	8	the	the	DET
dpc-5196	91	9	groups	group	NOUN
dpc-5196	91	10	in	in	ADP
dpc-5196	91	11	the	the	DET
dpc-5196	91	12	time	time	NOUN
dpc-5196	91	13	to	to	PART
dpc-5196	91	14	relapse	relapse	VERB
dpc-5196	91	15	based	base	VERB
dpc-5196	91	16	on	on	ADP
dpc-5196	91	17	the	the	DET
dpc-5196	91	18	method	method	NOUN
dpc-5196	91	19	of	of	ADP
dpc-5196	91	20	discontinuation	discontinuation	NOUN
dpc-5196	91	21	(	(	PUNCT
dpc-5196	91	22	p=0.841	p=0.841	NOUN
dpc-5196	91	23	)	)	PUNCT
dpc-5196	91	24	.	.	PUNCT
dpc-5196	92	1	in	in	ADP
dpc-5196	92	2	addition	addition	NOUN
dpc-5196	92	3	to	to	ADP
dpc-5196	92	4	the	the	DET
dpc-5196	92	5	method	method	NOUN
dpc-5196	92	6	of	of	ADP
dpc-5196	92	7	discontinuation	discontinuation	NOUN
dpc-5196	92	8	of	of	ADP
dpc-5196	92	9	omalizumab	omalizumab	NOUN
dpc-5196	92	10	treatment	treatment	NOUN
dpc-5196	92	11	,	,	PUNCT
dpc-5196	92	12	the	the	DET
dpc-5196	92	13	impact	impact	NOUN
dpc-5196	92	14	of	of	ADP
dpc-5196	92	15	other	other	ADJ
dpc-5196	92	16	demographic	demographic	ADJ
dpc-5196	92	17	and	and	CCONJ
dpc-5196	92	18	clinical	clinical	ADJ
dpc-5196	92	19	characteristics	characteristic	NOUN
dpc-5196	92	20	of	of	ADP
dpc-5196	92	21	patients	patient	NOUN
dpc-5196	92	22	with	with	ADP
dpc-5196	92	23	cu	cu	PROPN
dpc-5196	92	24	on	on	ADP
dpc-5196	92	25	relapse	relapse	NOUN
dpc-5196	92	26	rates	rate	NOUN
dpc-5196	92	27	was	be	AUX
dpc-5196	92	28	evaluated	evaluate	VERB
dpc-5196	92	29	(	(	PUNCT
dpc-5196	92	30	table	table	NOUN
dpc-5196	92	31	4	4	NUM
dpc-5196	92	32	)	)	PUNCT
dpc-5196	92	33	.	.	PUNCT
dpc-5196	93	1	the	the	DET
dpc-5196	93	2	total	total	ADJ
dpc-5196	93	3	disease	disease	NOUN
dpc-5196	93	4	duration	duration	NOUN
dpc-5196	93	5	before	before	ADP
dpc-5196	93	6	omalizumab	omalizumab	NOUN
dpc-5196	93	7	treatment	treatment	NOUN
dpc-5196	93	8	was	be	AUX
dpc-5196	93	9	7.67	7.67	NUM
dpc-5196	93	10	months	month	NOUN
dpc-5196	93	11	in	in	ADP
dpc-5196	93	12	patients	patient	NOUN
dpc-5196	93	13	with	with	ADP
dpc-5196	93	14	relapses	relapse	NOUN
dpc-5196	93	15	,	,	PUNCT
dpc-5196	93	16	while	while	SCONJ
dpc-5196	93	17	it	it	PRON
dpc-5196	93	18	was	be	AUX
dpc-5196	93	19	4.51	4.51	NUM
dpc-5196	93	20	months	month	NOUN
dpc-5196	93	21	in	in	ADP
dpc-5196	93	22	patients	patient	NOUN
dpc-5196	93	23	without	without	ADP
dpc-5196	93	24	relapses	relapse	NOUN
dpc-5196	93	25	.	.	PUNCT
dpc-5196	94	1	the	the	DET
dpc-5196	94	2	pre	pre	ADJ
dpc-5196	94	3	-	-	ADJ
dpc-5196	94	4	treatment	treatment	ADJ
dpc-5196	94	5	disease	disease	NOUN
dpc-5196	94	6	duration	duration	NOUN
dpc-5196	94	7	was	be	AUX
dpc-5196	94	8	significantly	significantly	ADV
dpc-5196	94	9	longer	long	ADJ
dpc-5196	94	10	in	in	ADP
dpc-5196	94	11	the	the	DET
dpc-5196	94	12	relapse	relapse	NOUN
dpc-5196	94	13	group	group	NOUN
dpc-5196	94	14	(	(	PUNCT
dpc-5196	94	15	p<0.001	p<0.001	PROPN
dpc-5196	94	16	)	)	PUNCT
dpc-5196	94	17	.	.	PUNCT
dpc-5196	95	1	patients	patient	NOUN
dpc-5196	95	2	who	who	PRON
dpc-5196	95	3	discontinued	discontinue	VERB
dpc-5196	95	4	ahs	ah	NOUN
dpc-5196	95	5	within	within	ADP
dpc-5196	95	6	the	the	DET
dpc-5196	95	7	first	first	ADJ
dpc-5196	95	8	three	three	NUM
dpc-5196	95	9	months	month	NOUN
dpc-5196	95	10	of	of	ADP
dpc-5196	95	11	omalizumab	omalizumab	NOUN
dpc-5196	95	12	treatment	treatment	NOUN
dpc-5196	95	13	had	have	VERB
dpc-5196	95	14	a	a	DET
dpc-5196	95	15	significantly	significantly	ADV
dpc-5196	95	16	lower	low	ADJ
dpc-5196	95	17	relapse	relapse	NOUN
dpc-5196	95	18	rate	rate	NOUN
dpc-5196	95	19	than	than	SCONJ
dpc-5196	95	20	did	do	VERB
dpc-5196	95	21	those	those	PRON
dpc-5196	95	22	who	who	PRON
dpc-5196	95	23	continued	continue	VERB
dpc-5196	95	24	ahs	ah	NOUN
dpc-5196	95	25	for	for	ADP
dpc-5196	95	26	a	a	DET
dpc-5196	95	27	longer	long	ADJ
dpc-5196	95	28	duration	duration	NOUN
dpc-5196	95	29	(	(	PUNCT
dpc-5196	95	30	p=0.005	p=0.005	NOUN
dpc-5196	95	31	)	)	PUNCT
dpc-5196	95	32	.	.	PUNCT
dpc-5196	96	1	the	the	DET
dpc-5196	96	2	mean	mean	ADJ
dpc-5196	96	3	baseline	baseline	PROPN
dpc-5196	96	4	uas7	uas7	PROPN
dpc-5196	96	5	score	score	NOUN
dpc-5196	96	6	was	be	AUX
dpc-5196	96	7	39.21	39.21	NUM
dpc-5196	96	8	for	for	ADP
dpc-5196	96	9	patients	patient	NOUN
dpc-5196	96	10	who	who	PRON
dpc-5196	96	11	experienced	experience	VERB
dpc-5196	96	12	a	a	DET
dpc-5196	96	13	relapse	relapse	NOUN
dpc-5196	96	14	(	(	PUNCT
dpc-5196	96	15	n=78	n=78	NOUN
dpc-5196	96	16	)	)	PUNCT
dpc-5196	96	17	compared	compare	VERB
dpc-5196	96	18	to	to	ADP
dpc-5196	96	19	35.64	35.64	NUM
dpc-5196	96	20	for	for	ADP
dpc-5196	96	21	those	those	PRON
dpc-5196	96	22	who	who	PRON
dpc-5196	96	23	did	do	VERB
dpc-5196	96	24	not	not	PART
dpc-5196	96	25	(	(	PUNCT
dpc-5196	96	26	n=76	n=76	NOUN
dpc-5196	96	27	)	)	PUNCT
dpc-5196	96	28	.	.	PUNCT
dpc-5196	97	1	a	a	DET
dpc-5196	97	2	significantly	significantly	ADV
dpc-5196	97	3	higher	high	ADJ
dpc-5196	97	4	relapse	relapse	NOUN
dpc-5196	97	5	rate	rate	NOUN
dpc-5196	97	6	was	be	AUX
dpc-5196	97	7	observed	observe	VERB
dpc-5196	97	8	in	in	ADP
dpc-5196	97	9	patients	patient	NOUN
dpc-5196	97	10	with	with	ADP
dpc-5196	97	11	higher	high	ADJ
dpc-5196	97	12	baseline	baseline	NOUN
dpc-5196	97	13	uas7	uas7	PROPN
dpc-5196	97	14	scores	score	NOUN
dpc-5196	97	15	(	(	PUNCT
dpc-5196	97	16	p=0.004	p=0.004	NOUN
dpc-5196	97	17	)	)	PUNCT
dpc-5196	97	18	.	.	PUNCT
dpc-5196	98	1	subgroup	subgroup	NOUN
dpc-5196	98	2	analysis	analysis	NOUN
dpc-5196	98	3	based	base	VERB
dpc-5196	98	4	on	on	ADP
dpc-5196	98	5	age	age	NOUN
dpc-5196	98	6	,	,	PUNCT
dpc-5196	98	7	sex	sex	NOUN
dpc-5196	98	8	,	,	PUNCT
dpc-5196	98	9	coexisting	coexist	VERB
dpc-5196	98	10	angioedema	angioedema	ADV
dpc-5196	98	11	,	,	PUNCT
dpc-5196	98	12	hypothyroidism	hypothyroidism	NOUN
dpc-5196	98	13	,	,	PUNCT
dpc-5196	98	14	basopenia	basopenia	NOUN
dpc-5196	98	15	,	,	PUNCT
dpc-5196	98	16	previous	previous	ADJ
dpc-5196	98	17	treatments	treatment	NOUN
dpc-5196	98	18	,	,	PUNCT
dpc-5196	98	19	treatment	treatment	NOUN
dpc-5196	98	20	response	response	NOUN
dpc-5196	98	21	time	time	NOUN
dpc-5196	98	22	,	,	PUNCT
dpc-5196	98	23	baseline	baseline	VERB
dpc-5196	98	24	serum	serum	PROPN
dpc-5196	98	25	ige	ige	PROPN
dpc-5196	98	26	level	level	NOUN
dpc-5196	98	27	,	,	PUNCT
dpc-5196	98	28	reduction	reduction	NOUN
dpc-5196	98	29	in	in	ADP
dpc-5196	98	30	uas7	uas7	PROPN
dpc-5196	98	31	score	score	NOUN
dpc-5196	98	32	,	,	PUNCT
dpc-5196	98	33	and	and	CCONJ
dpc-5196	98	34	increase	increase	VERB
dpc-5196	98	35	in	in	ADP
dpc-5196	98	36	serum	serum	NOUN
dpc-5196	98	37	ige	ige	PROPN
dpc-5196	98	38	level	level	NOUN
dpc-5196	98	39	at	at	ADP
dpc-5196	98	40	week	week	NOUN
dpc-5196	98	41	4	4	NUM
dpc-5196	98	42	of	of	ADP
dpc-5196	98	43	therapy	therapy	NOUN
dpc-5196	98	44	did	do	AUX
dpc-5196	98	45	not	not	PART
dpc-5196	98	46	reveal	reveal	VERB
dpc-5196	98	47	a	a	DET
dpc-5196	98	48	statistically	statistically	ADV
dpc-5196	98	49	significant	significant	ADJ
dpc-5196	98	50	difference	difference	NOUN
dpc-5196	98	51	in	in	ADP
dpc-5196	98	52	terms	term	NOUN
dpc-5196	98	53	of	of	ADP
dpc-5196	98	54	post	post	ADJ
dpc-5196	98	55	-	-	ADJ
dpc-5196	98	56	treatment	treatment	ADJ
dpc-5196	98	57	relapse	relapse	NOUN
dpc-5196	98	58	rates	rate	NOUN
dpc-5196	98	59	.	.	PUNCT
dpc-5196	99	1	after	after	ADP
dpc-5196	99	2	experiencing	experience	VERB
dpc-5196	99	3	a	a	DET
dpc-5196	99	4	post	post	NOUN
dpc-5196	99	5	treatment	treatment	NOUN
dpc-5196	99	6	relapse	relapse	NOUN
dpc-5196	99	7	,	,	PUNCT
dpc-5196	99	8	10	10	NUM
dpc-5196	99	9	patients	patient	NOUN
dpc-5196	99	10	(	(	PUNCT
dpc-5196	99	11	10	10	NUM
dpc-5196	99	12	%	%	NOUN
dpc-5196	99	13	)	)	PUNCT
dpc-5196	99	14	achieved	achieve	VERB
dpc-5196	99	15	adequate	adequate	ADJ
dpc-5196	99	16	symptom	symptom	NOUN
dpc-5196	99	17	control	control	NOUN
dpc-5196	99	18	with	with	ADP
dpc-5196	99	19	ah	ah	INTJ
dpc-5196	99	20	treatment	treatment	NOUN
dpc-5196	99	21	,	,	PUNCT
dpc-5196	99	22	while	while	SCONJ
dpc-5196	99	23	90	90	NUM
dpc-5196	99	24	patients	patient	NOUN
dpc-5196	99	25	(	(	PUNCT
dpc-5196	99	26	90	90	NUM
dpc-5196	99	27	%	%	NOUN
dpc-5196	99	28	)	)	PUNCT
dpc-5196	99	29	reinitiated	reinitiate	VERB
dpc-5196	99	30	omalizumab	omalizumab	NOUN
dpc-5196	99	31	therapy	therapy	NOUN
dpc-5196	99	32	.	.	PUNCT
dpc-5196	100	1	discussion	discussion	NOUN
dpc-5196	100	2	this	this	DET
dpc-5196	100	3	study	study	NOUN
dpc-5196	100	4	showed	show	VERB
dpc-5196	100	5	that	that	SCONJ
dpc-5196	100	6	the	the	DET
dpc-5196	100	7	method	method	NOUN
dpc-5196	100	8	of	of	ADP
dpc-5196	100	9	discontinuation	discontinuation	NOUN
dpc-5196	100	10	of	of	ADP
dpc-5196	100	11	omalizumab	omalizumab	NOUN
dpc-5196	100	12	significantly	significantly	ADV
dpc-5196	100	13	impacts	impact	VERB
dpc-5196	100	14	the	the	DET
dpc-5196	100	15	rate	rate	NOUN
dpc-5196	100	16	of	of	ADP
dpc-5196	100	17	post	post	ADJ
dpc-5196	100	18	-	-	ADJ
dpc-5196	100	19	treatment	treatment	NOUN
dpc-5196	100	20	relapses	relapse	NOUN
dpc-5196	100	21	.	.	PUNCT
dpc-5196	101	1	to	to	ADP
dpc-5196	101	2	our	our	PRON
dpc-5196	101	3	knowledge	knowledge	NOUN
dpc-5196	101	4	,	,	PUNCT
dpc-5196	101	5	this	this	PRON
dpc-5196	101	6	is	be	AUX
dpc-5196	101	7	the	the	DET
dpc-5196	101	8	first	first	ADJ
dpc-5196	101	9	study	study	NOUN
dpc-5196	101	10	to	to	PART
dpc-5196	101	11	compare	compare	VERB
dpc-5196	101	12	three	three	NUM
dpc-5196	101	13	different	different	ADJ
dpc-5196	101	14	methods	method	NOUN
dpc-5196	101	15	of	of	ADP
dpc-5196	101	16	treatment	treatment	NOUN
dpc-5196	101	17	discontinuation	discontinuation	NOUN
dpc-5196	101	18	in	in	ADP
dpc-5196	101	19	terms	term	NOUN
dpc-5196	101	20	of	of	ADP
dpc-5196	101	21	relapse	relapse	NOUN
dpc-5196	101	22	rates	rate	NOUN
dpc-5196	101	23	.	.	PUNCT
dpc-5196	102	1	our	our	PRON
dpc-5196	102	2	results	result	NOUN
dpc-5196	102	3	suggest	suggest	VERB
dpc-5196	102	4	that	that	SCONJ
dpc-5196	102	5	reducing	reduce	VERB
dpc-5196	102	6	the	the	DET
dpc-5196	102	7	dose	dose	NOUN
dpc-5196	102	8	or	or	CCONJ
dpc-5196	102	9	gradually	gradually	ADV
dpc-5196	102	10	increasing	increase	VERB
dpc-5196	102	11	the	the	DET
dpc-5196	102	12	intervals	interval	NOUN
dpc-5196	102	13	between	between	ADP
dpc-5196	102	14	doses	dose	NOUN
dpc-5196	102	15	,	,	PUNCT
dpc-5196	102	16	as	as	SCONJ
dpc-5196	102	17	opposed	oppose	VERB
dpc-5196	102	18	to	to	ADP
dpc-5196	102	19	direct	direct	ADJ
dpc-5196	102	20	discontinuation	discontinuation	NOUN
dpc-5196	102	21	,	,	PUNCT
dpc-5196	102	22	leads	lead	VERB
dpc-5196	102	23	to	to	ADP
dpc-5196	102	24	reduced	reduced	ADJ
dpc-5196	102	25	relapse	relapse	NOUN
dpc-5196	102	26	rates	rate	NOUN
dpc-5196	102	27	after	after	ADP
dpc-5196	102	28	omalizumab	omalizumab	NOUN
dpc-5196	102	29	treatment	treatment	NOUN
dpc-5196	102	30	.	.	PUNCT
dpc-5196	103	1	the	the	DET
dpc-5196	103	2	female	female	NOUN
dpc-5196	103	3	-	-	PUNCT
dpc-5196	103	4	to	to	ADP
dpc-5196	103	5	-	-	PUNCT
dpc-5196	103	6	male	male	NOUN
dpc-5196	103	7	ratio	ratio	NOUN
dpc-5196	103	8	for	for	ADP
dpc-5196	103	9	csu	csu	PROPN
dpc-5196	103	10	reported	report	VERB
dpc-5196	103	11	in	in	ADP
dpc-5196	103	12	the	the	DET
dpc-5196	103	13	literature	literature	NOUN
dpc-5196	103	14	is	be	AUX
dpc-5196	103	15	consistent	consistent	ADJ
dpc-5196	103	16	with	with	ADP
dpc-5196	103	17	our	our	PRON
dpc-5196	103	18	study	study	NOUN
dpc-5196	103	19	findings	finding	NOUN
dpc-5196	103	20	[	[	X
dpc-5196	103	21	9	9	NUM
dpc-5196	103	22	]	]	PUNCT
dpc-5196	103	23	.	.	PUNCT
dpc-5196	104	1	a	a	DET
dpc-5196	104	2	previous	previous	ADJ
dpc-5196	104	3	study	study	NOUN
dpc-5196	104	4	reported	report	VERB
dpc-5196	104	5	that	that	SCONJ
dpc-5196	104	6	the	the	DET
dpc-5196	104	7	prevalence	prevalence	NOUN
dpc-5196	104	8	of	of	ADP
dpc-5196	104	9	csu	csu	PROPN
dpc-5196	104	10	was	be	AUX
dpc-5196	104	11	lowest	low	ADJ
dpc-5196	104	12	in	in	ADP
dpc-5196	104	13	patients	patient	NOUN
dpc-5196	104	14	aged	age	VERB
dpc-5196	104	15	18	18	NUM
dpc-5196	104	16	-	-	SYM
dpc-5196	104	17	24	24	NUM
dpc-5196	104	18	years	year	NOUN
dpc-5196	104	19	,	,	PUNCT
dpc-5196	104	20	while	while	SCONJ
dpc-5196	104	21	the	the	DET
dpc-5196	104	22	disease	disease	NOUN
dpc-5196	104	23	was	be	AUX
dpc-5196	104	24	most	most	ADV
dpc-5196	104	25	commonly	commonly	ADV
dpc-5196	104	26	observed	observe	VERB
dpc-5196	104	27	in	in	ADP
dpc-5196	104	28	the	the	DET
dpc-5196	104	29	45	45	NUM
dpc-5196	104	30	-	-	SYM
dpc-5196	104	31	54	54	NUM
dpc-5196	104	32	age	age	NOUN
dpc-5196	104	33	group	group	NOUN
dpc-5196	105	1	[	[	X
dpc-5196	105	2	10	10	NUM
dpc-5196	105	3	]	]	PUNCT
dpc-5196	105	4	.	.	PUNCT
dpc-5196	106	1	the	the	DET
dpc-5196	106	2	mean	mean	ADJ
dpc-5196	106	3	age	age	NOUN
dpc-5196	106	4	4	4	NUM
dpc-5196	106	5	original	original	ADJ
dpc-5196	106	6	article	article	NOUN
dpc-5196	106	7	|	|	ADV
dpc-5196	106	8	dermatol	dermatol	ADJ
dpc-5196	106	9	pract	pract	NOUN
dpc-5196	106	10	concept	concept	NOUN
dpc-5196	106	11	.	.	PUNCT
dpc-5196	107	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	107	2	table	table	NOUN
dpc-5196	107	3	1	1	NUM
dpc-5196	107	4	.	.	PUNCT
dpc-5196	108	1	the	the	DET
dpc-5196	108	2	demographic	demographic	ADJ
dpc-5196	108	3	,	,	PUNCT
dpc-5196	108	4	clinical	clinical	ADJ
dpc-5196	108	5	,	,	PUNCT
dpc-5196	108	6	and	and	CCONJ
dpc-5196	108	7	laboratory	laboratory	NOUN
dpc-5196	108	8	characteristics	characteristic	NOUN
dpc-5196	108	9	of	of	ADP
dpc-5196	108	10	the	the	DET
dpc-5196	108	11	patients	patient	NOUN
dpc-5196	108	12	.	.	PUNCT
dpc-5196	109	1	characteristics	characteristic	NOUN
dpc-5196	109	2	n	n	NOUN
dpc-5196	109	3	=	=	NUM
dpc-5196	109	4	200	200	NUM
dpc-5196	109	5	sex	sex	NOUN
dpc-5196	109	6	,	,	PUNCT
dpc-5196	109	7	n	n	CCONJ
dpc-5196	109	8	(	(	PUNCT
dpc-5196	109	9	%	%	INTJ
dpc-5196	109	10	)	)	PUNCT
dpc-5196	109	11	female	female	ADJ
dpc-5196	109	12	male	male	NOUN
dpc-5196	109	13	132	132	NUM
dpc-5196	109	14	(	(	PUNCT
dpc-5196	109	15	66	66	NUM
dpc-5196	109	16	)	)	PUNCT
dpc-5196	109	17	68	68	NUM
dpc-5196	109	18	(	(	PUNCT
dpc-5196	109	19	34	34	NUM
dpc-5196	109	20	)	)	PUNCT
dpc-5196	109	21	age	age	NOUN
dpc-5196	109	22	,	,	PUNCT
dpc-5196	109	23	years	year	NOUN
dpc-5196	109	24	mean	mean	VERB
dpc-5196	109	25	±	±	NUM
dpc-5196	109	26	sd	sd	NOUN
dpc-5196	109	27	(	(	PUNCT
dpc-5196	109	28	range	range	NOUN
dpc-5196	109	29	)	)	PUNCT
dpc-5196	109	30	45.86	45.86	NUM
dpc-5196	109	31	±	±	NUM
dpc-5196	109	32	14.97	14.97	NUM
dpc-5196	109	33	(	(	PUNCT
dpc-5196	109	34	12	12	NUM
dpc-5196	109	35	-	-	SYM
dpc-5196	109	36	79	79	NUM
dpc-5196	109	37	)	)	PUNCT
dpc-5196	109	38	duration	duration	NOUN
dpc-5196	109	39	of	of	ADP
dpc-5196	109	40	disease	disease	PROPN
dpc-5196	109	41	†	†	PROPN
dpc-5196	109	42	,	,	PUNCT
dpc-5196	109	43	months	month	NOUN
dpc-5196	109	44	median	median	NOUN
dpc-5196	109	45	(	(	PUNCT
dpc-5196	109	46	range	range	NOUN
dpc-5196	109	47	)	)	PUNCT
dpc-5196	109	48	6.09	6.09	NUM
dpc-5196	109	49	(	(	PUNCT
dpc-5196	109	50	1	1	NUM
dpc-5196	109	51	-	-	NUM
dpc-5196	109	52	39	39	NUM
dpc-5196	109	53	)	)	PUNCT
dpc-5196	109	54	angioedema	angioedema	VERB
dpc-5196	109	55	,	,	PUNCT
dpc-5196	109	56	n	n	PROPN
dpc-5196	109	57	(	(	PUNCT
dpc-5196	109	58	%	%	INTJ
dpc-5196	109	59	)	)	PUNCT
dpc-5196	110	1	present	present	ADJ
dpc-5196	110	2	absent	absent	ADJ
dpc-5196	110	3	99	99	NUM
dpc-5196	110	4	(	(	PUNCT
dpc-5196	110	5	49.5	49.5	NUM
dpc-5196	110	6	)	)	PUNCT
dpc-5196	110	7	101	101	NUM
dpc-5196	110	8	(	(	PUNCT
dpc-5196	110	9	50.5	50.5	NUM
dpc-5196	110	10	)	)	PUNCT
dpc-5196	110	11	comorbidities	comorbiditie	NOUN
dpc-5196	110	12	,	,	PUNCT
dpc-5196	110	13	n	n	CCONJ
dpc-5196	110	14	(	(	PUNCT
dpc-5196	110	15	%	%	INTJ
dpc-5196	110	16	)	)	PUNCT
dpc-5196	110	17	hypertension	hypertension	NOUN
dpc-5196	110	18	allergic	allergic	ADJ
dpc-5196	110	19	diseases	disease	NOUN
dpc-5196	110	20	diabetes	diabetes	VERB
dpc-5196	110	21	mellitus	mellitus	PROPN
dpc-5196	110	22	hypothyroidism	hypothyroidism	PROPN
dpc-5196	110	23	hyperlipidemia	hyperlipidemia	NOUN
dpc-5196	110	24	psychiatric	psychiatric	ADJ
dpc-5196	110	25	diseases	disease	NOUN
dpc-5196	110	26	109	109	NUM
dpc-5196	110	27	(	(	PUNCT
dpc-5196	110	28	54.5	54.5	NUM
dpc-5196	110	29	)	)	PUNCT
dpc-5196	110	30	30	30	NUM
dpc-5196	110	31	(	(	PUNCT
dpc-5196	110	32	15	15	NUM
dpc-5196	110	33	)	)	SYM
dpc-5196	110	34	21	21	NUM
dpc-5196	110	35	(	(	PUNCT
dpc-5196	110	36	10.5	10.5	NUM
dpc-5196	110	37	)	)	SYM
dpc-5196	110	38	18	18	NUM
dpc-5196	110	39	(	(	PUNCT
dpc-5196	110	40	9	9	NUM
dpc-5196	110	41	)	)	SYM
dpc-5196	110	42	14	14	NUM
dpc-5196	110	43	(	(	PUNCT
dpc-5196	110	44	7	7	NUM
dpc-5196	110	45	)	)	SYM
dpc-5196	110	46	8	8	NUM
dpc-5196	110	47	(	(	PUNCT
dpc-5196	110	48	4	4	NUM
dpc-5196	110	49	)	)	PUNCT
dpc-5196	110	50	6	6	NUM
dpc-5196	110	51	(	(	PUNCT
dpc-5196	110	52	3	3	X
dpc-5196	110	53	)	)	PUNCT
dpc-5196	110	54	trigger	trigger	NOUN
dpc-5196	110	55	factors	factor	NOUN
dpc-5196	110	56	,	,	PUNCT
dpc-5196	110	57	n	n	CCONJ
dpc-5196	110	58	(	(	PUNCT
dpc-5196	110	59	%	%	INTJ
dpc-5196	110	60	)	)	PUNCT
dpc-5196	110	61	stress	stress	NOUN
dpc-5196	110	62	physical	physical	ADJ
dpc-5196	110	63	factors	factor	NOUN
dpc-5196	110	64	pressure	pressure	NOUN
dpc-5196	110	65	heat	heat	NOUN
dpc-5196	110	66	cold	cold	ADJ
dpc-5196	110	67	dermographism	dermographism	NOUN
dpc-5196	110	68	drug	drug	NOUN
dpc-5196	110	69	food	food	NOUN
dpc-5196	110	70	i̇nfection	i̇nfection	NOUN
dpc-5196	110	71	150	150	NUM
dpc-5196	110	72	(	(	PUNCT
dpc-5196	110	73	75	75	NUM
dpc-5196	110	74	)	)	PUNCT
dpc-5196	110	75	90	90	NUM
dpc-5196	110	76	(	(	PUNCT
dpc-5196	110	77	45	45	NUM
dpc-5196	110	78	)	)	PUNCT
dpc-5196	110	79	37	37	NUM
dpc-5196	110	80	(	(	PUNCT
dpc-5196	110	81	18.5	18.5	NUM
dpc-5196	110	82	)	)	PUNCT
dpc-5196	110	83	10	10	NUM
dpc-5196	110	84	(	(	PUNCT
dpc-5196	110	85	5	5	NUM
dpc-5196	110	86	)	)	PUNCT
dpc-5196	110	87	9	9	NUM
dpc-5196	110	88	(	(	PUNCT
dpc-5196	110	89	4.5	4.5	NUM
dpc-5196	110	90	)	)	PUNCT
dpc-5196	110	91	5	5	NUM
dpc-5196	110	92	(	(	PUNCT
dpc-5196	110	93	2.5	2.5	NUM
dpc-5196	110	94	)	)	SYM
dpc-5196	110	95	5	5	NUM
dpc-5196	110	96	(	(	PUNCT
dpc-5196	110	97	2.5	2.5	NUM
dpc-5196	110	98	)	)	PUNCT
dpc-5196	110	99	25	25	NUM
dpc-5196	110	100	(	(	PUNCT
dpc-5196	110	101	12.5	12.5	NUM
dpc-5196	110	102	)	)	SYM
dpc-5196	110	103	24	24	NUM
dpc-5196	110	104	(	(	PUNCT
dpc-5196	110	105	12	12	NUM
dpc-5196	110	106	)	)	PUNCT
dpc-5196	110	107	10	10	NUM
dpc-5196	110	108	(	(	PUNCT
dpc-5196	110	109	5	5	NUM
dpc-5196	110	110	)	)	PUNCT
dpc-5196	110	111	cu	cu	PROPN
dpc-5196	110	112	subtypes	subtype	NOUN
dpc-5196	110	113	,	,	PUNCT
dpc-5196	110	114	n	n	PROPN
dpc-5196	110	115	(	(	PUNCT
dpc-5196	110	116	%	%	INTJ
dpc-5196	110	117	)	)	PUNCT
dpc-5196	110	118	csu	csu	PROPN
dpc-5196	110	119	ciu	ciu	PROPN
dpc-5196	110	120	csu	csu	PROPN
dpc-5196	110	121	+	+	CCONJ
dpc-5196	110	122	ciu	ciu	PROPN
dpc-5196	110	123	163	163	NUM
dpc-5196	110	124	(	(	PUNCT
dpc-5196	110	125	81.5	81.5	NUM
dpc-5196	110	126	)	)	PUNCT
dpc-5196	110	127	14	14	NUM
dpc-5196	110	128	(	(	PUNCT
dpc-5196	110	129	7	7	NUM
dpc-5196	110	130	)	)	PUNCT
dpc-5196	110	131	23	23	NUM
dpc-5196	110	132	(	(	PUNCT
dpc-5196	110	133	11.5	11.5	NUM
dpc-5196	110	134	)	)	PUNCT
dpc-5196	110	135	previous	previous	ADJ
dpc-5196	110	136	treatments	treatment	NOUN
dpc-5196	110	137	,	,	PUNCT
dpc-5196	110	138	n	n	CCONJ
dpc-5196	110	139	(	(	PUNCT
dpc-5196	110	140	%	%	INTJ
dpc-5196	110	141	)	)	PUNCT
dpc-5196	110	142	ah	ah	INTJ
dpc-5196	110	143	monotherapy	monotherapy	NOUN
dpc-5196	110	144	in	in	ADP
dpc-5196	110	145	combination‡	combination‡	PROPN
dpc-5196	110	146	systemic	systemic	ADJ
dpc-5196	110	147	cs	cs	PROPN
dpc-5196	110	148	cyclosporine	cyclosporine	PROPN
dpc-5196	110	149	doxepin	doxepin	NOUN
dpc-5196	110	150	200	200	NUM
dpc-5196	110	151	(	(	PUNCT
dpc-5196	110	152	100	100	NUM
dpc-5196	110	153	)	)	PUNCT
dpc-5196	110	154	110	110	NUM
dpc-5196	110	155	(	(	PUNCT
dpc-5196	110	156	55	55	NUM
dpc-5196	110	157	)	)	SYM
dpc-5196	110	158	90	90	NUM
dpc-5196	110	159	(	(	PUNCT
dpc-5196	110	160	45	45	NUM
dpc-5196	110	161	)	)	PUNCT
dpc-5196	110	162	78	78	NUM
dpc-5196	110	163	(	(	PUNCT
dpc-5196	110	164	39	39	NUM
dpc-5196	110	165	)	)	PUNCT
dpc-5196	110	166	5	5	NUM
dpc-5196	110	167	(	(	PUNCT
dpc-5196	110	168	2.5	2.5	NUM
dpc-5196	110	169	)	)	PUNCT
dpc-5196	110	170	3	3	NUM
dpc-5196	110	171	(	(	PUNCT
dpc-5196	110	172	1.5	1.5	NUM
dpc-5196	110	173	)	)	PUNCT
dpc-5196	110	174	uas7	uas7	NOUN
dpc-5196	110	175	score	score	NOUN
dpc-5196	110	176	,	,	PUNCT
dpc-5196	110	177	mean	mean	VERB
dpc-5196	110	178	±	±	PROPN
dpc-5196	110	179	sd	sd	ADP
dpc-5196	110	180	baseline	baseline	VERB
dpc-5196	110	181	4th	4th	ADJ
dpc-5196	110	182	week	week	NOUN
dpc-5196	110	183	of	of	ADP
dpc-5196	110	184	the	the	DET
dpc-5196	110	185	treatment	treatment	NOUN
dpc-5196	110	186	37.45	37.45	NUM
dpc-5196	110	187	±	±	NUM
dpc-5196	110	188	7.67	7.67	NUM
dpc-5196	110	189	7.79	7.79	NUM
dpc-5196	110	190	±	±	NUM
dpc-5196	110	191	10.75	10.75	NUM
dpc-5196	110	192	serum	serum	NOUN
dpc-5196	110	193	ige	ige	PROPN
dpc-5196	110	194	level	level	NOUN
dpc-5196	110	195	,	,	PUNCT
dpc-5196	110	196	(	(	PUNCT
dpc-5196	110	197	iu	iu	NOUN
dpc-5196	110	198	/	/	SYM
dpc-5196	110	199	ml	ml	NOUN
dpc-5196	110	200	)	)	PUNCT
dpc-5196	110	201	,	,	PUNCT
dpc-5196	110	202	median	median	NOUN
dpc-5196	110	203	baseline	baseline	VERB
dpc-5196	110	204	4th	4th	ADJ
dpc-5196	110	205	weeks	week	NOUN
dpc-5196	110	206	of	of	ADP
dpc-5196	110	207	the	the	DET
dpc-5196	110	208	treatment	treatment	NOUN
dpc-5196	110	209	4th	4th	ADJ
dpc-5196	110	210	weeks	week	NOUN
dpc-5196	110	211	of	of	ADP
dpc-5196	110	212	the	the	DET
dpc-5196	110	213	treatment	treatment	NOUN
dpc-5196	110	214	101.5	101.5	NUM
dpc-5196	110	215	275	275	NUM
dpc-5196	110	216	2.7	2.7	NUM
dpc-5196	110	217	blood	blood	NOUN
dpc-5196	110	218	basophil	basophil	NOUN
dpc-5196	110	219	level§	level§	PROPN
dpc-5196	110	220	,	,	PUNCT
dpc-5196	110	221	(	(	PUNCT
dpc-5196	110	222	1000/µl	1000/µl	NUM
dpc-5196	110	223	)	)	PUNCT
dpc-5196	110	224	,	,	PUNCT
dpc-5196	110	225	mean	mean	VERB
dpc-5196	110	226	±	±	NUM
dpc-5196	110	227	sd	sd	NOUN
dpc-5196	110	228	(	(	PUNCT
dpc-5196	110	229	range	range	NOUN
dpc-5196	110	230	)	)	PUNCT
dpc-5196	110	231	baseline	baseline	VERB
dpc-5196	110	232	4th	4th	ADJ
dpc-5196	110	233	week	week	NOUN
dpc-5196	110	234	0.03	0.03	NUM
dpc-5196	110	235	±	±	NUM
dpc-5196	110	236	0.02	0.02	NUM
dpc-5196	110	237	0.03	0.03	NUM
dpc-5196	110	238	±	±	NUM
dpc-5196	110	239	0.03	0.03	NUM
dpc-5196	110	240	note	note	NOUN
dpc-5196	110	241	:	:	PUNCT
dpc-5196	110	242	†the	†the	DET
dpc-5196	110	243	duration	duration	NOUN
dpc-5196	110	244	of	of	ADP
dpc-5196	110	245	disease	disease	NOUN
dpc-5196	110	246	encompasses	encompass	VERB
dpc-5196	110	247	the	the	DET
dpc-5196	110	248	period	period	NOUN
dpc-5196	110	249	before	before	ADP
dpc-5196	110	250	starting	start	VERB
dpc-5196	110	251	omalizumab	omalizumab	NOUN
dpc-5196	110	252	treatment	treatment	NOUN
dpc-5196	110	253	.	.	PUNCT
dpc-5196	111	1	‡the	‡the	DET
dpc-5196	111	2	group	group	NOUN
dpc-5196	111	3	of	of	ADP
dpc-5196	111	4	patients	patient	NOUN
dpc-5196	111	5	utilizing	utilize	VERB
dpc-5196	111	6	antihistamines	antihistamine	NOUN
dpc-5196	111	7	in	in	ADP
dpc-5196	111	8	combination	combination	NOUN
dpc-5196	111	9	,	,	PUNCT
dpc-5196	111	10	also	also	ADV
dpc-5196	111	11	received	receive	VERB
dpc-5196	111	12	systemic	systemic	ADJ
dpc-5196	111	13	corticosteroids	corticosteroid	NOUN
dpc-5196	111	14	,	,	PUNCT
dpc-5196	111	15	doxepin	doxepin	NOUN
dpc-5196	111	16	,	,	PUNCT
dpc-5196	111	17	and	and	CCONJ
dpc-5196	111	18	dapsone	dapsone	NOUN
dpc-5196	111	19	concurrently	concurrently	ADV
dpc-5196	111	20	.	.	PUNCT
dpc-5196	112	1	§	§	VERB
dpc-5196	112	2	the	the	DET
dpc-5196	112	3	laboratory	laboratory	NOUN
dpc-5196	112	4	’s	’s	PART
dpc-5196	112	5	reference	reference	NOUN
dpc-5196	112	6	range	range	VERB
dpc-5196	112	7	for	for	ADP
dpc-5196	112	8	the	the	DET
dpc-5196	112	9	measurements	measurement	NOUN
dpc-5196	112	10	was	be	AUX
dpc-5196	112	11	0.01–0.07	0.01–0.07	NUM
dpc-5196	112	12	(	(	PUNCT
dpc-5196	112	13	1000/µl	1000/µl	NUM
dpc-5196	112	14	)	)	PUNCT
dpc-5196	112	15	.	.	PUNCT
dpc-5196	113	1	sd	sd	NOUN
dpc-5196	113	2	,	,	PUNCT
dpc-5196	113	3	standard	standard	ADJ
dpc-5196	113	4	deviation	deviation	NOUN
dpc-5196	113	5	;	;	PUNCT
dpc-5196	113	6	cu	cu	PROPN
dpc-5196	113	7	,	,	PUNCT
dpc-5196	113	8	chronic	chronic	ADJ
dpc-5196	113	9	urticaria	urticaria	NOUN
dpc-5196	113	10	;	;	PUNCT
dpc-5196	113	11	csu	csu	VERB
dpc-5196	113	12	,	,	PUNCT
dpc-5196	113	13	chronic	chronic	ADJ
dpc-5196	113	14	spontaneous	spontaneous	ADJ
dpc-5196	113	15	urticaria	urticaria	NOUN
dpc-5196	113	16	;	;	PUNCT
dpc-5196	113	17	ciu	ciu	ADJ
dpc-5196	113	18	,	,	PUNCT
dpc-5196	113	19	chronic	chronic	ADJ
dpc-5196	113	20	inducible	inducible	ADJ
dpc-5196	113	21	urticaria	urticaria	NOUN
dpc-5196	113	22	;	;	PUNCT
dpc-5196	113	23	cs	cs	ADJ
dpc-5196	113	24	,	,	PUNCT
dpc-5196	113	25	corticosteroid	corticosteroid	ADJ
dpc-5196	113	26	;	;	PUNCT
dpc-5196	113	27	ah	ah	INTJ
dpc-5196	113	28	,	,	PUNCT
dpc-5196	113	29	antihistamine	antihistamine	PROPN
dpc-5196	113	30	;	;	PUNCT
dpc-5196	113	31	uas7	uas7	PROPN
dpc-5196	113	32	,	,	PUNCT
dpc-5196	113	33	urticaria	urticaria	NOUN
dpc-5196	113	34	activity	activity	NOUN
dpc-5196	113	35	score	score	NOUN
dpc-5196	113	36	over	over	ADP
dpc-5196	113	37	7	7	NUM
dpc-5196	113	38	days	day	NOUN
dpc-5196	113	39	;	;	PUNCT
dpc-5196	113	40	ige	ige	PROPN
dpc-5196	113	41	,	,	PUNCT
dpc-5196	113	42	immunoglobulin	immunoglobulin	NOUN
dpc-5196	113	43	e	e	NOUN
dpc-5196	113	44	;	;	PUNCT
dpc-5196	113	45	iu	iu	ADP
dpc-5196	113	46	,	,	PUNCT
dpc-5196	113	47	international	international	ADJ
dpc-5196	113	48	unit	unit	NOUN
dpc-5196	113	49	.	.	PUNCT
dpc-5196	114	1	original	original	ADJ
dpc-5196	114	2	article	article	NOUN
dpc-5196	114	3	|	|	ADV
dpc-5196	114	4	dermatol	dermatol	ADJ
dpc-5196	114	5	pract	pract	NOUN
dpc-5196	114	6	concept	concept	NOUN
dpc-5196	114	7	.	.	PUNCT
dpc-5196	115	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	115	2	5	5	NUM
dpc-5196	115	3	table	table	NOUN
dpc-5196	115	4	2	2	NUM
dpc-5196	115	5	.	.	PUNCT
dpc-5196	115	6	characteristics	characteristic	NOUN
dpc-5196	115	7	of	of	ADP
dpc-5196	115	8	omalizumab	omalizumab	NOUN
dpc-5196	115	9	treatment	treatment	NOUN
dpc-5196	115	10	and	and	CCONJ
dpc-5196	115	11	post	post	ADJ
dpc-5196	115	12	-	-	ADJ
dpc-5196	115	13	treatment	treatment	ADJ
dpc-5196	115	14	relapse	relapse	NOUN
dpc-5196	115	15	.	.	PUNCT
dpc-5196	116	1	characteristics	characteristic	NOUN
dpc-5196	116	2	duration	duration	NOUN
dpc-5196	116	3	of	of	ADP
dpc-5196	116	4	treatment	treatment	NOUN
dpc-5196	116	5	,	,	PUNCT
dpc-5196	116	6	months	month	NOUN
dpc-5196	116	7	mean	mean	VERB
dpc-5196	116	8	±	±	NUM
dpc-5196	116	9	sd	sd	NOUN
dpc-5196	116	10	(	(	PUNCT
dpc-5196	116	11	range	range	NOUN
dpc-5196	116	12	)	)	PUNCT
dpc-5196	116	13	19.47	19.47	NUM
dpc-5196	116	14	±	±	NUM
dpc-5196	116	15	15.53	15.53	NUM
dpc-5196	116	16	(	(	PUNCT
dpc-5196	116	17	3	3	NUM
dpc-5196	116	18	-	-	SYM
dpc-5196	116	19	39	39	NUM
dpc-5196	116	20	)	)	PUNCT
dpc-5196	116	21	concomitant	concomitant	ADJ
dpc-5196	116	22	ah	ah	INTJ
dpc-5196	116	23	use	use	NOUN
dpc-5196	116	24	,	,	PUNCT
dpc-5196	116	25	n	n	CCONJ
dpc-5196	116	26	(	(	PUNCT
dpc-5196	116	27	%	%	INTJ
dpc-5196	116	28	)	)	PUNCT
dpc-5196	116	29	present	present	ADJ
dpc-5196	116	30	regular	regular	ADJ
dpc-5196	116	31	occasional	occasional	ADJ
dpc-5196	116	32	absent	absent	ADJ
dpc-5196	116	33	173	173	NUM
dpc-5196	116	34	(	(	PUNCT
dpc-5196	116	35	86.5	86.5	NUM
dpc-5196	116	36	)	)	PUNCT
dpc-5196	116	37	125	125	NUM
dpc-5196	116	38	(	(	PUNCT
dpc-5196	116	39	62.5	62.5	NUM
dpc-5196	116	40	)	)	PUNCT
dpc-5196	116	41	48	48	NUM
dpc-5196	116	42	(	(	PUNCT
dpc-5196	116	43	24	24	NUM
dpc-5196	116	44	)	)	PUNCT
dpc-5196	116	45	27	27	NUM
dpc-5196	116	46	(	(	PUNCT
dpc-5196	116	47	13.5	13.5	NUM
dpc-5196	116	48	)	)	PUNCT
dpc-5196	116	49	treatment	treatment	NOUN
dpc-5196	116	50	response	response	NOUN
dpc-5196	116	51	time	time	NOUN
dpc-5196	116	52	,	,	PUNCT
dpc-5196	116	53	months	month	NOUN
dpc-5196	116	54	,	,	PUNCT
dpc-5196	116	55	median	median	NOUN
dpc-5196	116	56	(	(	PUNCT
dpc-5196	116	57	range	range	NOUN
dpc-5196	116	58	)	)	PUNCT
dpc-5196	116	59	fast	fast	ADV
dpc-5196	116	60	(	(	PUNCT
dpc-5196	116	61	1st	1st	ADJ
dpc-5196	116	62	month	month	NOUN
dpc-5196	116	63	)	)	PUNCT
dpc-5196	116	64	,	,	PUNCT
dpc-5196	116	65	n	n	PROPN
dpc-5196	116	66	(	(	PUNCT
dpc-5196	116	67	%	%	INTJ
dpc-5196	116	68	)	)	PUNCT
dpc-5196	116	69	slow	slow	ADJ
dpc-5196	116	70	(	(	PUNCT
dpc-5196	116	71	>	>	SYM
dpc-5196	116	72	1	1	NUM
dpc-5196	116	73	month	month	NOUN
dpc-5196	116	74	)	)	PUNCT
dpc-5196	116	75	,	,	PUNCT
dpc-5196	116	76	n	n	PROPN
dpc-5196	116	77	(	(	PUNCT
dpc-5196	116	78	%	%	INTJ
dpc-5196	116	79	)	)	PUNCT
dpc-5196	116	80	1	1	NUM
dpc-5196	116	81	(	(	PUNCT
dpc-5196	116	82	1	1	NUM
dpc-5196	116	83	-	-	SYM
dpc-5196	116	84	12	12	NUM
dpc-5196	116	85	)	)	PUNCT
dpc-5196	116	86	126	126	NUM
dpc-5196	116	87	(	(	PUNCT
dpc-5196	116	88	70.3	70.3	NUM
dpc-5196	116	89	)	)	PUNCT
dpc-5196	116	90	52	52	NUM
dpc-5196	116	91	(	(	PUNCT
dpc-5196	116	92	29.7	29.7	NUM
dpc-5196	116	93	)	)	PUNCT
dpc-5196	116	94	duration	duration	NOUN
dpc-5196	116	95	of	of	ADP
dpc-5196	116	96	ah	ah	INTJ
dpc-5196	116	97	use	use	NOUN
dpc-5196	116	98	,	,	PUNCT
dpc-5196	116	99	months	month	NOUN
dpc-5196	116	100	mean	mean	VERB
dpc-5196	116	101	±	±	NUM
dpc-5196	116	102	sd	sd	NOUN
dpc-5196	116	103	(	(	PUNCT
dpc-5196	116	104	range	range	NOUN
dpc-5196	116	105	)	)	PUNCT
dpc-5196	116	106	4.90	4.90	NUM
dpc-5196	116	107	±	±	NUM
dpc-5196	116	108	4.13	4.13	NUM
dpc-5196	116	109	(	(	PUNCT
dpc-5196	116	110	1	1	NUM
dpc-5196	116	111	-	-	SYM
dpc-5196	116	112	24	24	NUM
dpc-5196	116	113	)	)	PUNCT
dpc-5196	116	114	treatment	treatment	NOUN
dpc-5196	116	115	discontinuation	discontinuation	NOUN
dpc-5196	116	116	method†	method†	NOUN
dpc-5196	116	117	,	,	PUNCT
dpc-5196	116	118	n	n	CCONJ
dpc-5196	116	119	(	(	PUNCT
dpc-5196	116	120	%	%	INTJ
dpc-5196	116	121	)	)	PUNCT
dpc-5196	116	122	300	300	NUM
dpc-5196	116	123	mg/4	mg/4	NOUN
dpc-5196	116	124	weeks	week	VERB
dpc-5196	116	125	300	300	NUM
dpc-5196	116	126	mg/8	mg/8	NOUN
dpc-5196	116	127	weeks	week	NOUN
dpc-5196	116	128	150	150	NUM
dpc-5196	116	129	mg/4	mg/4	NOUN
dpc-5196	116	130	weeks	week	NOUN
dpc-5196	116	131	109	109	NUM
dpc-5196	116	132	(	(	PUNCT
dpc-5196	116	133	54.5	54.5	NUM
dpc-5196	116	134	)	)	PUNCT
dpc-5196	116	135	59	59	NUM
dpc-5196	116	136	(	(	PUNCT
dpc-5196	116	137	29.5	29.5	NUM
dpc-5196	116	138	)	)	PUNCT
dpc-5196	116	139	32	32	NUM
dpc-5196	116	140	(	(	PUNCT
dpc-5196	116	141	16	16	NUM
dpc-5196	116	142	)	)	PUNCT
dpc-5196	116	143	relapse	relapse	NOUN
dpc-5196	116	144	rate	rate	NOUN
dpc-5196	116	145	,	,	PUNCT
dpc-5196	116	146	n	n	PROPN
dpc-5196	116	147	(	(	PUNCT
dpc-5196	116	148	%	%	INTJ
dpc-5196	116	149	)	)	PUNCT
dpc-5196	116	150	present	present	ADJ
dpc-5196	116	151	absent	absent	ADJ
dpc-5196	116	152	100	100	NUM
dpc-5196	116	153	(	(	PUNCT
dpc-5196	116	154	50	50	NUM
dpc-5196	116	155	)	)	PUNCT
dpc-5196	116	156	100	100	NUM
dpc-5196	116	157	(	(	PUNCT
dpc-5196	116	158	50	50	NUM
dpc-5196	116	159	)	)	PUNCT
dpc-5196	116	160	time	time	NOUN
dpc-5196	116	161	to	to	PART
dpc-5196	116	162	relapse	relapse	VERB
dpc-5196	116	163	,	,	PUNCT
dpc-5196	116	164	months	month	NOUN
dpc-5196	116	165	median	median	NOUN
dpc-5196	116	166	(	(	PUNCT
dpc-5196	116	167	range	range	NOUN
dpc-5196	116	168	)	)	PUNCT
dpc-5196	116	169	4	4	NUM
dpc-5196	116	170	(	(	PUNCT
dpc-5196	116	171	1	1	NUM
dpc-5196	116	172	-	-	SYM
dpc-5196	116	173	40	40	NUM
dpc-5196	116	174	)	)	PUNCT
dpc-5196	116	175	relapse	relapse	NOUN
dpc-5196	116	176	time	time	NOUN
dpc-5196	116	177	,	,	PUNCT
dpc-5196	116	178	n	n	PROPN
dpc-5196	116	179	(	(	PUNCT
dpc-5196	116	180	%	%	NOUN
dpc-5196	116	181	)	)	PUNCT
dpc-5196	116	182	1	1	NUM
dpc-5196	116	183	-	-	SYM
dpc-5196	116	184	3	3	NUM
dpc-5196	116	185	months	month	NOUN
dpc-5196	116	186	4	4	NUM
dpc-5196	116	187	-	-	SYM
dpc-5196	116	188	6	6	NUM
dpc-5196	116	189	months	month	NOUN
dpc-5196	116	190	7	7	NUM
dpc-5196	116	191	-	-	SYM
dpc-5196	116	192	12	12	NUM
dpc-5196	116	193	months	month	NOUN
dpc-5196	116	194	>	>	PUNCT
dpc-5196	116	195	12	12	NUM
dpc-5196	116	196	months	month	NOUN
dpc-5196	116	197	49	49	NUM
dpc-5196	116	198	(	(	PUNCT
dpc-5196	116	199	49	49	NUM
dpc-5196	116	200	)	)	PUNCT
dpc-5196	116	201	21	21	NUM
dpc-5196	116	202	(	(	PUNCT
dpc-5196	116	203	21	21	NUM
dpc-5196	116	204	)	)	SYM
dpc-5196	116	205	19	19	NUM
dpc-5196	116	206	(	(	PUNCT
dpc-5196	116	207	19	19	NUM
dpc-5196	116	208	)	)	PUNCT
dpc-5196	116	209	11	11	NUM
dpc-5196	116	210	(	(	PUNCT
dpc-5196	116	211	11	11	NUM
dpc-5196	116	212	)	)	PUNCT
dpc-5196	116	213	post	post	ADJ
dpc-5196	116	214	-	-	ADJ
dpc-5196	116	215	relapse	relapse	NOUN
dpc-5196	116	216	treatment	treatment	NOUN
dpc-5196	116	217	,	,	PUNCT
dpc-5196	116	218	n	n	CCONJ
dpc-5196	116	219	(	(	PUNCT
dpc-5196	116	220	%	%	INTJ
dpc-5196	116	221	)	)	PUNCT
dpc-5196	116	222	ah	ah	INTJ
dpc-5196	116	223	omalizumab	omalizumab	NOUN
dpc-5196	116	224	10	10	NUM
dpc-5196	116	225	(	(	PUNCT
dpc-5196	116	226	10	10	NUM
dpc-5196	116	227	)	)	PUNCT
dpc-5196	116	228	90	90	NUM
dpc-5196	116	229	(	(	PUNCT
dpc-5196	116	230	90	90	NUM
dpc-5196	116	231	)	)	PUNCT
dpc-5196	116	232	†patients	†patient	NOUN
dpc-5196	116	233	were	be	AUX
dpc-5196	116	234	categorized	categorize	VERB
dpc-5196	116	235	based	base	VERB
dpc-5196	116	236	on	on	ADP
dpc-5196	116	237	their	their	PRON
dpc-5196	116	238	approach	approach	NOUN
dpc-5196	116	239	to	to	ADP
dpc-5196	116	240	discontinuing	discontinue	VERB
dpc-5196	116	241	omalizumab	omalizumab	NOUN
dpc-5196	116	242	treatment	treatment	NOUN
dpc-5196	116	243	:	:	PUNCT
dpc-5196	116	244	cessation	cessation	NOUN
dpc-5196	116	245	directly	directly	ADV
dpc-5196	116	246	(	(	PUNCT
dpc-5196	116	247	300	300	NUM
dpc-5196	116	248	mg	mg	NOUN
dpc-5196	116	249	every	every	DET
dpc-5196	116	250	4	4	NUM
dpc-5196	116	251	weeks	week	NOUN
dpc-5196	116	252	)	)	PUNCT
dpc-5196	116	253	,	,	PUNCT
dpc-5196	116	254	prolonging	prolong	VERB
dpc-5196	116	255	the	the	DET
dpc-5196	116	256	dosing	dose	VERB
dpc-5196	116	257	interval	interval	NOUN
dpc-5196	116	258	to	to	ADP
dpc-5196	116	259	8	8	NUM
dpc-5196	116	260	weeks	week	NOUN
dpc-5196	116	261	(	(	PUNCT
dpc-5196	116	262	300	300	NUM
dpc-5196	116	263	mg	mg	NOUN
dpc-5196	116	264	every	every	DET
dpc-5196	116	265	8	8	NUM
dpc-5196	116	266	weeks	week	NOUN
dpc-5196	116	267	)	)	PUNCT
dpc-5196	116	268	,	,	PUNCT
dpc-5196	116	269	and	and	CCONJ
dpc-5196	116	270	reducing	reduce	VERB
dpc-5196	116	271	the	the	DET
dpc-5196	116	272	dosage	dosage	NOUN
dpc-5196	116	273	to	to	ADP
dpc-5196	116	274	150	150	NUM
dpc-5196	116	275	mg	mg	NOUN
dpc-5196	116	276	every	every	DET
dpc-5196	116	277	4	4	NUM
dpc-5196	116	278	weeks	week	NOUN
dpc-5196	116	279	.	.	PUNCT
dpc-5196	117	1	sd	sd	NOUN
dpc-5196	117	2	,	,	PUNCT
dpc-5196	117	3	standard	standard	ADJ
dpc-5196	117	4	deviation	deviation	NOUN
dpc-5196	117	5	;	;	PUNCT
dpc-5196	117	6	ah	ah	INTJ
dpc-5196	117	7	,	,	PUNCT
dpc-5196	117	8	antihistamines	antihistamine	NOUN
dpc-5196	117	9	table	table	NOUN
dpc-5196	117	10	3	3	NUM
dpc-5196	117	11	.	.	PUNCT
dpc-5196	118	1	relapse	relapse	NOUN
dpc-5196	118	2	rates	rate	NOUN
dpc-5196	118	3	according	accord	VERB
dpc-5196	118	4	to	to	ADP
dpc-5196	118	5	the	the	DET
dpc-5196	118	6	method	method	NOUN
dpc-5196	118	7	of	of	ADP
dpc-5196	118	8	discontinuing	discontinuing	NOUN
dpc-5196	118	9	treatment	treatment	NOUN
dpc-5196	118	10	.	.	PUNCT
dpc-5196	119	1	relapsed	relapse	VERB
dpc-5196	119	2	,	,	PUNCT
dpc-5196	119	3	n	n	CCONJ
dpc-5196	119	4	(	(	PUNCT
dpc-5196	119	5	%	%	INTJ
dpc-5196	119	6	)	)	PUNCT
dpc-5196	119	7	non	non	ADJ
dpc-5196	119	8	-	-	ADJ
dpc-5196	119	9	relapsed	relapsed	ADJ
dpc-5196	119	10	,	,	PUNCT
dpc-5196	119	11	n(%	n(%	PROPN
dpc-5196	119	12	)	)	PUNCT
dpc-5196	120	1	p	p	NOUN
dpc-5196	120	2	value	value	NOUN
dpc-5196	120	3	300	300	NUM
dpc-5196	120	4	mg/4	mg/4	NOUN
dpc-5196	120	5	weeks	week	NOUN
dpc-5196	120	6	71	71	NUM
dpc-5196	120	7	(	(	PUNCT
dpc-5196	120	8	65.1	65.1	NUM
dpc-5196	120	9	)	)	PUNCT
dpc-5196	120	10	38	38	NUM
dpc-5196	120	11	(	(	PUNCT
dpc-5196	120	12	34.9	34.9	NUM
dpc-5196	120	13	)	)	PUNCT
dpc-5196	120	14	<	<	X
dpc-5196	120	15	0.001	0.001	NUM
dpc-5196	120	16	*	*	SYM
dpc-5196	120	17	300	300	NUM
dpc-5196	120	18	mg/8	mg/8	NOUN
dpc-5196	120	19	weeks	week	NOUN
dpc-5196	120	20	24	24	NUM
dpc-5196	120	21	(	(	PUNCT
dpc-5196	120	22	40.7	40.7	NUM
dpc-5196	120	23	)	)	PUNCT
dpc-5196	120	24	35	35	NUM
dpc-5196	120	25	(	(	PUNCT
dpc-5196	120	26	59.3	59.3	NUM
dpc-5196	120	27	)	)	PUNCT
dpc-5196	120	28	150	150	NUM
dpc-5196	120	29	mg/4	mg/4	NOUN
dpc-5196	120	30	weeks	week	NOUN
dpc-5196	120	31	5	5	NUM
dpc-5196	120	32	(	(	PUNCT
dpc-5196	120	33	15.6	15.6	NUM
dpc-5196	120	34	)	)	PUNCT
dpc-5196	120	35	27	27	NUM
dpc-5196	120	36	(	(	PUNCT
dpc-5196	120	37	84.4	84.4	NUM
dpc-5196	120	38	)	)	PUNCT
dpc-5196	120	39	*	*	PUNCT
dpc-5196	120	40	continuity	continuity	NOUN
dpc-5196	120	41	correction	correction	NOUN
dpc-5196	120	42	test	test	NOUN
dpc-5196	120	43	figure	figure	NOUN
dpc-5196	120	44	1	1	NUM
dpc-5196	120	45	.	.	PUNCT
dpc-5196	121	1	a	a	DET
dpc-5196	121	2	statistically	statistically	ADV
dpc-5196	121	3	significant	significant	ADJ
dpc-5196	121	4	difference	difference	NOUN
dpc-5196	121	5	in	in	ADP
dpc-5196	121	6	the	the	DET
dpc-5196	121	7	post	post	ADJ
dpc-5196	121	8	-	-	ADJ
dpc-5196	121	9	treatment	treatment	ADJ
dpc-5196	121	10	relapse	relapse	NOUN
dpc-5196	121	11	was	be	AUX
dpc-5196	121	12	observed	observe	VERB
dpc-5196	121	13	according	accord	VERB
dpc-5196	121	14	to	to	ADP
dpc-5196	121	15	the	the	DET
dpc-5196	121	16	method	method	NOUN
dpc-5196	121	17	of	of	ADP
dpc-5196	121	18	treatment	treatment	NOUN
dpc-5196	121	19	discontinuation	discontinuation	NOUN
dpc-5196	121	20	(	(	PUNCT
dpc-5196	121	21	p<0.001	p<0.001	X
dpc-5196	121	22	)	)	PUNCT
dpc-5196	121	23	in	in	ADP
dpc-5196	121	24	our	our	PRON
dpc-5196	121	25	study	study	NOUN
dpc-5196	121	26	fell	fall	VERB
dpc-5196	121	27	within	within	ADP
dpc-5196	121	28	the	the	DET
dpc-5196	121	29	age	age	NOUN
dpc-5196	121	30	range	range	NOUN
dpc-5196	121	31	where	where	SCONJ
dpc-5196	121	32	the	the	DET
dpc-5196	121	33	highest	high	ADJ
dpc-5196	121	34	prevalence	prevalence	NOUN
dpc-5196	121	35	has	have	AUX
dpc-5196	121	36	been	be	AUX
dpc-5196	121	37	reported	report	VERB
dpc-5196	121	38	in	in	ADP
dpc-5196	121	39	the	the	DET
dpc-5196	121	40	literature	literature	NOUN
dpc-5196	121	41	.	.	PUNCT
dpc-5196	122	1	the	the	DET
dpc-5196	122	2	relapse	relapse	NOUN
dpc-5196	122	3	rate	rate	NOUN
dpc-5196	122	4	in	in	ADP
dpc-5196	122	5	this	this	DET
dpc-5196	122	6	study	study	NOUN
dpc-5196	122	7	is	be	AUX
dpc-5196	122	8	comparable	comparable	ADJ
dpc-5196	122	9	to	to	ADP
dpc-5196	122	10	the	the	DET
dpc-5196	122	11	44.4	44.4	NUM
dpc-5196	122	12	%	%	NOUN
dpc-5196	122	13	and	and	CCONJ
dpc-5196	122	14	50	50	NUM
dpc-5196	122	15	%	%	NOUN
dpc-5196	122	16	rates	rate	NOUN
dpc-5196	122	17	reported	report	VERB
dpc-5196	122	18	in	in	ADP
dpc-5196	122	19	the	the	DET
dpc-5196	122	20	6	6	NUM
dpc-5196	122	21	-	-	PUNCT
dpc-5196	122	22	month	month	NOUN
dpc-5196	122	23	optima	optima	PROPN
dpc-5196	122	24	study	study	NOUN
dpc-5196	122	25	and	and	CCONJ
dpc-5196	122	26	the	the	DET
dpc-5196	122	27	43.4	43.4	NUM
dpc-5196	122	28	%	%	NOUN
dpc-5196	122	29	and	and	CCONJ
dpc-5196	122	30	45.1	45.1	NUM
dpc-5196	122	31	%	%	NOUN
dpc-5196	122	32	rates	rate	NOUN
dpc-5196	122	33	reported	report	VERB
dpc-5196	122	34	in	in	ADP
dpc-5196	122	35	the	the	DET
dpc-5196	122	36	24	24	NUM
dpc-5196	122	37	-	-	PUNCT
dpc-5196	122	38	to-48week	to-48week	NOUN
dpc-5196	122	39	xtend	xtend	PROPN
dpc-5196	122	40	-	-	PUNCT
dpc-5196	122	41	ciu	ciu	ADJ
dpc-5196	122	42	study	study	NOUN
dpc-5196	122	43	[	[	X
dpc-5196	122	44	11	11	NUM
dpc-5196	122	45	]	]	PUNCT
dpc-5196	122	46	.	.	PUNCT
dpc-5196	123	1	gradual	gradual	ADJ
dpc-5196	123	2	tapering	tapering	NOUN
dpc-5196	123	3	has	have	AUX
dpc-5196	123	4	been	be	AUX
dpc-5196	123	5	6	6	NUM
dpc-5196	123	6	original	original	ADJ
dpc-5196	123	7	article	article	NOUN
dpc-5196	123	8	|	|	ADV
dpc-5196	123	9	dermatol	dermatol	ADJ
dpc-5196	123	10	pract	pract	NOUN
dpc-5196	123	11	concept	concept	NOUN
dpc-5196	123	12	.	.	PUNCT
dpc-5196	124	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	124	2	table	table	NOUN
dpc-5196	124	3	4	4	NUM
dpc-5196	124	4	.	.	PUNCT
dpc-5196	125	1	the	the	DET
dpc-5196	125	2	association	association	NOUN
dpc-5196	125	3	between	between	ADP
dpc-5196	125	4	characteristics	characteristic	NOUN
dpc-5196	125	5	of	of	ADP
dpc-5196	125	6	patients	patient	NOUN
dpc-5196	125	7	and	and	CCONJ
dpc-5196	125	8	relapse	relapse	NOUN
dpc-5196	125	9	rate	rate	NOUN
dpc-5196	125	10	.	.	PUNCT
dpc-5196	126	1	relapse	relapse	NOUN
dpc-5196	126	2	rate	rate	NOUN
dpc-5196	126	3	,	,	PUNCT
dpc-5196	126	4	n	n	PROPN
dpc-5196	126	5	(	(	PUNCT
dpc-5196	126	6	%	%	INTJ
dpc-5196	126	7	)	)	PUNCT
dpc-5196	126	8	p	p	NOUN
dpc-5196	126	9	valuerelapsed	valuerelapse	VERB
dpc-5196	126	10	non	non	ADJ
dpc-5196	126	11	-	-	ADJ
dpc-5196	126	12	relapsed	relapsed	ADJ
dpc-5196	126	13	sex	sex	NOUN
dpc-5196	126	14	female	female	ADJ
dpc-5196	126	15	male	male	NOUN
dpc-5196	126	16	total	total	NOUN
dpc-5196	126	17	64	64	NUM
dpc-5196	126	18	(	(	PUNCT
dpc-5196	126	19	48.5	48.5	NUM
dpc-5196	126	20	)	)	PUNCT
dpc-5196	126	21	36	36	NUM
dpc-5196	126	22	(	(	PUNCT
dpc-5196	126	23	52.9	52.9	NUM
dpc-5196	126	24	)	)	PUNCT
dpc-5196	126	25	100	100	NUM
dpc-5196	126	26	(	(	PUNCT
dpc-5196	126	27	50	50	NUM
dpc-5196	126	28	)	)	PUNCT
dpc-5196	126	29	68	68	NUM
dpc-5196	126	30	(	(	PUNCT
dpc-5196	126	31	51.5	51.5	NUM
dpc-5196	126	32	)	)	PUNCT
dpc-5196	126	33	32	32	NUM
dpc-5196	126	34	(	(	PUNCT
dpc-5196	126	35	47.1	47.1	NUM
dpc-5196	126	36	)	)	PUNCT
dpc-5196	126	37	100	100	NUM
dpc-5196	126	38	(	(	PUNCT
dpc-5196	126	39	50	50	NUM
dpc-5196	126	40	)	)	PUNCT
dpc-5196	126	41	0.550	0.550	NUM
dpc-5196	126	42	*	*	NOUN
dpc-5196	126	43	age	age	NOUN
dpc-5196	126	44	mean	mean	NOUN
dpc-5196	126	45	±	±	NUM
dpc-5196	126	46	sd	sd	ADP
dpc-5196	126	47	(	(	PUNCT
dpc-5196	126	48	years	year	NOUN
dpc-5196	126	49	)	)	PUNCT
dpc-5196	126	50	total	total	NOUN
dpc-5196	126	51	46.43	46.43	NUM
dpc-5196	126	52	±	±	NUM
dpc-5196	126	53	14.15	14.15	NUM
dpc-5196	126	54	100	100	NUM
dpc-5196	126	55	(	(	PUNCT
dpc-5196	126	56	50	50	NUM
dpc-5196	126	57	)	)	PUNCT
dpc-5196	126	58	45.30	45.30	NUM
dpc-5196	126	59	±	±	NUM
dpc-5196	126	60	15.74	15.74	NUM
dpc-5196	126	61	100	100	NUM
dpc-5196	126	62	(	(	PUNCT
dpc-5196	126	63	50	50	NUM
dpc-5196	126	64	)	)	PUNCT
dpc-5196	126	65	0.594	0.594	NUM
dpc-5196	126	66	*	*	PUNCT
dpc-5196	126	67	*	*	PUNCT
dpc-5196	126	68	angioedema	angioedema	ADV
dpc-5196	126	69	present	present	ADJ
dpc-5196	126	70	absent	absent	ADJ
dpc-5196	126	71	total	total	NOUN
dpc-5196	126	72	54	54	NUM
dpc-5196	126	73	(	(	PUNCT
dpc-5196	126	74	54.5	54.5	NUM
dpc-5196	126	75	)	)	PUNCT
dpc-5196	126	76	46	46	NUM
dpc-5196	126	77	(	(	PUNCT
dpc-5196	126	78	45.5	45.5	NUM
dpc-5196	126	79	)	)	PUNCT
dpc-5196	126	80	100	100	NUM
dpc-5196	126	81	(	(	PUNCT
dpc-5196	126	82	50	50	NUM
dpc-5196	126	83	)	)	PUNCT
dpc-5196	126	84	45	45	NUM
dpc-5196	126	85	(	(	PUNCT
dpc-5196	126	86	45.5	45.5	NUM
dpc-5196	126	87	)	)	PUNCT
dpc-5196	126	88	55	55	NUM
dpc-5196	126	89	(	(	PUNCT
dpc-5196	126	90	54.5	54.5	NUM
dpc-5196	126	91	)	)	PUNCT
dpc-5196	126	92	100	100	NUM
dpc-5196	126	93	(	(	PUNCT
dpc-5196	126	94	50	50	NUM
dpc-5196	126	95	)	)	PUNCT
dpc-5196	126	96	0.203	0.203	NUM
dpc-5196	126	97	*	*	PUNCT
dpc-5196	126	98	hypothyroidism	hypothyroidism	NOUN
dpc-5196	126	99	present	present	ADJ
dpc-5196	126	100	absent	absent	ADJ
dpc-5196	126	101	total	total	NOUN
dpc-5196	126	102	6	6	NUM
dpc-5196	126	103	(	(	PUNCT
dpc-5196	126	104	42.9	42.9	NUM
dpc-5196	126	105	)	)	PUNCT
dpc-5196	126	106	94	94	NUM
dpc-5196	126	107	(	(	PUNCT
dpc-5196	126	108	50.5	50.5	NUM
dpc-5196	126	109	)	)	PUNCT
dpc-5196	126	110	100	100	NUM
dpc-5196	126	111	(	(	PUNCT
dpc-5196	126	112	50	50	NUM
dpc-5196	126	113	)	)	PUNCT
dpc-5196	126	114	8	8	NUM
dpc-5196	126	115	(	(	PUNCT
dpc-5196	126	116	57.1	57.1	NUM
dpc-5196	126	117	)	)	PUNCT
dpc-5196	126	118	92	92	NUM
dpc-5196	126	119	(	(	PUNCT
dpc-5196	126	120	49.5	49.5	NUM
dpc-5196	126	121	)	)	PUNCT
dpc-5196	126	122	100	100	NUM
dpc-5196	126	123	(	(	PUNCT
dpc-5196	126	124	50	50	NUM
dpc-5196	126	125	)	)	PUNCT
dpc-5196	126	126	0.782	0.782	NUM
dpc-5196	126	127	*	*	PUNCT
dpc-5196	126	128	*	*	PUNCT
dpc-5196	126	129	*	*	PUNCT
dpc-5196	126	130	duration	duration	NOUN
dpc-5196	126	131	of	of	ADP
dpc-5196	126	132	disease	disease	NOUN
dpc-5196	126	133	mean	mean	VERB
dpc-5196	126	134	±	±	NUM
dpc-5196	126	135	sd	sd	ADP
dpc-5196	126	136	(	(	PUNCT
dpc-5196	126	137	months	month	NOUN
dpc-5196	126	138	)	)	PUNCT
dpc-5196	126	139	total	total	NOUN
dpc-5196	126	140	7.67	7.67	NUM
dpc-5196	126	141	±	±	NUM
dpc-5196	126	142	6.55	6.55	NUM
dpc-5196	126	143	100	100	NUM
dpc-5196	126	144	(	(	PUNCT
dpc-5196	126	145	50	50	NUM
dpc-5196	126	146	)	)	PUNCT
dpc-5196	126	147	4.51	4.51	NUM
dpc-5196	126	148	±	±	NUM
dpc-5196	126	149	4.40	4.40	NUM
dpc-5196	126	150	100	100	NUM
dpc-5196	126	151	(	(	PUNCT
dpc-5196	126	152	50	50	NUM
dpc-5196	126	153	)	)	PUNCT
dpc-5196	126	154	<	<	X
dpc-5196	126	155	0.001	0.001	NUM
dpc-5196	126	156	*	*	NOUN
dpc-5196	126	157	*	*	NOUN
dpc-5196	126	158	previous	previous	ADJ
dpc-5196	126	159	treatments	treatment	NOUN
dpc-5196	126	160	ah	ah	INTJ
dpc-5196	126	161	>	>	SYM
dpc-5196	126	162	1	1	NUM
dpc-5196	126	163	agent	agent	NOUN
dpc-5196	126	164	total	total	NOUN
dpc-5196	126	165	52	52	NUM
dpc-5196	126	166	(	(	PUNCT
dpc-5196	126	167	47.3	47.3	NUM
dpc-5196	126	168	)	)	PUNCT
dpc-5196	126	169	48	48	NUM
dpc-5196	126	170	(	(	PUNCT
dpc-5196	126	171	53.3	53.3	NUM
dpc-5196	126	172	)	)	PUNCT
dpc-5196	126	173	100	100	NUM
dpc-5196	126	174	(	(	PUNCT
dpc-5196	126	175	50	50	NUM
dpc-5196	126	176	)	)	PUNCT
dpc-5196	126	177	58	58	NUM
dpc-5196	126	178	(	(	PUNCT
dpc-5196	126	179	52.7	52.7	NUM
dpc-5196	126	180	)	)	PUNCT
dpc-5196	126	181	42	42	NUM
dpc-5196	126	182	(	(	PUNCT
dpc-5196	126	183	46.7	46.7	NUM
dpc-5196	126	184	)	)	PUNCT
dpc-5196	126	185	100	100	NUM
dpc-5196	126	186	(	(	PUNCT
dpc-5196	126	187	50	50	NUM
dpc-5196	126	188	)	)	PUNCT
dpc-5196	126	189	0.394	0.394	NUM
dpc-5196	126	190	*	*	PUNCT
dpc-5196	126	191	treatment	treatment	NOUN
dpc-5196	126	192	response	response	NOUN
dpc-5196	126	193	time	time	NOUN
dpc-5196	126	194	1st	1st	ADJ
dpc-5196	126	195	month	month	NOUN
dpc-5196	126	196	>	>	SYM
dpc-5196	126	197	1	1	NUM
dpc-5196	126	198	month	month	NOUN
dpc-5196	126	199	total	total	NOUN
dpc-5196	126	200	65	65	NUM
dpc-5196	126	201	(	(	PUNCT
dpc-5196	126	202	51.6	51.6	NUM
dpc-5196	126	203	)	)	PUNCT
dpc-5196	126	204	21	21	NUM
dpc-5196	126	205	(	(	PUNCT
dpc-5196	126	206	40.4	40.4	NUM
dpc-5196	126	207	)	)	PUNCT
dpc-5196	126	208	86	86	NUM
dpc-5196	126	209	(	(	PUNCT
dpc-5196	126	210	48.3	48.3	NUM
dpc-5196	126	211	)	)	PUNCT
dpc-5196	126	212	61	61	NUM
dpc-5196	126	213	(	(	PUNCT
dpc-5196	126	214	48.4	48.4	NUM
dpc-5196	126	215	)	)	PUNCT
dpc-5196	126	216	31	31	NUM
dpc-5196	126	217	(	(	PUNCT
dpc-5196	126	218	59.6	59.6	NUM
dpc-5196	126	219	)	)	PUNCT
dpc-5196	126	220	92	92	NUM
dpc-5196	126	221	(	(	PUNCT
dpc-5196	126	222	51.7	51.7	NUM
dpc-5196	126	223	)	)	PUNCT
dpc-5196	126	224	0.174	0.174	NUM
dpc-5196	126	225	*	*	PUNCT
dpc-5196	126	226	duration	duration	NOUN
dpc-5196	126	227	of	of	ADP
dpc-5196	126	228	ah	ah	INTJ
dpc-5196	126	229	use	use	VERB
dpc-5196	126	230	≤3	≤3	ADJ
dpc-5196	126	231	months	month	NOUN
dpc-5196	126	232	>	>	SYM
dpc-5196	126	233	3	3	NUM
dpc-5196	126	234	months	month	NOUN
dpc-5196	126	235	total	total	ADJ
dpc-5196	126	236	22	22	NUM
dpc-5196	126	237	(	(	PUNCT
dpc-5196	126	238	35.5	35.5	NUM
dpc-5196	126	239	)	)	PUNCT
dpc-5196	126	240	38	38	NUM
dpc-5196	126	241	(	(	PUNCT
dpc-5196	126	242	60.3	60.3	NUM
dpc-5196	126	243	)	)	SYM
dpc-5196	126	244	60	60	NUM
dpc-5196	126	245	(	(	PUNCT
dpc-5196	126	246	48	48	NUM
dpc-5196	126	247	)	)	PUNCT
dpc-5196	126	248	40	40	NUM
dpc-5196	126	249	(	(	PUNCT
dpc-5196	126	250	64.5	64.5	NUM
dpc-5196	126	251	)	)	PUNCT
dpc-5196	126	252	25	25	NUM
dpc-5196	126	253	(	(	PUNCT
dpc-5196	126	254	39.7	39.7	NUM
dpc-5196	126	255	)	)	PUNCT
dpc-5196	126	256	65	65	NUM
dpc-5196	126	257	(	(	PUNCT
dpc-5196	126	258	52	52	NUM
dpc-5196	126	259	)	)	PUNCT
dpc-5196	126	260	0.005	0.005	NUM
dpc-5196	126	261	*	*	PUNCT
dpc-5196	126	262	basopenia	basopenia	NOUN
dpc-5196	126	263	present	present	ADJ
dpc-5196	126	264	absent	absent	ADJ
dpc-5196	126	265	total	total	ADJ
dpc-5196	126	266	7	7	NUM
dpc-5196	126	267	(	(	PUNCT
dpc-5196	126	268	35	35	NUM
dpc-5196	126	269	)	)	PUNCT
dpc-5196	126	270	63	63	NUM
dpc-5196	126	271	(	(	PUNCT
dpc-5196	126	272	52.1	52.1	NUM
dpc-5196	126	273	)	)	PUNCT
dpc-5196	126	274	70	70	NUM
dpc-5196	126	275	(	(	PUNCT
dpc-5196	126	276	49.6	49.6	NUM
dpc-5196	126	277	)	)	PUNCT
dpc-5196	126	278	13	13	NUM
dpc-5196	126	279	(	(	PUNCT
dpc-5196	126	280	65	65	NUM
dpc-5196	126	281	)	)	PUNCT
dpc-5196	126	282	58	58	NUM
dpc-5196	126	283	(	(	PUNCT
dpc-5196	126	284	47.9	47.9	NUM
dpc-5196	126	285	)	)	PUNCT
dpc-5196	126	286	71	71	NUM
dpc-5196	126	287	(	(	PUNCT
dpc-5196	126	288	50.4	50.4	NUM
dpc-5196	126	289	)	)	PUNCT
dpc-5196	126	290	0.241	0.241	NUM
dpc-5196	126	291	*	*	PUNCT
dpc-5196	126	292	*	*	PUNCT
dpc-5196	126	293	*	*	ADJ
dpc-5196	126	294	baseline	baseline	PROPN
dpc-5196	126	295	uas7	uas7	NOUN
dpc-5196	126	296	score	score	NOUN
dpc-5196	126	297	mean	mean	VERB
dpc-5196	126	298	±	±	NUM
dpc-5196	126	299	sd	sd	ADP
dpc-5196	126	300	total	total	NOUN
dpc-5196	126	301	39.21	39.21	NUM
dpc-5196	126	302	±	±	NUM
dpc-5196	126	303	6.11	6.11	NUM
dpc-5196	126	304	78	78	NUM
dpc-5196	126	305	(	(	PUNCT
dpc-5196	126	306	50.65	50.65	NUM
dpc-5196	126	307	)	)	PUNCT
dpc-5196	126	308	35.64	35.64	NUM
dpc-5196	126	309	±	±	NUM
dpc-5196	126	310	8.66	8.66	NUM
dpc-5196	126	311	76	76	NUM
dpc-5196	126	312	(	(	PUNCT
dpc-5196	126	313	49.35	49.35	NUM
dpc-5196	126	314	)	)	PUNCT
dpc-5196	126	315	0.004	0.004	NUM
dpc-5196	126	316	*	*	PUNCT
dpc-5196	126	317	*	*	PUNCT
dpc-5196	126	318	the	the	DET
dpc-5196	126	319	decrease	decrease	NOUN
dpc-5196	126	320	in	in	ADP
dpc-5196	126	321	uas7	uas7	NOUN
dpc-5196	126	322	score	score	NOUN
dpc-5196	126	323	at	at	ADP
dpc-5196	126	324	the	the	DET
dpc-5196	126	325	1st	1st	ADJ
dpc-5196	126	326	month	month	NOUN
dpc-5196	127	1	mean	mean	NOUN
dpc-5196	127	2	±	±	NUM
dpc-5196	127	3	sd	sd	NOUN
dpc-5196	127	4	(	(	PUNCT
dpc-5196	127	5	∆	∆	X
dpc-5196	127	6	)	)	PUNCT
dpc-5196	127	7	total	total	VERB
dpc-5196	127	8	31.22	31.22	NUM
dpc-5196	127	9	±	±	NUM
dpc-5196	127	10	12.32	12.32	NUM
dpc-5196	127	11	76	76	NUM
dpc-5196	127	12	(	(	PUNCT
dpc-5196	127	13	50.33	50.33	NUM
dpc-5196	127	14	)	)	PUNCT
dpc-5196	127	15	27.84	27.84	NUM
dpc-5196	127	16	±	±	NUM
dpc-5196	127	17	12.18	12.18	NUM
dpc-5196	127	18	75	75	NUM
dpc-5196	127	19	(	(	PUNCT
dpc-5196	127	20	49.66	49.66	NUM
dpc-5196	127	21	)	)	PUNCT
dpc-5196	127	22	0.092	0.092	NUM
dpc-5196	127	23	*	*	PUNCT
dpc-5196	127	24	*	*	PUNCT
dpc-5196	127	25	baseline	baseline	PROPN
dpc-5196	127	26	serum	serum	PROPN
dpc-5196	127	27	ige	ige	PROPN
dpc-5196	127	28	level	level	NOUN
dpc-5196	127	29	(	(	PUNCT
dpc-5196	127	30	iu	iu	NOUN
dpc-5196	127	31	/	/	SYM
dpc-5196	127	32	ml	ml	NOUN
dpc-5196	127	33	)	)	PUNCT
dpc-5196	127	34	median	median	ADJ
dpc-5196	127	35	total	total	NOUN
dpc-5196	127	36	111	111	NUM
dpc-5196	127	37	55	55	NUM
dpc-5196	127	38	(	(	PUNCT
dpc-5196	127	39	51.88	51.88	NUM
dpc-5196	127	40	)	)	PUNCT
dpc-5196	127	41	89	89	NUM
dpc-5196	127	42	51	51	NUM
dpc-5196	127	43	(	(	PUNCT
dpc-5196	127	44	48.12	48.12	NUM
dpc-5196	127	45	)	)	PUNCT
dpc-5196	127	46	0.410	0.410	NUM
dpc-5196	127	47	*	*	PUNCT
dpc-5196	127	48	*	*	PUNCT
dpc-5196	127	49	ratio	ratio	NOUN
dpc-5196	127	50	of	of	ADP
dpc-5196	127	51	serum	serum	NOUN
dpc-5196	127	52	ige	ige	PROPN
dpc-5196	127	53	level	level	NOUN
dpc-5196	127	54	at	at	ADP
dpc-5196	127	55	week	week	NOUN
dpc-5196	127	56	4	4	NUM
dpc-5196	127	57	to	to	PART
dpc-5196	127	58	baseline	baseline	VERB
dpc-5196	127	59	mean	mean	ADJ
dpc-5196	127	60	±	±	NUM
dpc-5196	127	61	sd	sd	ADP
dpc-5196	127	62	total	total	ADJ
dpc-5196	127	63	3.97	3.97	NUM
dpc-5196	127	64	±	±	NUM
dpc-5196	127	65	1.73	1.73	NUM
dpc-5196	127	66	25	25	NUM
dpc-5196	127	67	(	(	PUNCT
dpc-5196	127	68	48.07	48.07	NUM
dpc-5196	127	69	)	)	PUNCT
dpc-5196	127	70	4.31	4.31	NUM
dpc-5196	127	71	±	±	NUM
dpc-5196	127	72	2.19	2.19	NUM
dpc-5196	127	73	27	27	NUM
dpc-5196	127	74	(	(	PUNCT
dpc-5196	127	75	51.93	51.93	NUM
dpc-5196	127	76	)	)	PUNCT
dpc-5196	127	77	0.544	0.544	NUM
dpc-5196	127	78	*	*	PUNCT
dpc-5196	127	79	*	*	PUNCT
dpc-5196	127	80	*	*	PUNCT
dpc-5196	127	81	pearson	pearson	PROPN
dpc-5196	127	82	chi	chi	ADJ
dpc-5196	127	83	-	-	PUNCT
dpc-5196	127	84	squared	square	VERB
dpc-5196	127	85	test	test	NOUN
dpc-5196	127	86	;	;	PUNCT
dpc-5196	127	87	*	*	PUNCT
dpc-5196	127	88	*	*	PUNCT
dpc-5196	127	89	independent	independent	ADJ
dpc-5196	127	90	sample	sample	NOUN
dpc-5196	127	91	t	t	NOUN
dpc-5196	127	92	-	-	PUNCT
dpc-5196	127	93	test	test	NOUN
dpc-5196	127	94	;	;	PUNCT
dpc-5196	127	95	*	*	PUNCT
dpc-5196	127	96	*	*	PUNCT
dpc-5196	127	97	*	*	PUNCT
dpc-5196	127	98	continuity	continuity	NOUN
dpc-5196	127	99	correction	correction	NOUN
dpc-5196	127	100	test	test	NOUN
dpc-5196	127	101	sd	sd	NOUN
dpc-5196	127	102	,	,	PUNCT
dpc-5196	127	103	standard	standard	ADJ
dpc-5196	127	104	deviation	deviation	NOUN
dpc-5196	127	105	;	;	PUNCT
dpc-5196	127	106	ah	ah	INTJ
dpc-5196	127	107	,	,	PUNCT
dpc-5196	127	108	antihistamines	antihistamine	NOUN
dpc-5196	127	109	;	;	PUNCT
dpc-5196	127	110	uas7	uas7	NOUN
dpc-5196	127	111	,	,	PUNCT
dpc-5196	127	112	urticaria	urticaria	NOUN
dpc-5196	127	113	activity	activity	NOUN
dpc-5196	127	114	score	score	NOUN
dpc-5196	127	115	over	over	ADP
dpc-5196	127	116	7	7	NUM
dpc-5196	127	117	days	day	NOUN
dpc-5196	127	118	;	;	PUNCT
dpc-5196	127	119	ige	ige	PROPN
dpc-5196	127	120	,	,	PUNCT
dpc-5196	127	121	immunoglobulin	immunoglobulin	NOUN
dpc-5196	127	122	e	e	NOUN
dpc-5196	127	123	;	;	PUNCT
dpc-5196	127	124	iu	iu	ADP
dpc-5196	127	125	,	,	PUNCT
dpc-5196	127	126	international	international	ADJ
dpc-5196	127	127	unit	unit	NOUN
dpc-5196	127	128	.	.	PUNCT
dpc-5196	128	1	associated	associate	VERB
dpc-5196	128	2	with	with	ADP
dpc-5196	128	3	better	well	ADJ
dpc-5196	128	4	disease	disease	NOUN
dpc-5196	128	5	control	control	NOUN
dpc-5196	128	6	and	and	CCONJ
dpc-5196	128	7	longer	long	ADJ
dpc-5196	128	8	remissions	remission	NOUN
dpc-5196	128	9	[	[	X
dpc-5196	128	10	4	4	NUM
dpc-5196	128	11	]	]	PUNCT
dpc-5196	128	12	.	.	PUNCT
dpc-5196	129	1	our	our	PRON
dpc-5196	129	2	study	study	NOUN
dpc-5196	129	3	results	result	NOUN
dpc-5196	129	4	support	support	VERB
dpc-5196	129	5	these	these	DET
dpc-5196	129	6	findings	finding	NOUN
dpc-5196	129	7	.	.	PUNCT
dpc-5196	130	1	when	when	SCONJ
dpc-5196	130	2	comparing	compare	VERB
dpc-5196	130	3	discontinuation	discontinuation	NOUN
dpc-5196	130	4	methods	method	NOUN
dpc-5196	130	5	,	,	PUNCT
dpc-5196	130	6	the	the	DET
dpc-5196	130	7	lowest	low	ADJ
dpc-5196	130	8	relapse	relapse	NOUN
dpc-5196	130	9	rates	rate	NOUN
dpc-5196	130	10	were	be	AUX
dpc-5196	130	11	observed	observe	VERB
dpc-5196	130	12	in	in	ADP
dpc-5196	130	13	patients	patient	NOUN
dpc-5196	130	14	who	who	PRON
dpc-5196	130	15	discontinued	discontinue	VERB
dpc-5196	130	16	omalizumab	omalizumab	NOUN
dpc-5196	130	17	treatment	treatment	NOUN
dpc-5196	130	18	by	by	ADP
dpc-5196	130	19	reducing	reduce	VERB
dpc-5196	130	20	the	the	DET
dpc-5196	130	21	dose	dose	NOUN
dpc-5196	130	22	,	,	PUNCT
dpc-5196	130	23	followed	follow	VERB
dpc-5196	130	24	by	by	ADP
dpc-5196	130	25	those	those	PRON
dpc-5196	130	26	who	who	PRON
dpc-5196	130	27	gradually	gradually	ADV
dpc-5196	130	28	extended	extend	VERB
dpc-5196	130	29	the	the	DET
dpc-5196	130	30	dose	dose	NOUN
dpc-5196	130	31	intervals	interval	NOUN
dpc-5196	130	32	.	.	PUNCT
dpc-5196	131	1	the	the	DET
dpc-5196	131	2	highest	high	ADJ
dpc-5196	131	3	relapse	relapse	NOUN
dpc-5196	131	4	rates	rate	NOUN
dpc-5196	131	5	were	be	AUX
dpc-5196	131	6	observed	observe	VERB
dpc-5196	131	7	in	in	ADP
dpc-5196	131	8	patients	patient	NOUN
dpc-5196	131	9	who	who	PRON
dpc-5196	131	10	discontinued	discontinue	VERB
dpc-5196	131	11	treatment	treatment	NOUN
dpc-5196	131	12	directly	directly	ADV
dpc-5196	131	13	without	without	ADP
dpc-5196	131	14	altering	alter	VERB
dpc-5196	131	15	the	the	DET
dpc-5196	131	16	dose	dose	NOUN
dpc-5196	131	17	or	or	CCONJ
dpc-5196	131	18	dose	dose	NOUN
dpc-5196	131	19	interval	interval	NOUN
dpc-5196	131	20	.	.	PUNCT
dpc-5196	132	1	previous	previous	ADJ
dpc-5196	132	2	studies	study	NOUN
dpc-5196	132	3	have	have	AUX
dpc-5196	132	4	shown	show	VERB
dpc-5196	132	5	that	that	SCONJ
dpc-5196	132	6	patients	patient	NOUN
dpc-5196	132	7	who	who	PRON
dpc-5196	132	8	gradually	gradually	ADV
dpc-5196	132	9	tapered	taper	VERB
dpc-5196	132	10	treatment	treatment	NOUN
dpc-5196	132	11	by	by	ADP
dpc-5196	132	12	extending	extend	VERB
dpc-5196	132	13	the	the	DET
dpc-5196	132	14	dose	dose	NOUN
dpc-5196	132	15	intervals	interval	NOUN
dpc-5196	132	16	to	to	ADP
dpc-5196	132	17	eight	eight	NUM
dpc-5196	132	18	weeks	week	NOUN
dpc-5196	132	19	had	have	VERB
dpc-5196	132	20	a	a	DET
dpc-5196	132	21	lower	low	ADJ
dpc-5196	132	22	relapse	relapse	NOUN
dpc-5196	132	23	rate	rate	NOUN
dpc-5196	132	24	compared	compare	VERB
dpc-5196	132	25	to	to	ADP
dpc-5196	132	26	those	those	PRON
dpc-5196	132	27	who	who	PRON
dpc-5196	132	28	discontinued	discontinue	VERB
dpc-5196	132	29	treatment	treatment	NOUN
dpc-5196	132	30	directly	directly	ADV
dpc-5196	132	31	.	.	PUNCT
dpc-5196	133	1	in	in	ADP
dpc-5196	133	2	the	the	DET
dpc-5196	133	3	optima	optima	PROPN
dpc-5196	133	4	study	study	NOUN
dpc-5196	133	5	,	,	PUNCT
dpc-5196	133	6	patients	patient	NOUN
dpc-5196	133	7	who	who	PRON
dpc-5196	133	8	discontinued	discontinue	VERB
dpc-5196	133	9	omalizumab	omalizumab	NOUN
dpc-5196	133	10	treatment	treatment	NOUN
dpc-5196	133	11	by	by	ADP
dpc-5196	133	12	reducing	reduce	VERB
dpc-5196	133	13	the	the	DET
dpc-5196	133	14	dose	dose	NOUN
dpc-5196	133	15	to	to	ADP
dpc-5196	133	16	150	150	NUM
dpc-5196	133	17	mg/4	mg/4	PROPN
dpc-5196	133	18	weeks	week	NOUN
dpc-5196	133	19	had	have	VERB
dpc-5196	133	20	a	a	DET
dpc-5196	133	21	relapse	relapse	NOUN
dpc-5196	133	22	rate	rate	NOUN
dpc-5196	133	23	of	of	ADP
dpc-5196	133	24	44	44	NUM
dpc-5196	133	25	%	%	NOUN
dpc-5196	133	26	,	,	PUNCT
dpc-5196	133	27	while	while	SCONJ
dpc-5196	133	28	patients	patient	NOUN
dpc-5196	133	29	who	who	PRON
dpc-5196	133	30	discontinued	discontinue	VERB
dpc-5196	133	31	treatment	treatment	NOUN
dpc-5196	133	32	at	at	ADP
dpc-5196	133	33	a	a	DET
dpc-5196	133	34	dose	dose	NOUN
dpc-5196	133	35	of	of	ADP
dpc-5196	133	36	300	300	NUM
dpc-5196	133	37	mg/4	mg/4	NOUN
dpc-5196	133	38	weeks	week	NOUN
dpc-5196	133	39	had	have	VERB
dpc-5196	133	40	a	a	DET
dpc-5196	133	41	relapse	relapse	NOUN
dpc-5196	133	42	rate	rate	NOUN
dpc-5196	133	43	of	of	ADP
dpc-5196	133	44	50	50	NUM
dpc-5196	133	45	%	%	NOUN
dpc-5196	134	1	[	[	X
dpc-5196	134	2	4,5	4,5	NUM
dpc-5196	134	3	]	]	PUNCT
dpc-5196	134	4	.	.	PUNCT
dpc-5196	135	1	this	this	PRON
dpc-5196	135	2	may	may	AUX
dpc-5196	135	3	be	be	AUX
dpc-5196	135	4	because	because	SCONJ
dpc-5196	135	5	patients	patient	NOUN
dpc-5196	135	6	who	who	PRON
dpc-5196	135	7	tapered	taper	VERB
dpc-5196	135	8	were	be	AUX
dpc-5196	135	9	able	able	ADJ
dpc-5196	135	10	to	to	PART
dpc-5196	135	11	stop	stop	VERB
dpc-5196	135	12	treatment	treatment	NOUN
dpc-5196	135	13	in	in	ADP
dpc-5196	135	14	a	a	DET
dpc-5196	135	15	more	more	ADV
dpc-5196	135	16	controlled	control	VERB
dpc-5196	135	17	manner	manner	NOUN
dpc-5196	135	18	.	.	PUNCT
dpc-5196	136	1	some	some	DET
dpc-5196	136	2	patients	patient	NOUN
dpc-5196	136	3	who	who	PRON
dpc-5196	136	4	discontinued	discontinue	VERB
dpc-5196	136	5	treatment	treatment	NOUN
dpc-5196	136	6	directly	directly	ADV
dpc-5196	136	7	did	do	VERB
dpc-5196	136	8	so	so	ADV
dpc-5196	136	9	independently	independently	ADV
dpc-5196	136	10	of	of	ADP
dpc-5196	136	11	their	their	PRON
dpc-5196	136	12	physician	physician	NOUN
dpc-5196	136	13	,	,	PUNCT
dpc-5196	136	14	believing	believe	VERB
dpc-5196	136	15	they	they	PRON
dpc-5196	136	16	had	have	AUX
dpc-5196	136	17	recovered	recover	VERB
dpc-5196	136	18	,	,	PUNCT
dpc-5196	136	19	which	which	PRON
dpc-5196	136	20	likely	likely	ADV
dpc-5196	136	21	contributed	contribute	VERB
dpc-5196	136	22	to	to	ADP
dpc-5196	136	23	higher	high	ADJ
dpc-5196	136	24	relapse	relapse	NOUN
dpc-5196	136	25	rates	rate	NOUN
dpc-5196	136	26	in	in	ADP
dpc-5196	136	27	this	this	DET
dpc-5196	136	28	group	group	NOUN
dpc-5196	136	29	.	.	PUNCT
dpc-5196	137	1	patients	patient	NOUN
dpc-5196	137	2	who	who	PRON
dpc-5196	137	3	tolerate	tolerate	VERB
dpc-5196	137	4	step	step	NOUN
dpc-5196	137	5	therapy	therapy	NOUN
dpc-5196	137	6	not	not	PART
dpc-5196	137	7	only	only	ADV
dpc-5196	137	8	require	require	VERB
dpc-5196	137	9	less	less	ADJ
dpc-5196	137	10	medication	medication	NOUN
dpc-5196	137	11	but	but	CCONJ
dpc-5196	137	12	are	be	AUX
dpc-5196	137	13	also	also	ADV
dpc-5196	137	14	more	more	ADV
dpc-5196	137	15	likely	likely	ADJ
dpc-5196	137	16	to	to	PART
dpc-5196	137	17	discontinue	discontinue	VERB
dpc-5196	137	18	treatment	treatment	NOUN
dpc-5196	137	19	.	.	PUNCT
dpc-5196	138	1	the	the	DET
dpc-5196	138	2	duration	duration	NOUN
dpc-5196	138	3	that	that	PRON
dpc-5196	138	4	patients	patient	NOUN
dpc-5196	138	5	can	can	AUX
dpc-5196	138	6	tolerate	tolerate	VERB
dpc-5196	138	7	varies	varie	NOUN
dpc-5196	138	8	as	as	SCONJ
dpc-5196	138	9	dose	dose	NOUN
dpc-5196	138	10	intervals	interval	NOUN
dpc-5196	138	11	are	be	AUX
dpc-5196	138	12	increased	increase	VERB
dpc-5196	138	13	.	.	PUNCT
dpc-5196	139	1	in	in	ADP
dpc-5196	139	2	one	one	NUM
dpc-5196	139	3	study	study	NOUN
dpc-5196	139	4	,	,	PUNCT
dpc-5196	139	5	patients	patient	NOUN
dpc-5196	139	6	were	be	AUX
dpc-5196	139	7	followed	follow	VERB
dpc-5196	139	8	at	at	ADP
dpc-5196	139	9	12	12	NUM
dpc-5196	139	10	-	-	PUNCT
dpc-5196	139	11	week	week	NOUN
dpc-5196	139	12	intervals	interval	NOUN
dpc-5196	139	13	,	,	PUNCT
dpc-5196	139	14	while	while	SCONJ
dpc-5196	139	15	in	in	ADP
dpc-5196	139	16	another	another	DET
dpc-5196	139	17	study	study	NOUN
dpc-5196	139	18	,	,	PUNCT
dpc-5196	139	19	6	6	NUM
dpc-5196	139	20	-	-	PUNCT
dpc-5196	139	21	week	week	NOUN
dpc-5196	139	22	intervals	interval	NOUN
dpc-5196	139	23	were	be	AUX
dpc-5196	139	24	found	find	VERB
dpc-5196	139	25	to	to	PART
dpc-5196	139	26	be	be	AUX
dpc-5196	139	27	adequate	adequate	ADJ
dpc-5196	139	28	for	for	ADP
dpc-5196	139	29	symptom	symptom	NOUN
dpc-5196	139	30	control	control	NOUN
dpc-5196	139	31	;	;	PUNCT
dpc-5196	139	32	however	however	ADV
dpc-5196	139	33	,	,	PUNCT
dpc-5196	139	34	original	original	ADJ
dpc-5196	139	35	article	article	NOUN
dpc-5196	139	36	|	|	ADV
dpc-5196	139	37	dermatol	dermatol	ADJ
dpc-5196	139	38	pract	pract	NOUN
dpc-5196	139	39	concept	concept	NOUN
dpc-5196	139	40	.	.	PUNCT
dpc-5196	140	1	2025;15(3):5196	2025;15(3):5196	NOUN
dpc-5196	140	2	7	7	NUM
dpc-5196	140	3	marzano	marzano	NOUN
dpc-5196	140	4	et	et	PROPN
dpc-5196	140	5	al	al	PROPN
dpc-5196	140	6	.	.	PROPN
dpc-5196	140	7	found	find	VERB
dpc-5196	140	8	that	that	SCONJ
dpc-5196	140	9	high	high	ADJ
dpc-5196	140	10	baseline	baseline	NOUN
dpc-5196	140	11	uas7	uas7	PROPN
dpc-5196	140	12	scores	score	NOUN
dpc-5196	140	13	and	and	CCONJ
dpc-5196	140	14	longer	long	ADJ
dpc-5196	140	15	disease	disease	NOUN
dpc-5196	140	16	duration	duration	NOUN
dpc-5196	140	17	were	be	AUX
dpc-5196	140	18	associated	associate	VERB
dpc-5196	140	19	with	with	ADP
dpc-5196	140	20	higher	high	ADJ
dpc-5196	140	21	relapse	relapse	NOUN
dpc-5196	140	22	rates	rate	NOUN
dpc-5196	140	23	,	,	PUNCT
dpc-5196	140	24	while	while	SCONJ
dpc-5196	140	25	salman	salman	PROPN
dpc-5196	140	26	et	et	PROPN
dpc-5196	140	27	al	al	PROPN
dpc-5196	140	28	.	.	PROPN
dpc-5196	140	29	identified	identify	VERB
dpc-5196	140	30	younger	young	ADJ
dpc-5196	140	31	age	age	NOUN
dpc-5196	140	32	(	(	PUNCT
dpc-5196	140	33	<	<	X
dpc-5196	140	34	40	40	NUM
dpc-5196	140	35	years	year	NOUN
dpc-5196	140	36	)	)	PUNCT
dpc-5196	140	37	as	as	ADP
dpc-5196	140	38	a	a	DET
dpc-5196	140	39	factor	factor	NOUN
dpc-5196	140	40	contributing	contribute	VERB
dpc-5196	140	41	to	to	ADP
dpc-5196	140	42	more	more	ADV
dpc-5196	140	43	frequent	frequent	ADJ
dpc-5196	140	44	relapses	relapse	NOUN
dpc-5196	140	45	[	[	X
dpc-5196	140	46	4,16	4,16	NUM
dpc-5196	140	47	]	]	X
dpc-5196	140	48	.	.	PUNCT
dpc-5196	141	1	in	in	ADP
dpc-5196	141	2	a	a	DET
dpc-5196	141	3	study	study	NOUN
dpc-5196	141	4	of	of	ADP
dpc-5196	141	5	152	152	NUM
dpc-5196	141	6	patients	patient	NOUN
dpc-5196	141	7	,	,	PUNCT
dpc-5196	141	8	su	su	PROPN
dpc-5196	141	9	et	et	PROPN
dpc-5196	141	10	al	al	PROPN
dpc-5196	141	11	.	.	PROPN
dpc-5196	141	12	found	find	VERB
dpc-5196	141	13	that	that	SCONJ
dpc-5196	141	14	longer	long	ADJ
dpc-5196	141	15	disease	disease	NOUN
dpc-5196	141	16	duration	duration	NOUN
dpc-5196	141	17	was	be	AUX
dpc-5196	141	18	significantly	significantly	ADV
dpc-5196	141	19	associated	associate	VERB
dpc-5196	141	20	with	with	ADP
dpc-5196	141	21	higher	high	ADJ
dpc-5196	141	22	relapse	relapse	NOUN
dpc-5196	141	23	rates	rate	NOUN
dpc-5196	141	24	,	,	PUNCT
dpc-5196	141	25	whereas	whereas	SCONJ
dpc-5196	141	26	duration	duration	NOUN
dpc-5196	141	27	of	of	ADP
dpc-5196	141	28	omalizumab	omalizumab	NOUN
dpc-5196	141	29	treatment	treatment	NOUN
dpc-5196	141	30	did	do	AUX
dpc-5196	141	31	not	not	PART
dpc-5196	141	32	affect	affect	VERB
dpc-5196	141	33	the	the	DET
dpc-5196	141	34	occurrence	occurrence	NOUN
dpc-5196	141	35	of	of	ADP
dpc-5196	141	36	relapses	relapse	NOUN
dpc-5196	141	37	[	[	X
dpc-5196	141	38	15	15	NUM
dpc-5196	141	39	]	]	PUNCT
dpc-5196	141	40	.	.	PUNCT
dpc-5196	142	1	similarly	similarly	ADV
dpc-5196	142	2	,	,	PUNCT
dpc-5196	142	3	sardana	sardana	PROPN
dpc-5196	142	4	et	et	PROPN
dpc-5196	142	5	al	al	PROPN
dpc-5196	142	6	.	.	PROPN
dpc-5196	142	7	concluded	conclude	VERB
dpc-5196	142	8	that	that	SCONJ
dpc-5196	142	9	omalizumab	omalizumab	NOUN
dpc-5196	142	10	administration	administration	NOUN
dpc-5196	142	11	for	for	ADP
dpc-5196	142	12	longer	long	ADJ
dpc-5196	142	13	than	than	ADP
dpc-5196	142	14	6–12	6–12	NOUN
dpc-5196	142	15	months	month	NOUN
dpc-5196	142	16	did	do	AUX
dpc-5196	142	17	not	not	PART
dpc-5196	142	18	reduce	reduce	VERB
dpc-5196	142	19	relapse	relapse	NOUN
dpc-5196	142	20	rates	rate	NOUN
dpc-5196	142	21	[	[	X
dpc-5196	142	22	17	17	NUM
dpc-5196	142	23	]	]	PUNCT
dpc-5196	142	24	.	.	PUNCT
dpc-5196	143	1	these	these	DET
dpc-5196	143	2	findings	finding	NOUN
dpc-5196	143	3	underscore	underscore	VERB
dpc-5196	143	4	the	the	DET
dpc-5196	143	5	lack	lack	NOUN
dpc-5196	143	6	of	of	ADP
dpc-5196	143	7	consensus	consensus	NOUN
dpc-5196	143	8	among	among	ADP
dpc-5196	143	9	researchers	researcher	NOUN
dpc-5196	143	10	regarding	regard	VERB
dpc-5196	143	11	the	the	DET
dpc-5196	143	12	factors	factor	NOUN
dpc-5196	143	13	influencing	influence	VERB
dpc-5196	143	14	relapse	relapse	NOUN
dpc-5196	143	15	rates	rate	NOUN
dpc-5196	143	16	.	.	PUNCT
dpc-5196	144	1	recent	recent	ADJ
dpc-5196	144	2	studies	study	NOUN
dpc-5196	144	3	have	have	AUX
dpc-5196	144	4	reported	report	VERB
dpc-5196	144	5	that	that	SCONJ
dpc-5196	144	6	even	even	ADV
dpc-5196	144	7	when	when	SCONJ
dpc-5196	144	8	treatment	treatment	NOUN
dpc-5196	144	9	was	be	AUX
dpc-5196	144	10	continued	continue	VERB
dpc-5196	144	11	for	for	ADP
dpc-5196	144	12	at	at	ADV
dpc-5196	144	13	least	least	ADV
dpc-5196	144	14	one	one	NUM
dpc-5196	144	15	year	year	NOUN
dpc-5196	144	16	,	,	PUNCT
dpc-5196	144	17	symptoms	symptom	NOUN
dpc-5196	144	18	returned	return	VERB
dpc-5196	144	19	in	in	ADP
dpc-5196	144	20	approximately	approximately	ADV
dpc-5196	144	21	61	61	NUM
dpc-5196	144	22	%	%	NOUN
dpc-5196	144	23	of	of	ADP
dpc-5196	144	24	patients	patient	NOUN
dpc-5196	144	25	after	after	ADP
dpc-5196	144	26	omalizumab	omalizumab	NOUN
dpc-5196	144	27	discontinuation	discontinuation	NOUN
dpc-5196	144	28	.	.	PUNCT
dpc-5196	145	1	when	when	SCONJ
dpc-5196	145	2	symptoms	symptom	NOUN
dpc-5196	145	3	worsened	worsen	VERB
dpc-5196	145	4	,	,	PUNCT
dpc-5196	145	5	ahs	ah	NOUN
dpc-5196	145	6	often	often	ADV
dpc-5196	145	7	proved	prove	VERB
dpc-5196	145	8	to	to	PART
dpc-5196	145	9	be	be	AUX
dpc-5196	145	10	inadequate	inadequate	ADJ
dpc-5196	145	11	,	,	PUNCT
dpc-5196	145	12	prompting	prompt	VERB
dpc-5196	145	13	the	the	DET
dpc-5196	145	14	majority	majority	NOUN
dpc-5196	145	15	of	of	ADP
dpc-5196	145	16	patients	patient	NOUN
dpc-5196	145	17	to	to	PART
dpc-5196	145	18	resume	resume	VERB
dpc-5196	145	19	omalizumab	omalizumab	NOUN
dpc-5196	145	20	treatment	treatment	NOUN
dpc-5196	145	21	.	.	PUNCT
dpc-5196	146	1	türk	türk	PROPN
dpc-5196	146	2	et	et	PROPN
dpc-5196	146	3	al	al	PROPN
dpc-5196	146	4	.	.	PROPN
dpc-5196	146	5	reported	report	VERB
dpc-5196	146	6	that	that	SCONJ
dpc-5196	146	7	91	91	NUM
dpc-5196	146	8	%	%	NOUN
dpc-5196	146	9	of	of	ADP
dpc-5196	146	10	patients	patient	NOUN
dpc-5196	146	11	who	who	PRON
dpc-5196	146	12	achieved	achieve	VERB
dpc-5196	146	13	a	a	DET
dpc-5196	146	14	complete	complete	ADJ
dpc-5196	146	15	response	response	NOUN
dpc-5196	146	16	to	to	ADP
dpc-5196	146	17	omalizumab	omalizumab	NOUN
dpc-5196	146	18	and	and	CCONJ
dpc-5196	146	19	experienced	experience	VERB
dpc-5196	146	20	relapse	relapse	NOUN
dpc-5196	146	21	after	after	ADP
dpc-5196	146	22	discontinuation	discontinuation	NOUN
dpc-5196	146	23	needed	need	VERB
dpc-5196	146	24	to	to	PART
dpc-5196	146	25	restart	restart	VERB
dpc-5196	146	26	omalizumab	omalizumab	NOUN
dpc-5196	146	27	[	[	X
dpc-5196	146	28	11,18	11,18	X
dpc-5196	146	29	]	]	X
dpc-5196	146	30	.	.	PUNCT
dpc-5196	147	1	similarly	similarly	ADV
dpc-5196	147	2	,	,	PUNCT
dpc-5196	147	3	most	most	ADJ
dpc-5196	147	4	patients	patient	NOUN
dpc-5196	147	5	in	in	ADP
dpc-5196	147	6	our	our	PRON
dpc-5196	147	7	study	study	NOUN
dpc-5196	147	8	restarted	restart	VERB
dpc-5196	147	9	omalizumab	omalizumab	NOUN
dpc-5196	147	10	due	due	ADP
dpc-5196	147	11	to	to	ADP
dpc-5196	147	12	an	an	DET
dpc-5196	147	13	inadequate	inadequate	ADJ
dpc-5196	147	14	response	response	NOUN
dpc-5196	147	15	to	to	ADP
dpc-5196	147	16	ahs	ahs	PROPN
dpc-5196	147	17	.	.	PUNCT
dpc-5196	148	1	when	when	SCONJ
dpc-5196	148	2	considering	consider	VERB
dpc-5196	148	3	retreatment	retreatment	NOUN
dpc-5196	148	4	with	with	ADP
dpc-5196	148	5	omalizumab	omalizumab	NOUN
dpc-5196	148	6	in	in	ADP
dpc-5196	148	7	relapsing	relapse	VERB
dpc-5196	148	8	patients	patient	NOUN
dpc-5196	148	9	,	,	PUNCT
dpc-5196	148	10	the	the	DET
dpc-5196	148	11	clinician	clinician	NOUN
dpc-5196	148	12	’s	’s	PART
dpc-5196	148	13	assessment	assessment	NOUN
dpc-5196	148	14	and	and	CCONJ
dpc-5196	148	15	the	the	DET
dpc-5196	148	16	patient	patient	NOUN
dpc-5196	148	17	’s	’s	PART
dpc-5196	148	18	expectations	expectation	NOUN
dpc-5196	148	19	are	be	AUX
dpc-5196	148	20	important	important	ADJ
dpc-5196	148	21	.	.	PUNCT
dpc-5196	149	1	according	accord	VERB
dpc-5196	149	2	to	to	ADP
dpc-5196	149	3	an	an	DET
dpc-5196	149	4	established	establish	VERB
dpc-5196	149	5	algorithm	algorithm	NOUN
dpc-5196	149	6	,	,	PUNCT
dpc-5196	149	7	omalizumab	omalizumab	NOUN
dpc-5196	149	8	should	should	AUX
dpc-5196	149	9	be	be	AUX
dpc-5196	149	10	reinitiated	reinitiate	VERB
dpc-5196	149	11	in	in	ADP
dpc-5196	149	12	relapsing	relapse	VERB
dpc-5196	149	13	patients	patient	NOUN
dpc-5196	149	14	if	if	SCONJ
dpc-5196	149	15	the	the	DET
dpc-5196	149	16	uas7	uas7	NOUN
dpc-5196	149	17	score	score	NOUN
dpc-5196	149	18	is	be	AUX
dpc-5196	149	19	>	>	X
dpc-5196	149	20	6	6	NUM
dpc-5196	149	21	or	or	CCONJ
dpc-5196	149	22	the	the	DET
dpc-5196	149	23	uct	uct	PROPN
dpc-5196	149	24	is	be	AUX
dpc-5196	149	25	<	<	X
dpc-5196	149	26	12	12	NUM
dpc-5196	149	27	.	.	PUNCT
dpc-5196	150	1	furthermore	furthermore	ADV
dpc-5196	150	2	,	,	PUNCT
dpc-5196	150	3	disease	disease	NOUN
dpc-5196	150	4	severity	severity	NOUN
dpc-5196	150	5	and	and	CCONJ
dpc-5196	150	6	history	history	NOUN
dpc-5196	150	7	of	of	ADP
dpc-5196	150	8	angioedema	angioedema	ADV
dpc-5196	150	9	are	be	AUX
dpc-5196	150	10	also	also	ADV
dpc-5196	150	11	important	important	ADJ
dpc-5196	150	12	factors	factor	NOUN
dpc-5196	150	13	.	.	PUNCT
dpc-5196	151	1	from	from	ADP
dpc-5196	151	2	another	another	DET
dpc-5196	151	3	perspective	perspective	NOUN
dpc-5196	151	4	,	,	PUNCT
dpc-5196	151	5	if	if	SCONJ
dpc-5196	151	6	the	the	DET
dpc-5196	151	7	patient	patient	NOUN
dpc-5196	151	8	’s	’s	PART
dpc-5196	151	9	symptoms	symptom	NOUN
dpc-5196	151	10	are	be	AUX
dpc-5196	151	11	milder	mild	ADJ
dpc-5196	151	12	,	,	PUNCT
dpc-5196	151	13	the	the	DET
dpc-5196	151	14	patient	patient	NOUN
dpc-5196	151	15	should	should	AUX
dpc-5196	151	16	be	be	AUX
dpc-5196	151	17	followed	follow	VERB
dpc-5196	151	18	and	and	CCONJ
dpc-5196	151	19	omalizumab	omalizumab	NOUN
dpc-5196	151	20	treatment	treatment	NOUN
dpc-5196	151	21	should	should	AUX
dpc-5196	151	22	be	be	AUX
dpc-5196	151	23	considered	consider	VERB
dpc-5196	151	24	if	if	SCONJ
dpc-5196	151	25	the	the	DET
dpc-5196	151	26	uas7	uas7	NOUN
dpc-5196	151	27	score	score	NOUN
dpc-5196	151	28	is	be	AUX
dpc-5196	151	29	>	>	X
dpc-5196	151	30	16	16	NUM
dpc-5196	152	1	[	[	X
dpc-5196	152	2	19	19	NUM
dpc-5196	152	3	]	]	PUNCT
dpc-5196	152	4	.	.	PUNCT
dpc-5196	153	1	limitations	limitation	NOUN
dpc-5196	153	2	there	there	PRON
dpc-5196	153	3	are	be	VERB
dpc-5196	153	4	several	several	ADJ
dpc-5196	153	5	limitations	limitation	NOUN
dpc-5196	153	6	to	to	ADP
dpc-5196	153	7	this	this	DET
dpc-5196	153	8	study	study	NOUN
dpc-5196	153	9	,	,	PUNCT
dpc-5196	153	10	including	include	VERB
dpc-5196	153	11	its	its	PRON
dpc-5196	153	12	retrospective	retrospective	ADJ
dpc-5196	153	13	nature	nature	NOUN
dpc-5196	153	14	,	,	PUNCT
dpc-5196	153	15	small	small	ADJ
dpc-5196	153	16	sample	sample	NOUN
dpc-5196	153	17	size	size	NOUN
dpc-5196	153	18	,	,	PUNCT
dpc-5196	153	19	lack	lack	NOUN
dpc-5196	153	20	of	of	ADP
dpc-5196	153	21	a	a	DET
dpc-5196	153	22	control	control	NOUN
dpc-5196	153	23	group	group	NOUN
dpc-5196	153	24	,	,	PUNCT
dpc-5196	153	25	and	and	CCONJ
dpc-5196	153	26	short	short	ADJ
dpc-5196	153	27	follow	follow	NOUN
dpc-5196	153	28	-	-	PUNCT
dpc-5196	153	29	up	up	NOUN
dpc-5196	153	30	period	period	NOUN
dpc-5196	153	31	.	.	PUNCT
dpc-5196	154	1	extending	extend	VERB
dpc-5196	154	2	the	the	DET
dpc-5196	154	3	follow	follow	NOUN
dpc-5196	154	4	-	-	PUNCT
dpc-5196	154	5	up	up	NOUN
dpc-5196	154	6	period	period	NOUN
dpc-5196	154	7	might	might	AUX
dpc-5196	154	8	have	have	AUX
dpc-5196	154	9	provided	provide	VERB
dpc-5196	154	10	more	more	ADJ
dpc-5196	154	11	comprehensive	comprehensive	ADJ
dpc-5196	154	12	results	result	NOUN
dpc-5196	154	13	,	,	PUNCT
dpc-5196	154	14	particularly	particularly	ADV
dpc-5196	154	15	with	with	ADP
dpc-5196	154	16	regard	regard	NOUN
dpc-5196	154	17	to	to	ADP
dpc-5196	154	18	the	the	DET
dpc-5196	154	19	occurrence	occurrence	NOUN
dpc-5196	154	20	of	of	ADP
dpc-5196	154	21	relapses	relapse	NOUN
dpc-5196	154	22	beyond	beyond	ADP
dpc-5196	154	23	the	the	DET
dpc-5196	154	24	initial	initial	ADJ
dpc-5196	154	25	15	15	NUM
dpc-5196	154	26	months	month	NOUN
dpc-5196	154	27	.	.	PUNCT
dpc-5196	155	1	conclusion	conclusion	NOUN
dpc-5196	155	2	the	the	DET
dpc-5196	155	3	present	present	ADJ
dpc-5196	155	4	study	study	NOUN
dpc-5196	155	5	found	find	VERB
dpc-5196	155	6	a	a	DET
dpc-5196	155	7	higher	high	ADJ
dpc-5196	155	8	relapse	relapse	NOUN
dpc-5196	155	9	rate	rate	NOUN
dpc-5196	155	10	in	in	ADP
dpc-5196	155	11	patients	patient	NOUN
dpc-5196	155	12	with	with	ADP
dpc-5196	155	13	longer	long	ADJ
dpc-5196	155	14	disease	disease	NOUN
dpc-5196	155	15	duration	duration	NOUN
dpc-5196	155	16	,	,	PUNCT
dpc-5196	155	17	higher	high	ADJ
dpc-5196	155	18	baseline	baseline	PROPN
dpc-5196	155	19	uas7	uas7	PROPN
dpc-5196	155	20	scores	score	NOUN
dpc-5196	155	21	,	,	PUNCT
dpc-5196	155	22	and	and	CCONJ
dpc-5196	155	23	prolonged	prolong	VERB
dpc-5196	155	24	use	use	NOUN
dpc-5196	155	25	of	of	ADP
dpc-5196	155	26	ahs	ahs	NOUN
dpc-5196	155	27	with	with	ADP
dpc-5196	155	28	omalizumab	omalizumab	NOUN
dpc-5196	155	29	for	for	ADP
dpc-5196	155	30	more	more	ADJ
dpc-5196	155	31	than	than	ADP
dpc-5196	155	32	three	three	NUM
dpc-5196	155	33	months	month	NOUN
dpc-5196	155	34	.	.	PUNCT
dpc-5196	156	1	these	these	DET
dpc-5196	156	2	factors	factor	NOUN
dpc-5196	156	3	may	may	AUX
dpc-5196	156	4	serve	serve	VERB
dpc-5196	156	5	as	as	ADP
dpc-5196	156	6	useful	useful	ADJ
dpc-5196	156	7	indicators	indicator	NOUN
dpc-5196	156	8	for	for	ADP
dpc-5196	156	9	patient	patient	ADJ
dpc-5196	156	10	monitoring	monitoring	NOUN
dpc-5196	156	11	and	and	CCONJ
dpc-5196	156	12	treatment	treatment	NOUN
dpc-5196	156	13	decisions	decision	NOUN
dpc-5196	156	14	.	.	PUNCT
dpc-5196	157	1	gradual	gradual	ADJ
dpc-5196	157	2	tapering	tapering	NOUN
dpc-5196	157	3	of	of	ADP
dpc-5196	157	4	treatment	treatment	NOUN
dpc-5196	157	5	rather	rather	ADV
dpc-5196	157	6	than	than	ADP
dpc-5196	157	7	direct	direct	ADJ
dpc-5196	157	8	discontinuation	discontinuation	NOUN
dpc-5196	157	9	has	have	AUX
dpc-5196	157	10	been	be	AUX
dpc-5196	157	11	shown	show	VERB
dpc-5196	157	12	to	to	PART
dpc-5196	157	13	prolong	prolong	VERB
dpc-5196	157	14	remission	remission	NOUN
dpc-5196	157	15	.	.	PUNCT
dpc-5196	158	1	achieving	achieve	VERB
dpc-5196	158	2	the	the	DET
dpc-5196	158	3	lowest	low	ADJ
dpc-5196	158	4	relapse	relapse	NOUN
dpc-5196	158	5	rate	rate	NOUN
dpc-5196	158	6	by	by	ADP
dpc-5196	158	7	reducing	reduce	VERB
dpc-5196	158	8	the	the	DET
dpc-5196	158	9	treatment	treatment	NOUN
dpc-5196	158	10	dose	dose	VERB
dpc-5196	158	11	to	to	ADP
dpc-5196	158	12	150	150	NUM
dpc-5196	158	13	mg/4	mg/4	PROPN
dpc-5196	158	14	weeks	week	NOUN
dpc-5196	158	15	is	be	AUX
dpc-5196	158	16	crucial	crucial	ADJ
dpc-5196	158	17	to	to	ADP
dpc-5196	158	18	designing	design	VERB
dpc-5196	158	19	the	the	DET
dpc-5196	158	20	omalizumab	omalizumab	NOUN
dpc-5196	158	21	discontinuation	discontinuation	NOUN
dpc-5196	158	22	protocol	protocol	NOUN
dpc-5196	158	23	and	and	CCONJ
dpc-5196	158	24	provides	provide	VERB
dpc-5196	158	25	valuable	valuable	ADJ
dpc-5196	158	26	insights	insight	NOUN
dpc-5196	158	27	for	for	ADP
dpc-5196	158	28	future	future	ADJ
dpc-5196	158	29	studies	study	NOUN
dpc-5196	158	30	.	.	PUNCT
dpc-5196	159	1	patients	patient	NOUN
dpc-5196	159	2	could	could	AUX
dpc-5196	159	3	not	not	PART
dpc-5196	159	4	tolerate	tolerate	VERB
dpc-5196	159	5	further	further	ADJ
dpc-5196	159	6	increases	increase	NOUN
dpc-5196	159	7	in	in	ADP
dpc-5196	159	8	dose	dose	NOUN
dpc-5196	159	9	intervals	interval	NOUN
dpc-5196	159	10	[	[	X
dpc-5196	159	11	3	3	NUM
dpc-5196	159	12	]	]	PUNCT
dpc-5196	159	13	.	.	PUNCT
dpc-5196	160	1	in	in	ADP
dpc-5196	160	2	our	our	PRON
dpc-5196	160	3	study	study	NOUN
dpc-5196	160	4	,	,	PUNCT
dpc-5196	160	5	patients	patient	NOUN
dpc-5196	160	6	whose	whose	DET
dpc-5196	160	7	symptoms	symptom	NOUN
dpc-5196	160	8	remained	remain	VERB
dpc-5196	160	9	controlled	control	VERB
dpc-5196	160	10	or	or	CCONJ
dpc-5196	160	11	were	be	AUX
dpc-5196	160	12	well	well	ADV
dpc-5196	160	13	controlled	control	VERB
dpc-5196	160	14	(	(	PUNCT
dpc-5196	160	15	uas7	uas7	PROPN
dpc-5196	160	16	<	<	X
dpc-5196	160	17	6	6	NUM
dpc-5196	160	18	)	)	PUNCT
dpc-5196	160	19	for	for	ADP
dpc-5196	160	20	at	at	ADV
dpc-5196	160	21	least	least	ADV
dpc-5196	160	22	two	two	NUM
dpc-5196	160	23	months	month	NOUN
dpc-5196	160	24	were	be	AUX
dpc-5196	160	25	discontinued	discontinue	VERB
dpc-5196	160	26	after	after	ADP
dpc-5196	160	27	tolerating	tolerate	VERB
dpc-5196	160	28	8	8	NUM
dpc-5196	160	29	-	-	PUNCT
dpc-5196	160	30	week	week	NOUN
dpc-5196	160	31	dose	dose	NOUN
dpc-5196	160	32	intervals	interval	NOUN
dpc-5196	160	33	.	.	PUNCT
dpc-5196	161	1	to	to	ADP
dpc-5196	161	2	date	date	NOUN
dpc-5196	161	3	,	,	PUNCT
dpc-5196	161	4	no	no	DET
dpc-5196	161	5	study	study	NOUN
dpc-5196	161	6	has	have	AUX
dpc-5196	161	7	compared	compare	VERB
dpc-5196	161	8	relapse	relapse	NOUN
dpc-5196	161	9	rates	rate	NOUN
dpc-5196	161	10	in	in	ADP
dpc-5196	161	11	patients	patient	NOUN
dpc-5196	161	12	who	who	PRON
dpc-5196	161	13	were	be	AUX
dpc-5196	161	14	tapered	taper	VERB
dpc-5196	161	15	to	to	ADP
dpc-5196	161	16	150	150	NUM
dpc-5196	161	17	mg/4	mg/4	NOUN
dpc-5196	161	18	weeks	week	NOUN
dpc-5196	161	19	versus	versus	ADP
dpc-5196	161	20	those	those	PRON
dpc-5196	161	21	who	who	PRON
dpc-5196	161	22	had	have	VERB
dpc-5196	161	23	their	their	PRON
dpc-5196	161	24	intervals	interval	NOUN
dpc-5196	161	25	extended	extend	VERB
dpc-5196	161	26	to	to	ADP
dpc-5196	161	27	eight	eight	NUM
dpc-5196	161	28	weeks	week	NOUN
dpc-5196	161	29	.	.	PUNCT
dpc-5196	162	1	the	the	DET
dpc-5196	162	2	observation	observation	NOUN
dpc-5196	162	3	of	of	ADP
dpc-5196	162	4	the	the	DET
dpc-5196	162	5	lowest	low	ADJ
dpc-5196	162	6	relapse	relapse	NOUN
dpc-5196	162	7	rate	rate	NOUN
dpc-5196	162	8	after	after	ADP
dpc-5196	162	9	dose	dose	NOUN
dpc-5196	162	10	reduction	reduction	NOUN
dpc-5196	162	11	in	in	ADP
dpc-5196	162	12	our	our	PRON
dpc-5196	162	13	study	study	NOUN
dpc-5196	162	14	is	be	AUX
dpc-5196	162	15	an	an	DET
dpc-5196	162	16	important	important	ADJ
dpc-5196	162	17	finding	finding	NOUN
dpc-5196	162	18	for	for	ADP
dpc-5196	162	19	omalizumab	omalizumab	NOUN
dpc-5196	162	20	discontinuation	discontinuation	NOUN
dpc-5196	162	21	strategies	strategy	NOUN
dpc-5196	162	22	.	.	PUNCT
dpc-5196	163	1	further	further	ADJ
dpc-5196	163	2	comprehensive	comprehensive	ADJ
dpc-5196	163	3	studies	study	NOUN
dpc-5196	163	4	are	be	AUX
dpc-5196	163	5	needed	need	VERB
dpc-5196	163	6	to	to	PART
dpc-5196	163	7	support	support	VERB
dpc-5196	163	8	this	this	DET
dpc-5196	163	9	hypothesis	hypothesis	NOUN
dpc-5196	163	10	.	.	PUNCT
dpc-5196	164	1	when	when	SCONJ
dpc-5196	164	2	analyzing	analyze	VERB
dpc-5196	164	3	the	the	DET
dpc-5196	164	4	results	result	NOUN
dpc-5196	164	5	of	of	ADP
dpc-5196	164	6	our	our	PRON
dpc-5196	164	7	study	study	NOUN
dpc-5196	164	8	,	,	PUNCT
dpc-5196	164	9	no	no	DET
dpc-5196	164	10	significant	significant	ADJ
dpc-5196	164	11	correlation	correlation	NOUN
dpc-5196	164	12	was	be	AUX
dpc-5196	164	13	found	find	VERB
dpc-5196	164	14	between	between	ADP
dpc-5196	164	15	the	the	DET
dpc-5196	164	16	relapse	relapse	NOUN
dpc-5196	164	17	rates	rate	NOUN
dpc-5196	164	18	and	and	CCONJ
dpc-5196	164	19	the	the	DET
dpc-5196	164	20	clinical	clinical	ADJ
dpc-5196	164	21	and	and	CCONJ
dpc-5196	164	22	demographic	demographic	ADJ
dpc-5196	164	23	characteristics	characteristic	NOUN
dpc-5196	164	24	of	of	ADP
dpc-5196	164	25	the	the	DET
dpc-5196	164	26	patients	patient	NOUN
dpc-5196	164	27	.	.	PUNCT
dpc-5196	165	1	in	in	ADP
dpc-5196	165	2	a	a	DET
dpc-5196	165	3	study	study	NOUN
dpc-5196	165	4	conducted	conduct	VERB
dpc-5196	165	5	in	in	ADP
dpc-5196	165	6	china	china	PROPN
dpc-5196	165	7	involving	involve	VERB
dpc-5196	165	8	235	235	NUM
dpc-5196	165	9	patients	patient	NOUN
dpc-5196	165	10	,	,	PUNCT
dpc-5196	165	11	sex	sex	NOUN
dpc-5196	165	12	,	,	PUNCT
dpc-5196	165	13	age	age	NOUN
dpc-5196	165	14	,	,	PUNCT
dpc-5196	165	15	disease	disease	NOUN
dpc-5196	165	16	duration	duration	NOUN
dpc-5196	165	17	,	,	PUNCT
dpc-5196	165	18	baseline	baseline	ADJ
dpc-5196	165	19	ige	ige	NOUN
dpc-5196	165	20	level	level	NOUN
dpc-5196	165	21	,	,	PUNCT
dpc-5196	165	22	and	and	CCONJ
dpc-5196	165	23	,	,	PUNCT
dpc-5196	165	24	unlike	unlike	ADP
dpc-5196	165	25	in	in	ADP
dpc-5196	165	26	our	our	PRON
dpc-5196	165	27	study	study	NOUN
dpc-5196	165	28	,	,	PUNCT
dpc-5196	165	29	baseline	baseline	PROPN
dpc-5196	165	30	uas7	uas7	NOUN
dpc-5196	165	31	score	score	NOUN
dpc-5196	165	32	did	do	AUX
dpc-5196	165	33	not	not	PART
dpc-5196	165	34	differ	differ	VERB
dpc-5196	165	35	significantly	significantly	ADV
dpc-5196	165	36	between	between	ADP
dpc-5196	165	37	the	the	DET
dpc-5196	165	38	relapse	relapse	NOUN
dpc-5196	165	39	and	and	CCONJ
dpc-5196	165	40	non	non	ADJ
dpc-5196	165	41	-	-	ADJ
dpc-5196	165	42	relapse	relapse	ADJ
dpc-5196	165	43	groups	group	NOUN
dpc-5196	165	44	[	[	X
dpc-5196	165	45	12	12	NUM
dpc-5196	165	46	]	]	PUNCT
dpc-5196	165	47	.	.	PUNCT
dpc-5196	166	1	however	however	ADV
dpc-5196	166	2	,	,	PUNCT
dpc-5196	166	3	chen	chen	PROPN
dpc-5196	166	4	et	et	PROPN
dpc-5196	166	5	al	al	PROPN
dpc-5196	166	6	.	.	PROPN
dpc-5196	166	7	found	find	VERB
dpc-5196	166	8	that	that	SCONJ
dpc-5196	166	9	shorter	short	ADJ
dpc-5196	166	10	disease	disease	NOUN
dpc-5196	166	11	duration	duration	NOUN
dpc-5196	166	12	and	and	CCONJ
dpc-5196	166	13	low	low	ADJ
dpc-5196	166	14	baseline	baseline	ADJ
dpc-5196	166	15	ige	ige	PROPN
dpc-5196	166	16	levels	level	NOUN
dpc-5196	166	17	(	(	PUNCT
dpc-5196	166	18	<	<	X
dpc-5196	166	19	100	100	NUM
dpc-5196	166	20	iu	iu	ADP
dpc-5196	166	21	/	/	SYM
dpc-5196	166	22	ml	ml	VERB
dpc-5196	166	23	)	)	PUNCT
dpc-5196	166	24	were	be	AUX
dpc-5196	166	25	associated	associate	VERB
dpc-5196	166	26	with	with	ADP
dpc-5196	166	27	a	a	DET
dpc-5196	166	28	lower	low	ADJ
dpc-5196	166	29	relapse	relapse	NOUN
dpc-5196	166	30	rate	rate	NOUN
dpc-5196	167	1	[	[	X
dpc-5196	167	2	13	13	NUM
dpc-5196	167	3	]	]	PUNCT
dpc-5196	167	4	.	.	PUNCT
dpc-5196	168	1	similarly	similarly	ADV
dpc-5196	168	2	,	,	PUNCT
dpc-5196	168	3	ertaş	ertaş	NOUN
dpc-5196	168	4	et	et	PROPN
dpc-5196	168	5	al	al	PROPN
dpc-5196	168	6	.	.	PROPN
dpc-5196	168	7	suggested	suggest	VERB
dpc-5196	168	8	that	that	SCONJ
dpc-5196	168	9	high	high	ADJ
dpc-5196	168	10	baseline	baseline	NOUN
dpc-5196	168	11	ige	ige	PROPN
dpc-5196	168	12	levels	level	NOUN
dpc-5196	168	13	(	(	PUNCT
dpc-5196	168	14	>	>	X
dpc-5196	168	15	100	100	NUM
dpc-5196	168	16	iu	iu	ADP
dpc-5196	168	17	/	/	SYM
dpc-5196	168	18	ml	ml	VERB
dpc-5196	168	19	)	)	PUNCT
dpc-5196	168	20	correlated	correlate	VERB
dpc-5196	168	21	with	with	ADP
dpc-5196	168	22	faster	fast	ADJ
dpc-5196	168	23	relapse	relapse	NOUN
dpc-5196	168	24	compared	compare	VERB
dpc-5196	168	25	to	to	ADP
dpc-5196	168	26	normal	normal	ADJ
dpc-5196	168	27	serum	serum	NOUN
dpc-5196	168	28	ige	ige	PROPN
dpc-5196	168	29	levels	level	NOUN
dpc-5196	168	30	.	.	PUNCT
dpc-5196	169	1	they	they	PRON
dpc-5196	169	2	also	also	ADV
dpc-5196	169	3	found	find	VERB
dpc-5196	169	4	that	that	SCONJ
dpc-5196	169	5	ige	ige	PROPN
dpc-5196	169	6	levels	level	NOUN
dpc-5196	169	7	did	do	AUX
dpc-5196	169	8	not	not	PART
dpc-5196	169	9	influence	influence	VERB
dpc-5196	169	10	the	the	DET
dpc-5196	169	11	response	response	NOUN
dpc-5196	169	12	to	to	ADP
dpc-5196	169	13	omalizumab	omalizumab	NOUN
dpc-5196	169	14	.	.	PUNCT
dpc-5196	170	1	it	it	PRON
dpc-5196	170	2	has	have	AUX
dpc-5196	170	3	been	be	AUX
dpc-5196	170	4	hypothesized	hypothesize	VERB
dpc-5196	170	5	that	that	SCONJ
dpc-5196	170	6	in	in	ADP
dpc-5196	170	7	patients	patient	NOUN
dpc-5196	170	8	with	with	ADP
dpc-5196	170	9	high	high	ADJ
dpc-5196	170	10	baseline	baseline	ADJ
dpc-5196	170	11	ige	ige	PROPN
dpc-5196	170	12	levels	level	NOUN
dpc-5196	170	13	,	,	PUNCT
dpc-5196	170	14	ige	ige	PROPN
dpc-5196	170	15	is	be	AUX
dpc-5196	170	16	cleared	clear	VERB
dpc-5196	170	17	from	from	ADP
dpc-5196	170	18	the	the	DET
dpc-5196	170	19	blood	blood	NOUN
dpc-5196	170	20	within	within	ADP
dpc-5196	170	21	a	a	DET
dpc-5196	170	22	few	few	ADJ
dpc-5196	170	23	days	day	NOUN
dpc-5196	170	24	after	after	ADP
dpc-5196	170	25	treatment	treatment	NOUN
dpc-5196	170	26	discontinuation	discontinuation	NOUN
dpc-5196	170	27	,	,	PUNCT
dpc-5196	170	28	leading	lead	VERB
dpc-5196	170	29	to	to	ADP
dpc-5196	170	30	a	a	DET
dpc-5196	170	31	faster	fast	ADJ
dpc-5196	170	32	onset	onset	NOUN
dpc-5196	170	33	of	of	ADP
dpc-5196	170	34	relapse	relapse	NOUN
dpc-5196	170	35	due	due	ADP
dpc-5196	170	36	to	to	ADP
dpc-5196	170	37	rapid	rapid	ADJ
dpc-5196	170	38	ige	ige	NOUN
dpc-5196	170	39	synthesis	synthesis	NOUN
dpc-5196	171	1	[	[	X
dpc-5196	171	2	14	14	NUM
dpc-5196	171	3	]	]	PUNCT
dpc-5196	171	4	.	.	PUNCT
dpc-5196	172	1	in	in	ADP
dpc-5196	172	2	contrast	contrast	NOUN
dpc-5196	172	3	to	to	ADP
dpc-5196	172	4	analyses	analysis	NOUN
dpc-5196	172	5	suggesting	suggest	VERB
dpc-5196	172	6	that	that	SCONJ
dpc-5196	172	7	baseline	baseline	VERB
dpc-5196	172	8	serum	serum	PROPN
dpc-5196	172	9	ige	ige	PROPN
dpc-5196	172	10	levels	level	NOUN
dpc-5196	172	11	influence	influence	VERB
dpc-5196	172	12	both	both	DET
dpc-5196	172	13	relapse	relapse	NOUN
dpc-5196	172	14	rate	rate	NOUN
dpc-5196	172	15	and	and	CCONJ
dpc-5196	172	16	frequency	frequency	NOUN
dpc-5196	172	17	,	,	PUNCT
dpc-5196	172	18	our	our	PRON
dpc-5196	172	19	study	study	NOUN
dpc-5196	172	20	found	find	VERB
dpc-5196	172	21	no	no	DET
dpc-5196	172	22	significant	significant	ADJ
dpc-5196	172	23	association	association	NOUN
dpc-5196	172	24	between	between	ADP
dpc-5196	172	25	baseline	baseline	PROPN
dpc-5196	172	26	serum	serum	PROPN
dpc-5196	172	27	ige	ige	PROPN
dpc-5196	172	28	levels	level	NOUN
dpc-5196	172	29	and	and	CCONJ
dpc-5196	172	30	these	these	DET
dpc-5196	172	31	outcomes	outcome	NOUN
dpc-5196	172	32	.	.	PUNCT
dpc-5196	173	1	further	further	ADJ
dpc-5196	173	2	comprehensive	comprehensive	ADJ
dpc-5196	173	3	studies	study	NOUN
dpc-5196	173	4	are	be	AUX
dpc-5196	173	5	needed	need	VERB
dpc-5196	173	6	to	to	PART
dpc-5196	173	7	fully	fully	ADV
dpc-5196	173	8	elucidate	elucidate	VERB
dpc-5196	173	9	the	the	DET
dpc-5196	173	10	effect	effect	NOUN
dpc-5196	173	11	of	of	ADP
dpc-5196	173	12	ige	ige	PROPN
dpc-5196	173	13	levels	level	NOUN
dpc-5196	173	14	on	on	ADP
dpc-5196	173	15	relapse	relapse	NOUN
dpc-5196	173	16	.	.	PUNCT
dpc-5196	174	1	there	there	PRON
dpc-5196	174	2	is	be	VERB
dpc-5196	174	3	limited	limited	ADJ
dpc-5196	174	4	knowledge	knowledge	NOUN
dpc-5196	174	5	in	in	ADP
dpc-5196	174	6	the	the	DET
dpc-5196	174	7	literature	literature	NOUN
dpc-5196	174	8	regarding	regard	VERB
dpc-5196	174	9	the	the	DET
dpc-5196	174	10	factors	factor	NOUN
dpc-5196	174	11	that	that	PRON
dpc-5196	174	12	influence	influence	VERB
dpc-5196	174	13	relapse	relapse	NOUN
dpc-5196	174	14	after	after	ADP
dpc-5196	174	15	omalizumab	omalizumab	NOUN
dpc-5196	174	16	treatment	treatment	NOUN
dpc-5196	174	17	.	.	PUNCT
dpc-5196	175	1	predicting	predict	VERB
dpc-5196	175	2	relapse	relapse	NOUN
dpc-5196	175	3	duration	duration	NOUN
dpc-5196	175	4	is	be	AUX
dpc-5196	175	5	crucial	crucial	ADJ
dpc-5196	175	6	to	to	ADP
dpc-5196	175	7	assessing	assess	VERB
dpc-5196	175	8	disease	disease	NOUN
dpc-5196	175	9	prognosis	prognosis	NOUN
dpc-5196	175	10	and	and	CCONJ
dpc-5196	175	11	determining	determine	VERB
dpc-5196	175	12	appropriate	appropriate	ADJ
dpc-5196	175	13	follow	follow	NOUN
dpc-5196	175	14	-	-	PUNCT
dpc-5196	175	15	up	up	NOUN
dpc-5196	175	16	and	and	CCONJ
dpc-5196	175	17	treatment	treatment	NOUN
dpc-5196	175	18	plans	plan	NOUN
dpc-5196	175	19	for	for	ADP
dpc-5196	175	20	patients	patient	NOUN
dpc-5196	175	21	[	[	X
dpc-5196	175	22	15	15	NUM
dpc-5196	175	23	]	]	PUNCT
dpc-5196	175	24	.	.	PUNCT
dpc-5196	176	1	factors	factor	NOUN
dpc-5196	176	2	such	such	ADJ
dpc-5196	176	3	as	as	ADP
dpc-5196	176	4	disease	disease	NOUN
dpc-5196	176	5	duration	duration	NOUN
dpc-5196	176	6	,	,	PUNCT
dpc-5196	176	7	baseline	baseline	PROPN
dpc-5196	176	8	uas7	uas7	PROPN
dpc-5196	176	9	score	score	NOUN
dpc-5196	176	10	,	,	PUNCT
dpc-5196	176	11	and	and	CCONJ
dpc-5196	176	12	duration	duration	NOUN
dpc-5196	176	13	of	of	ADP
dpc-5196	176	14	concomitant	concomitant	ADJ
dpc-5196	176	15	ah	ah	INTJ
dpc-5196	176	16	use	use	NOUN
dpc-5196	176	17	with	with	ADP
dpc-5196	176	18	omalizumab	omalizumab	NOUN
dpc-5196	176	19	have	have	AUX
dpc-5196	176	20	been	be	AUX
dpc-5196	176	21	significantly	significantly	ADV
dpc-5196	176	22	associated	associate	VERB
dpc-5196	176	23	with	with	ADP
dpc-5196	176	24	relapse	relapse	NOUN
dpc-5196	176	25	.	.	PUNCT
dpc-5196	177	1	higher	high	ADJ
dpc-5196	177	2	relapse	relapse	NOUN
dpc-5196	177	3	rates	rate	NOUN
dpc-5196	177	4	have	have	AUX
dpc-5196	177	5	been	be	AUX
dpc-5196	177	6	observed	observe	VERB
dpc-5196	177	7	in	in	ADP
dpc-5196	177	8	patients	patient	NOUN
dpc-5196	177	9	with	with	ADP
dpc-5196	177	10	longer	long	ADJ
dpc-5196	177	11	disease	disease	NOUN
dpc-5196	177	12	duration	duration	NOUN
dpc-5196	177	13	[	[	X
dpc-5196	177	14	15,16	15,16	NUM
dpc-5196	177	15	]	]	PUNCT
dpc-5196	177	16	,	,	PUNCT
dpc-5196	177	17	which	which	PRON
dpc-5196	177	18	aligns	align	VERB
dpc-5196	177	19	with	with	ADP
dpc-5196	177	20	our	our	PRON
dpc-5196	177	21	findings	finding	NOUN
dpc-5196	177	22	that	that	SCONJ
dpc-5196	177	23	more	more	ADV
dpc-5196	177	24	severe	severe	ADJ
dpc-5196	177	25	clinical	clinical	ADJ
dpc-5196	177	26	presentations	presentation	NOUN
dpc-5196	177	27	are	be	AUX
dpc-5196	177	28	linked	link	VERB
dpc-5196	177	29	to	to	ADP
dpc-5196	177	30	a	a	DET
dpc-5196	177	31	higher	high	ADJ
dpc-5196	177	32	risk	risk	NOUN
dpc-5196	177	33	of	of	ADP
dpc-5196	177	34	relapse	relapse	NOUN
dpc-5196	177	35	.	.	PUNCT
dpc-5196	178	1	similarly	similarly	ADV
dpc-5196	178	2	,	,	PUNCT
dpc-5196	178	3	patients	patient	NOUN
dpc-5196	178	4	with	with	ADP
dpc-5196	178	5	high	high	ADJ
dpc-5196	178	6	baseline	baseline	PROPN
dpc-5196	178	7	uas7	uas7	PROPN
dpc-5196	178	8	scores	score	NOUN
dpc-5196	178	9	demonstrated	demonstrate	VERB
dpc-5196	178	10	significantly	significantly	ADV
dpc-5196	178	11	higher	high	ADJ
dpc-5196	178	12	relapse	relapse	NOUN
dpc-5196	178	13	rates	rate	NOUN
dpc-5196	178	14	.	.	PUNCT
dpc-5196	179	1	additionally	additionally	ADV
dpc-5196	179	2	,	,	PUNCT
dpc-5196	179	3	those	those	PRON
dpc-5196	179	4	who	who	PRON
dpc-5196	179	5	used	use	VERB
dpc-5196	179	6	ahs	ah	NOUN
dpc-5196	179	7	with	with	ADP
dpc-5196	179	8	omalizumab	omalizumab	NOUN
dpc-5196	179	9	for	for	ADP
dpc-5196	179	10	more	more	ADJ
dpc-5196	179	11	than	than	ADP
dpc-5196	179	12	three	three	NUM
dpc-5196	179	13	months	month	NOUN
dpc-5196	179	14	had	have	VERB
dpc-5196	179	15	a	a	DET
dpc-5196	179	16	higher	high	ADJ
dpc-5196	179	17	relapse	relapse	NOUN
dpc-5196	179	18	rate	rate	NOUN
dpc-5196	179	19	than	than	SCONJ
dpc-5196	179	20	did	do	VERB
dpc-5196	179	21	those	those	PRON
dpc-5196	179	22	who	who	PRON
dpc-5196	179	23	used	use	VERB
dpc-5196	179	24	ahs	ahs	NOUN
dpc-5196	179	25	for	for	ADP
dpc-5196	179	26	three	three	NUM
dpc-5196	179	27	months	month	NOUN
dpc-5196	179	28	or	or	CCONJ
dpc-5196	179	29	less	less	ADJ
dpc-5196	179	30	.	.	PUNCT
dpc-5196	180	1	this	this	PRON
dpc-5196	180	2	suggests	suggest	VERB
dpc-5196	180	3	that	that	SCONJ
dpc-5196	180	4	prolonged	prolonged	ADJ
dpc-5196	180	5	use	use	NOUN
dpc-5196	180	6	of	of	ADP
dpc-5196	180	7	ahs	ahs	NOUN
dpc-5196	180	8	may	may	AUX
dpc-5196	180	9	indicate	indicate	VERB
dpc-5196	180	10	a	a	DET
dpc-5196	180	11	more	more	ADV
dpc-5196	180	12	severe	severe	ADJ
dpc-5196	180	13	course	course	NOUN
dpc-5196	180	14	of	of	ADP
dpc-5196	180	15	cu	cu	PROPN
dpc-5196	180	16	and	and	CCONJ
dpc-5196	180	17	an	an	DET
dpc-5196	180	18	increased	increase	VERB
dpc-5196	180	19	risk	risk	NOUN
dpc-5196	180	20	of	of	ADP
dpc-5196	180	21	relapse	relapse	NOUN
dpc-5196	180	22	.	.	PUNCT
dpc-5196	181	1	notably	notably	ADV
dpc-5196	181	2	,	,	PUNCT
dpc-5196	181	3	no	no	DET
dpc-5196	181	4	study	study	NOUN
dpc-5196	181	5	has	have	AUX
dpc-5196	181	6	been	be	AUX
dpc-5196	181	7	found	find	VERB
dpc-5196	181	8	in	in	ADP
dpc-5196	181	9	the	the	DET
dpc-5196	181	10	literature	literature	NOUN
dpc-5196	181	11	that	that	PRON
dpc-5196	181	12	specifically	specifically	ADV
dpc-5196	181	13	compared	compare	VERB
dpc-5196	181	14	the	the	DET
dpc-5196	181	15	duration	duration	NOUN
dpc-5196	181	16	of	of	ADP
dpc-5196	181	17	concomitant	concomitant	ADJ
dpc-5196	181	18	ah	ah	INTJ
dpc-5196	181	19	use	use	NOUN
dpc-5196	181	20	with	with	ADP
dpc-5196	181	21	relapse	relapse	NOUN
dpc-5196	181	22	frequency	frequency	NOUN
dpc-5196	181	23	.	.	PUNCT
dpc-5196	182	1	8	8	NUM
dpc-5196	182	2	original	original	ADJ
dpc-5196	182	3	article	article	NOUN
dpc-5196	182	4	|	|	ADV
dpc-5196	182	5	dermatol	dermatol	ADJ
dpc-5196	182	6	pract	pract	NOUN
dpc-5196	182	7	concept	concept	NOUN
dpc-5196	182	8	.	.	PUNCT
dpc-5196	183	1	2025;15(3):5196	2025;15(3):5196	NUM
dpc-5196	183	2	population	population	NOUN
dpc-5196	183	3	analysis	analysis	NOUN
dpc-5196	183	4	.	.	PUNCT
dpc-5196	184	1	j	j	PROPN
dpc-5196	184	2	am	be	AUX
dpc-5196	184	3	acad	acad	ADJ
dpc-5196	184	4	dermatol	dermatol	NOUN
dpc-5196	184	5	.	.	PUNCT
dpc-5196	185	1	2019	2019	NUM
dpc-5196	185	2	;	;	PUNCT
dpc-5196	185	3	81:152156	81:152156	NUM
dpc-5196	185	4	.	.	PUNCT
dpc-5196	185	5	 	 	SPACE
dpc-5196	185	6	doi	doi	NOUN
dpc-5196	185	7	:	:	PUNCT
dpc-5196	185	8	10.1016	10.1016	NUM
dpc-5196	185	9	/	/	SYM
dpc-5196	185	10	j.jaad.2019.02.064	j.jaad.2019.02.064	PROPN
dpc-5196	185	11	.	.	PUNCT
dpc-5196	186	1	pmid	pmid	NOUN
dpc-5196	186	2	:	:	PUNCT
dpc-5196	186	3	30872154	30872154	NUM
dpc-5196	186	4	.	.	PUNCT
dpc-5196	187	1	11	11	NUM
dpc-5196	187	2	.	.	PUNCT
dpc-5196	187	3	türk	türk	PROPN
dpc-5196	187	4	m	m	PROPN
dpc-5196	187	5	,	,	PUNCT
dpc-5196	187	6	carneiro	carneiro	PROPN
dpc-5196	187	7	-	-	PUNCT
dpc-5196	187	8	leão	leão	PROPN
dpc-5196	187	9	l	l	PROPN
dpc-5196	187	10	,	,	PUNCT
dpc-5196	187	11	kolkhir	kolkhir	PROPN
dpc-5196	187	12	p	p	NOUN
dpc-5196	187	13	,	,	PUNCT
dpc-5196	187	14	bonnekoh	bonnekoh	NOUN
dpc-5196	187	15	h	h	NOUN
dpc-5196	187	16	,	,	PUNCT
dpc-5196	187	17	buttgereit	buttgereit	PROPN
dpc-5196	187	18	t	t	PROPN
dpc-5196	187	19	,	,	PUNCT
dpc-5196	187	20	maurer	maurer	PROPN
dpc-5196	187	21	m.	m.	VERB
dpc-5196	187	22	how	how	SCONJ
dpc-5196	187	23	to	to	PART
dpc-5196	187	24	treat	treat	VERB
dpc-5196	187	25	patients	patient	NOUN
dpc-5196	187	26	with	with	ADP
dpc-5196	187	27	chronic	chronic	ADJ
dpc-5196	187	28	spontaneous	spontaneous	ADJ
dpc-5196	187	29	urticaria	urticaria	NOUN
dpc-5196	187	30	with	with	ADP
dpc-5196	187	31	omalizumab	omalizumab	NOUN
dpc-5196	187	32	:	:	PUNCT
dpc-5196	187	33	questions	question	NOUN
dpc-5196	187	34	and	and	CCONJ
dpc-5196	187	35	answers	answer	NOUN
dpc-5196	187	36	.	.	PUNCT
dpc-5196	188	1	j	j	PROPN
dpc-5196	188	2	allergy	allergy	PROPN
dpc-5196	188	3	clin	clin	PROPN
dpc-5196	188	4	immunol	immunol	PROPN
dpc-5196	188	5	pract	pract	PROPN
dpc-5196	188	6	.	.	PUNCT
dpc-5196	189	1	2020;8:113	2020;8:113	NUM
dpc-5196	189	2	-	-	SYM
dpc-5196	189	3	124	124	NUM
dpc-5196	189	4	.	.	PUNCT
dpc-5196	189	5	 	 	SPACE
dpc-5196	189	6	doi	doi	NOUN
dpc-5196	189	7	:	:	PUNCT
dpc-5196	189	8	10.1016	10.1016	NUM
dpc-5196	189	9	/j.jaip.2019.07.021	/j.jaip.2019.07.021	PUNCT
dpc-5196	189	10	.	.	PUNCT
dpc-5196	190	1	pmid	pmid	NOUN
dpc-5196	190	2	:	:	PUNCT
dpc-5196	190	3	31374358	31374358	NUM
dpc-5196	190	4	.	.	PUNCT
dpc-5196	191	1	12	12	NUM
dpc-5196	191	2	.	.	PUNCT
dpc-5196	192	1	wang	wang	PROPN
dpc-5196	192	2	a	a	PROPN
dpc-5196	192	3	,	,	PUNCT
dpc-5196	192	4	yun	yun	PROPN
dpc-5196	192	5	y	y	PROPN
dpc-5196	192	6	,	,	PUNCT
dpc-5196	192	7	wen	wen	PROPN
dpc-5196	192	8	z	z	PROPN
dpc-5196	192	9	,	,	PUNCT
dpc-5196	192	10	et	et	PROPN
dpc-5196	192	11	al	al	PROPN
dpc-5196	192	12	.	.	PROPN
dpc-5196	192	13	efficacy	efficacy	NOUN
dpc-5196	192	14	and	and	CCONJ
dpc-5196	192	15	safety	safety	NOUN
dpc-5196	192	16	of	of	ADP
dpc-5196	192	17	omalizumab	omalizumab	NOUN
dpc-5196	192	18	against	against	ADP
dpc-5196	192	19	chronic	chronic	ADJ
dpc-5196	192	20	spontaneous	spontaneous	ADJ
dpc-5196	192	21	urticaria	urticaria	NOUN
dpc-5196	192	22	:	:	PUNCT
dpc-5196	192	23	real	real	ADJ
dpc-5196	192	24	-	-	PUNCT
dpc-5196	192	25	world	world	NOUN
dpc-5196	192	26	study	study	NOUN
dpc-5196	192	27	from	from	ADP
dpc-5196	192	28	china	china	PROPN
dpc-5196	192	29	.	.	PUNCT
dpc-5196	193	1	world	world	PROPN
dpc-5196	193	2	allergy	allergy	PROPN
dpc-5196	193	3	organ	organ	PROPN
dpc-5196	193	4	j.	j.	PROPN
dpc-5196	193	5	2022	2022	NUM
dpc-5196	193	6	;	;	PUNCT
dpc-5196	194	1	15;15:100719	15;15:100719	NUM
dpc-5196	194	2	.	.	PUNCT
dpc-5196	194	3	doi	doi	NOUN
dpc-5196	194	4	:	:	PUNCT
dpc-5196	194	5	10.1016	10.1016	NUM
dpc-5196	194	6	/	/	SYM
dpc-5196	194	7	j.waojou.2022.100719	j.waojou.2022.100719	PROPN
dpc-5196	194	8	.	.	PUNCT
dpc-5196	195	1	pmid	pmid	NOUN
dpc-5196	195	2	:	:	PUNCT
dpc-5196	195	3	36438194	36438194	NUM
dpc-5196	195	4	.	.	PUNCT
dpc-5196	196	1	13	13	NUM
dpc-5196	196	2	.	.	PUNCT
dpc-5196	197	1	chen	chen	PROPN
dpc-5196	197	2	y	y	PROPN
dpc-5196	197	3	,	,	PUNCT
dpc-5196	197	4	yu	yu	PROPN
dpc-5196	197	5	m	m	PROPN
dpc-5196	197	6	,	,	PUNCT
dpc-5196	197	7	huang	huang	PROPN
dpc-5196	197	8	x	x	PROPN
dpc-5196	197	9	,	,	PUNCT
dpc-5196	197	10	et	et	PROPN
dpc-5196	197	11	al	al	PROPN
dpc-5196	197	12	.	.	PROPN
dpc-5196	197	13	omalizumab	omalizumab	NOUN
dpc-5196	197	14	treatment	treatment	NOUN
dpc-5196	197	15	and	and	CCONJ
dpc-5196	197	16	outcomes	outcome	NOUN
dpc-5196	197	17	in	in	ADP
dpc-5196	197	18	chinese	chinese	ADJ
dpc-5196	197	19	patients	patient	NOUN
dpc-5196	197	20	with	with	ADP
dpc-5196	197	21	chronic	chronic	ADJ
dpc-5196	197	22	spontaneous	spontaneous	ADJ
dpc-5196	197	23	urticaria	urticaria	NOUN
dpc-5196	197	24	,	,	PUNCT
dpc-5196	197	25	chronic	chronic	ADJ
dpc-5196	197	26	inducible	inducible	ADJ
dpc-5196	197	27	urticaria	urticaria	NOUN
dpc-5196	197	28	,	,	PUNCT
dpc-5196	197	29	or	or	CCONJ
dpc-5196	197	30	both	both	PRON
dpc-5196	197	31	.	.	PUNCT
dpc-5196	198	1	world	world	PROPN
dpc-5196	198	2	allergy	allergy	PROPN
dpc-5196	198	3	organ	organ	PROPN
dpc-5196	198	4	j.	j.	PROPN
dpc-5196	198	5	2021	2021	NUM
dpc-5196	198	6	;	;	PUNCT
dpc-5196	198	7	5;14:100501	5;14:100501	NUM
dpc-5196	198	8	.	.	PUNCT
dpc-5196	198	9	  	  	SPACE
dpc-5196	199	1	doi	doi	NOUN
dpc-5196	199	2	:	:	PUNCT
dpc-5196	199	3	10.1016	10.1016	NUM
dpc-5196	199	4	/	/	SYM
dpc-5196	199	5	j.waojou.2020.100501	j.waojou.2020.100501	ADJ
dpc-5196	199	6	.	.	PUNCT
dpc-5196	200	1	pmid	pmid	NOUN
dpc-5196	200	2	:	:	PUNCT
dpc-5196	200	3	33510832	33510832	NUM
dpc-5196	200	4	14	14	NUM
dpc-5196	200	5	.	.	PUNCT
dpc-5196	201	1	ertas	ertas	PROPN
dpc-5196	201	2	r	r	PROPN
dpc-5196	201	3	,	,	PUNCT
dpc-5196	201	4	ozyurt	ozyurt	NOUN
dpc-5196	201	5	k	k	PROPN
dpc-5196	201	6	,	,	PUNCT
dpc-5196	201	7	ozlu	ozlu	ADJ
dpc-5196	201	8	e	e	NOUN
dpc-5196	201	9	,	,	PUNCT
dpc-5196	201	10	et	et	PROPN
dpc-5196	201	11	al	al	PROPN
dpc-5196	201	12	.	.	PROPN
dpc-5196	201	13	increased	increase	VERB
dpc-5196	201	14	ige	ige	PROPN
dpc-5196	201	15	levels	level	NOUN
dpc-5196	201	16	are	be	AUX
dpc-5196	201	17	linked	link	VERB
dpc-5196	201	18	to	to	ADP
dpc-5196	201	19	faster	fast	ADJ
dpc-5196	201	20	relapse	relapse	VERB
dpc-5196	201	21	in	in	ADP
dpc-5196	201	22	patients	patient	NOUN
dpc-5196	201	23	with	with	ADP
dpc-5196	201	24	omalizumab	omalizumab	NOUN
dpc-5196	201	25	-	-	PUNCT
dpc-5196	201	26	discontinued	discontinue	VERB
dpc-5196	201	27	chronic	chronic	ADJ
dpc-5196	201	28	spontaneous	spontaneous	ADJ
dpc-5196	201	29	urticaria	urticaria	NOUN
dpc-5196	201	30	.	.	PUNCT
dpc-5196	202	1	j	j	PROPN
dpc-5196	202	2	allergy	allergy	PROPN
dpc-5196	202	3	clin	clin	PROPN
dpc-5196	202	4	immunol	immunol	PROPN
dpc-5196	202	5	.	.	PUNCT
dpc-5196	203	1	2017	2017	NUM
dpc-5196	203	2	;	;	PUNCT
dpc-5196	203	3	140	140	NUM
dpc-5196	203	4	:	:	SYM
dpc-5196	203	5	1749	1749	NUM
dpc-5196	203	6	-	-	SYM
dpc-5196	203	7	1751	1751	NUM
dpc-5196	203	8	.	.	PUNCT
dpc-5196	204	1	doi	doi	NOUN
dpc-5196	204	2	:	:	PUNCT
dpc-5196	204	3	10.1016	10.1016	NUM
dpc-5196	204	4	/	/	SYM
dpc-5196	204	5	j.jaci.2017.08.007	j.jaci.2017.08.007	PROPN
dpc-5196	204	6	.	.	PUNCT
dpc-5196	205	1	pmid	pmid	NOUN
dpc-5196	205	2	:	:	PUNCT
dpc-5196	205	3	28870460	28870460	NUM
dpc-5196	205	4	.	.	PUNCT
dpc-5196	206	1	15	15	NUM
dpc-5196	206	2	.	.	PUNCT
dpc-5196	207	1	su	su	PROPN
dpc-5196	207	2	o	o	PROPN
dpc-5196	207	3	,	,	PUNCT
dpc-5196	207	4	bahali	bahali	PROPN
dpc-5196	207	5	ag	ag	PROPN
dpc-5196	207	6	,	,	PUNCT
dpc-5196	207	7	onsun	onsun	PROPN
dpc-5196	207	8	n.	n.	NOUN
dpc-5196	207	9	the	the	DET
dpc-5196	207	10	effect	effect	NOUN
dpc-5196	207	11	of	of	ADP
dpc-5196	207	12	at	at	ADV
dpc-5196	207	13	least	least	ADJ
dpc-5196	207	14	1	1	NUM
dpc-5196	207	15	-	-	PUNCT
dpc-5196	207	16	year	year	NOUN
dpc-5196	207	17	use	use	NOUN
dpc-5196	207	18	of	of	ADP
dpc-5196	207	19	omalizumab	omalizumab	NOUN
dpc-5196	207	20	without	without	ADP
dpc-5196	207	21	interruption	interruption	NOUN
dpc-5196	207	22	on	on	ADP
dpc-5196	207	23	relapse	relapse	NOUN
dpc-5196	207	24	in	in	ADP
dpc-5196	207	25	patients	patient	NOUN
dpc-5196	207	26	with	with	ADP
dpc-5196	207	27	chronic	chronic	ADJ
dpc-5196	207	28	spontaneous	spontaneous	ADJ
dpc-5196	207	29	urticaria	urticaria	NOUN
dpc-5196	207	30	.	.	PUNCT
dpc-5196	208	1	dermatol	dermatol	NOUN
dpc-5196	208	2	ther	ther	ADV
dpc-5196	208	3	.	.	PUNCT
dpc-5196	209	1	2020	2020	NUM
dpc-5196	209	2	;	;	PUNCT
dpc-5196	209	3	33	33	NUM
dpc-5196	209	4	:	:	PUNCT
dpc-5196	209	5	e14192	e14192	NOUN
dpc-5196	209	6	.	.	PUNCT
dpc-5196	209	7	doi	doi	PROPN
dpc-5196	209	8	:	:	PUNCT
dpc-5196	209	9	10.1111	10.1111	NUM
dpc-5196	209	10	/	/	SYM
dpc-5196	209	11	dth.14192	dth.14192	NOUN
dpc-5196	209	12	.	.	PUNCT
dpc-5196	210	1	pmid	pmid	NOUN
dpc-5196	210	2	:	:	PUNCT
dpc-5196	210	3	32790183	32790183	NUM
dpc-5196	210	4	.	.	PUNCT
dpc-5196	211	1	16	16	NUM
dpc-5196	211	2	.	.	PUNCT
dpc-5196	212	1	marzano	marzano	PROPN
dpc-5196	212	2	av	av	PROPN
dpc-5196	212	3	,	,	PUNCT
dpc-5196	212	4	genovese	genovese	NOUN
dpc-5196	212	5	g	g	NOUN
dpc-5196	212	6	,	,	PUNCT
dpc-5196	212	7	casazza	casazza	NOUN
dpc-5196	212	8	g	g	NOUN
dpc-5196	212	9	,	,	PUNCT
dpc-5196	212	10	et	et	PROPN
dpc-5196	212	11	al	al	PROPN
dpc-5196	212	12	.	.	PUNCT
dpc-5196	212	13	predictors	predictor	NOUN
dpc-5196	212	14	of	of	ADP
dpc-5196	212	15	response	response	NOUN
dpc-5196	212	16	to	to	ADP
dpc-5196	212	17	omalizumab	omalizumab	NOUN
dpc-5196	212	18	and	and	CCONJ
dpc-5196	212	19	relapse	relapse	VERB
dpc-5196	212	20	in	in	ADP
dpc-5196	212	21	chronic	chronic	ADJ
dpc-5196	212	22	spontaneous	spontaneous	ADJ
dpc-5196	212	23	urticaria	urticaria	NOUN
dpc-5196	212	24	:	:	PUNCT
dpc-5196	212	25	a	a	DET
dpc-5196	212	26	study	study	NOUN
dpc-5196	212	27	of	of	ADP
dpc-5196	212	28	470	470	NUM
dpc-5196	212	29	patients	patient	NOUN
dpc-5196	212	30	.	.	PUNCT
dpc-5196	213	1	j	j	PROPN
dpc-5196	213	2	eur	eur	PROPN
dpc-5196	213	3	acad	acad	PROPN
dpc-5196	213	4	dermatol	dermatol	NOUN
dpc-5196	213	5	venereol	venereol	NOUN
dpc-5196	213	6	.	.	PUNCT
dpc-5196	214	1	2019	2019	NUM
dpc-5196	214	2	;	;	PUNCT
dpc-5196	214	3	33:918	33:918	NUM
dpc-5196	214	4	-	-	SYM
dpc-5196	214	5	924	924	NUM
dpc-5196	214	6	.	.	PUNCT
dpc-5196	214	7	 	 	SPACE
dpc-5196	214	8	doi	doi	NOUN
dpc-5196	214	9	:	:	PUNCT
dpc-5196	214	10	10.1111	10.1111	NUM
dpc-5196	214	11	/	/	SYM
dpc-5196	214	12	jdv.15350	jdv.15350	PROPN
dpc-5196	214	13	.	.	PUNCT
dpc-5196	215	1	pmid	pmid	NOUN
dpc-5196	215	2	:	:	PUNCT
dpc-5196	215	3	30451325	30451325	NUM
dpc-5196	215	4	.	.	PUNCT
dpc-5196	216	1	17	17	NUM
dpc-5196	216	2	.	.	PUNCT
dpc-5196	217	1	sardana	sardana	PROPN
dpc-5196	217	2	k	k	PROPN
dpc-5196	217	3	,	,	PUNCT
dpc-5196	217	4	dixit	dixit	PROPN
dpc-5196	217	5	n	n	PRON
dpc-5196	217	6	,	,	PUNCT
dpc-5196	217	7	arora	arora	PROPN
dpc-5196	217	8	p.	p.	PROPN
dpc-5196	217	9	a	a	DET
dpc-5196	217	10	real	real	ADJ
dpc-5196	217	11	-	-	PUNCT
dpc-5196	217	12	world	world	NOUN
dpc-5196	217	13	analysis	analysis	NOUN
dpc-5196	217	14	of	of	ADP
dpc-5196	217	15	relapse	relapse	NOUN
dpc-5196	217	16	rate	rate	NOUN
dpc-5196	217	17	and	and	CCONJ
dpc-5196	217	18	efficacy	efficacy	NOUN
dpc-5196	217	19	of	of	ADP
dpc-5196	217	20	a	a	DET
dpc-5196	217	21	restricted	restricted	ADJ
dpc-5196	217	22	monthly	monthly	ADJ
dpc-5196	217	23	dose	dose	NOUN
dpc-5196	217	24	of	of	ADP
dpc-5196	217	25	omalizumab	omalizumab	NOUN
dpc-5196	217	26	in	in	ADP
dpc-5196	217	27	recalcitrant	recalcitrant	ADJ
dpc-5196	217	28	chronic	chronic	ADJ
dpc-5196	217	29	spontaneous	spontaneous	ADJ
dpc-5196	217	30	urticaria	urticaria	NOUN
dpc-5196	217	31	in	in	ADP
dpc-5196	217	32	india	india	PROPN
dpc-5196	217	33	.	.	PUNCT
dpc-5196	218	1	indian	indian	ADJ
dpc-5196	218	2	dermatol	dermatol	NOUN
dpc-5196	218	3	online	online	PROPN
dpc-5196	218	4	j.	j.	PROPN
dpc-5196	218	5	19;11:835	19;11:835	PROPN
dpc-5196	218	6	-	-	PUNCT
dpc-5196	218	7	837	837	NUM
dpc-5196	218	8	.	.	PUNCT
dpc-5196	218	9	 	 	SPACE
dpc-5196	218	10	doi	doi	NOUN
dpc-5196	218	11	:	:	PUNCT
dpc-5196	218	12	10.4103	10.4103	NUM
dpc-5196	218	13	/	/	SYM
dpc-5196	218	14	idoj	idoj	NOUN
dpc-5196	218	15	.	.	PUNCT
dpc-5196	219	1	idoj_499_19	idoj_499_19	PROPN
dpc-5196	219	2	.	.	PUNCT
dpc-5196	220	1	pmid	pmid	PROPN
dpc-5196	220	2	:	:	PUNCT
dpc-5196	220	3	33235861	33235861	NUM
dpc-5196	220	4	18	18	NUM
dpc-5196	220	5	.	.	PUNCT
dpc-5196	220	6	türk	türk	PROPN
dpc-5196	220	7	m	m	PROPN
dpc-5196	220	8	,	,	PUNCT
dpc-5196	221	1	yılmaz	yılmaz	PROPN
dpc-5196	221	2	i̇	i̇	PROPN
dpc-5196	221	3	,	,	PUNCT
dpc-5196	221	4	bahçecioğlu	bahçecioğlu	X
dpc-5196	221	5	sn	sn	PROPN
dpc-5196	221	6	.	.	PUNCT
dpc-5196	221	7	treatment	treatment	NOUN
dpc-5196	221	8	and	and	CCONJ
dpc-5196	221	9	retreatment	retreatment	NOUN
dpc-5196	221	10	with	with	ADP
dpc-5196	221	11	omalizumab	omalizumab	NOUN
dpc-5196	221	12	in	in	ADP
dpc-5196	221	13	chronic	chronic	ADJ
dpc-5196	221	14	spontaneous	spontaneous	ADJ
dpc-5196	221	15	urticaria	urticaria	NOUN
dpc-5196	221	16	:	:	PUNCT
dpc-5196	221	17	real	real	ADJ
dpc-5196	221	18	life	life	NOUN
dpc-5196	221	19	experience	experience	NOUN
dpc-5196	221	20	with	with	ADP
dpc-5196	221	21	twenty	twenty	NUM
dpc-5196	221	22	-	-	PUNCT
dpc-5196	221	23	five	five	NUM
dpc-5196	221	24	patients	patient	NOUN
dpc-5196	221	25	.	.	PUNCT
dpc-5196	222	1	allergol	allergol	PROPN
dpc-5196	222	2	int	int	PROPN
dpc-5196	222	3	.	.	PUNCT
dpc-5196	223	1	2018	2018	NUM
dpc-5196	223	2	;	;	PUNCT
dpc-5196	223	3	67:85	67:85	NUM
dpc-5196	223	4	-	-	SYM
dpc-5196	223	5	89	89	NUM
dpc-5196	223	6	.	.	PUNCT
dpc-5196	224	1	doi	doi	NOUN
dpc-5196	224	2	:	:	PUNCT
dpc-5196	224	3	10.1016	10.1016	NUM
dpc-5196	224	4	/	/	SYM
dpc-5196	224	5	j.alit.2017.05.003	j.alit.2017.05.003	PROPN
dpc-5196	224	6	.	.	PUNCT
dpc-5196	225	1	pmid	pmid	NOUN
dpc-5196	225	2	:	:	PUNCT
dpc-5196	225	3	28566225	28566225	NUM
dpc-5196	225	4	.	.	PUNCT
dpc-5196	226	1	19	19	NUM
dpc-5196	226	2	.	.	X
dpc-5196	226	3	ferrer	ferrer	PROPN
dpc-5196	226	4	m	m	PROPN
dpc-5196	226	5	,	,	PUNCT
dpc-5196	226	6	boccon	boccon	NOUN
dpc-5196	226	7	-	-	PUNCT
dpc-5196	226	8	gibod	gibod	NOUN
dpc-5196	226	9	i	i	PROPN
dpc-5196	226	10	,	,	PUNCT
dpc-5196	226	11	gonçalo	gonçalo	PROPN
dpc-5196	226	12	m	m	PROPN
dpc-5196	226	13	,	,	PUNCT
dpc-5196	226	14	et	et	PROPN
dpc-5196	226	15	al	al	PROPN
dpc-5196	226	16	.	.	PUNCT
dpc-5196	226	17	expert	expert	ADJ
dpc-5196	226	18	opinion	opinion	NOUN
dpc-5196	226	19	:	:	PUNCT
dpc-5196	226	20	defining	define	VERB
dpc-5196	226	21	response	response	NOUN
dpc-5196	226	22	to	to	ADP
dpc-5196	226	23	omalizumab	omalizumab	NOUN
dpc-5196	226	24	in	in	ADP
dpc-5196	226	25	patients	patient	NOUN
dpc-5196	226	26	with	with	ADP
dpc-5196	226	27	chronic	chronic	ADJ
dpc-5196	226	28	spontaneous	spontaneous	ADJ
dpc-5196	226	29	urticaria	urticaria	NOUN
dpc-5196	226	30	.	.	PUNCT
dpc-5196	227	1	eur	eur	PROPN
dpc-5196	227	2	j	j	PROPN
dpc-5196	227	3	dermatol	dermatol	NOUN
dpc-5196	227	4	.	.	PUNCT
dpc-5196	228	1	2017	2017	NUM
dpc-5196	228	2	;	;	PUNCT
dpc-5196	228	3	1;27:455	1;27:455	NUM
dpc-5196	228	4	-	-	SYM
dpc-5196	228	5	463	463	NUM
dpc-5196	228	6	.	.	PUNCT
dpc-5196	228	7	  	  	SPACE
dpc-5196	229	1	doi	doi	NOUN
dpc-5196	229	2	:	:	PUNCT
dpc-5196	229	3	10.1684	10.1684	NUM
dpc-5196	229	4	/	/	SYM
dpc-5196	229	5	ejd.2017.3085	ejd.2017.3085	PROPN
dpc-5196	229	6	.	.	PROPN
dpc-5196	229	7	pmid	pmid	PROPN
dpc-5196	229	8	:	:	PUNCT
dpc-5196	229	9	29084635	29084635	NUM
dpc-5196	229	10	.	.	PUNCT
dpc-5196	230	1	references	reference	NOUN
dpc-5196	230	2	1	1	NUM
dpc-5196	230	3	.	.	PUNCT
dpc-5196	230	4	dias	dias	PROPN
dpc-5196	230	5	ga	ga	PROPN
dpc-5196	230	6	,	,	PUNCT
dpc-5196	230	7	pires	pire	VERB
dpc-5196	230	8	gv	gv	ADP
dpc-5196	230	9	,	,	PUNCT
dpc-5196	230	10	valle	valle	PROPN
dpc-5196	230	11	so	so	ADV
dpc-5196	230	12	,	,	PUNCT
dpc-5196	230	13	et	et	PROPN
dpc-5196	230	14	al	al	PROPN
dpc-5196	230	15	.	.	PROPN
dpc-5196	230	16	impact	impact	NOUN
dpc-5196	230	17	of	of	ADP
dpc-5196	230	18	chronic	chronic	ADJ
dpc-5196	230	19	urticaria	urticaria	NOUN
dpc-5196	230	20	on	on	ADP
dpc-5196	230	21	the	the	DET
dpc-5196	230	22	quality	quality	NOUN
dpc-5196	230	23	of	of	ADP
dpc-5196	230	24	life	life	NOUN
dpc-5196	230	25	of	of	ADP
dpc-5196	230	26	patients	patient	NOUN
dpc-5196	230	27	followed	follow	VERB
dpc-5196	230	28	up	up	ADP
dpc-5196	230	29	at	at	ADP
dpc-5196	230	30	a	a	DET
dpc-5196	230	31	university	university	NOUN
dpc-5196	230	32	hospital	hospital	NOUN
dpc-5196	230	33	.	.	PUNCT
dpc-5196	231	1	an	an	DET
dpc-5196	231	2	bras	bras	NOUN
dpc-5196	231	3	dermatol	dermatol	NOUN
dpc-5196	231	4	.	.	PUNCT
dpc-5196	232	1	2016	2016	NUM
dpc-5196	232	2	;	;	PUNCT
dpc-5196	232	3	91(6):754	91(6):754	NUM
dpc-5196	232	4	-	-	SYM
dpc-5196	232	5	759	759	NUM
dpc-5196	232	6	.	.	PUNCT
dpc-5196	233	1	doi	doi	NOUN
dpc-5196	233	2	:	:	PUNCT
dpc-5196	233	3	10.1590	10.1590	NUM
dpc-5196	233	4	/	/	SYM
dpc-5196	233	5	abd1806	abd1806	NOUN
dpc-5196	233	6	-	-	NOUN
dpc-5196	233	7	4841.20165071	4841.20165071	NOUN
dpc-5196	233	8	.	.	PUNCT
dpc-5196	234	1	pmid	pmid	NOUN
dpc-5196	234	2	:	:	PUNCT
dpc-5196	234	3	28099596	28099596	NUM
dpc-5196	234	4	;	;	PUNCT
dpc-5196	234	5	pmcid	pmcid	ADJ
dpc-5196	234	6	:	:	PUNCT
dpc-5196	234	7	pmc5193185	pmc5193185	ADJ
dpc-5196	234	8	.	.	PUNCT
dpc-5196	235	1	2	2	X
dpc-5196	235	2	.	.	X
dpc-5196	235	3	ferrer	ferrer	PROPN
dpc-5196	235	4	m	m	PROPN
dpc-5196	235	5	,	,	PUNCT
dpc-5196	235	6	giménez	giménez	PROPN
dpc-5196	235	7	-	-	PUNCT
dpc-5196	235	8	arnau	arnau	PROPN
dpc-5196	235	9	a	a	PRON
dpc-5196	235	10	,	,	PUNCT
dpc-5196	235	11	saldana	saldana	PROPN
dpc-5196	235	12	d	d	PROPN
dpc-5196	235	13	,	,	PUNCT
dpc-5196	235	14	et	et	PROPN
dpc-5196	235	15	al	al	PROPN
dpc-5196	235	16	.	.	PROPN
dpc-5196	235	17	predicting	predict	VERB
dpc-5196	235	18	chronic	chronic	ADJ
dpc-5196	235	19	spontaneous	spontaneous	ADJ
dpc-5196	235	20	urticaria	urticaria	NOUN
dpc-5196	235	21	symptom	symptom	NOUN
dpc-5196	235	22	return	return	NOUN
dpc-5196	235	23	after	after	ADP
dpc-5196	235	24	omalizumab	omalizumab	NOUN
dpc-5196	235	25	treatment	treatment	NOUN
dpc-5196	235	26	discontinuation	discontinuation	NOUN
dpc-5196	235	27	:	:	PUNCT
dpc-5196	235	28	exploratory	exploratory	ADJ
dpc-5196	235	29	analysis	analysis	NOUN
dpc-5196	235	30	.	.	PUNCT
dpc-5196	236	1	j	j	PROPN
dpc-5196	236	2	allergy	allergy	PROPN
dpc-5196	236	3	clin	clin	PROPN
dpc-5196	236	4	immunol	immunol	PROPN
dpc-5196	236	5	pract	pract	PROPN
dpc-5196	236	6	.	.	PUNCT
dpc-5196	237	1	2018	2018	NUM
dpc-5196	237	2	;	;	PUNCT
dpc-5196	237	3	6(4):1191	6(4):1191	X
dpc-5196	237	4	-	-	SYM
dpc-5196	237	5	1197.e5	1197.e5	NUM
dpc-5196	237	6	.	.	PUNCT
dpc-5196	238	1	doi	doi	NOUN
dpc-5196	238	2	:	:	PUNCT
dpc-5196	238	3	10.1016	10.1016	NUM
dpc-5196	238	4	/	/	SYM
dpc-5196	238	5	j.	j.	PROPN
dpc-5196	238	6	jaip.2018.04.003	jaip.2018.04.003	PROPN
dpc-5196	238	7	.	.	PUNCT
dpc-5196	239	1	pmid	pmid	NOUN
dpc-5196	239	2	:	:	PUNCT
dpc-5196	239	3	29655772	29655772	NUM
dpc-5196	239	4	.	.	PUNCT
dpc-5196	240	1	3	3	NUM
dpc-5196	240	2	.	.	NOUN
dpc-5196	240	3	türk	türk	PROPN
dpc-5196	240	4	m	m	PROPN
dpc-5196	240	5	,	,	PUNCT
dpc-5196	240	6	maurer	maurer	PROPN
dpc-5196	240	7	m	m	PROPN
dpc-5196	240	8	,	,	PUNCT
dpc-5196	240	9	yılmaz	yılmaz	PROPN
dpc-5196	240	10	i̇.	i̇.	VERB
dpc-5196	240	11	how	how	SCONJ
dpc-5196	240	12	to	to	PART
dpc-5196	240	13	discontinue	discontinue	VERB
dpc-5196	240	14	omalizumab	omalizumab	NOUN
dpc-5196	240	15	in	in	ADP
dpc-5196	240	16	chronic	chronic	ADJ
dpc-5196	240	17	spontaneous	spontaneous	ADJ
dpc-5196	240	18	urticaria	urticaria	NOUN
dpc-5196	240	19	?	?	PUNCT
dpc-5196	241	1	allergy	allergy	NOUN
dpc-5196	241	2	.	.	PUNCT
dpc-5196	242	1	2019	2019	NUM
dpc-5196	242	2	;	;	PUNCT
dpc-5196	242	3	74:821	74:821	NUM
dpc-5196	242	4	-	-	PUNCT
dpc-5196	242	5	824	824	NUM
dpc-5196	242	6	.	.	PUNCT
dpc-5196	243	1	doi	doi	NOUN
dpc-5196	243	2	:	:	PUNCT
dpc-5196	243	3	10.1111	10.1111	NUM
dpc-5196	243	4	/	/	SYM
dpc-5196	243	5	all.13675	all.13675	NUM
dpc-5196	243	6	.	.	PUNCT
dpc-5196	243	7	 	 	SPACE
dpc-5196	243	8	pmid	pmid	NOUN
dpc-5196	243	9	:	:	PUNCT
dpc-5196	243	10	30478912	30478912	NUM
dpc-5196	243	11	.	.	PUNCT
dpc-5196	244	1	4	4	X
dpc-5196	244	2	.	.	X
dpc-5196	244	3	salman	salman	PROPN
dpc-5196	244	4	a	a	PROPN
dpc-5196	244	5	,	,	PUNCT
dpc-5196	244	6	aktas	aktas	PROPN
dpc-5196	244	7	m	m	PROPN
dpc-5196	244	8	,	,	PUNCT
dpc-5196	244	9	apti	apti	PROPN
dpc-5196	244	10	sengun	sengun	PROPN
dpc-5196	245	1	o.	o.	PROPN
dpc-5196	245	2	remission	remission	NOUN
dpc-5196	245	3	of	of	ADP
dpc-5196	245	4	chronic	chronic	ADJ
dpc-5196	245	5	spontaneous	spontaneous	ADJ
dpc-5196	245	6	urticaria	urticaria	NOUN
dpc-5196	245	7	following	follow	VERB
dpc-5196	245	8	omalizumab	omalizumab	NOUN
dpc-5196	245	9	with	with	ADP
dpc-5196	245	10	gradually	gradually	ADV
dpc-5196	245	11	extended	extend	VERB
dpc-5196	245	12	dosing	dosing	NOUN
dpc-5196	245	13	intervals	interval	NOUN
dpc-5196	245	14	:	:	PUNCT
dpc-5196	245	15	real	real	ADJ
dpc-5196	245	16	-	-	PUNCT
dpc-5196	245	17	life	life	NOUN
dpc-5196	245	18	data	datum	NOUN
dpc-5196	245	19	.	.	PUNCT
dpc-5196	246	1	australas	australas	PROPN
dpc-5196	246	2	j	j	PROPN
dpc-5196	246	3	dermatol	dermatol	NOUN
dpc-5196	246	4	.	.	PUNCT
dpc-5196	247	1	2021	2021	NUM
dpc-5196	247	2	;	;	PUNCT
dpc-5196	248	1	62:398	62:398	X
dpc-5196	248	2	-	-	PUNCT
dpc-5196	248	3	402	402	NUM
dpc-5196	248	4	.	.	PUNCT
dpc-5196	248	5	doi	doi	NOUN
dpc-5196	248	6	:	:	PUNCT
dpc-5196	248	7	10.1111	10.1111	NUM
dpc-5196	248	8	/	/	SYM
dpc-5196	248	9	ajd.13656	ajd.13656	NOUN
dpc-5196	248	10	.	.	PUNCT
dpc-5196	249	1	pmid	pmid	NOUN
dpc-5196	249	2	:	:	PUNCT
dpc-5196	249	3	34156714	34156714	NUM
dpc-5196	249	4	.	.	PUNCT
dpc-5196	250	1	5	5	X
dpc-5196	250	2	.	.	X
dpc-5196	250	3	kocatürk	kocatürk	PROPN
dpc-5196	250	4	,	,	PUNCT
dpc-5196	250	5	e	e	PROPN
dpc-5196	250	6	,	,	PUNCT
dpc-5196	250	7	kızıltaç	kızıltaç	ADJ
dpc-5196	250	8	k	k	PROPN
dpc-5196	250	9	,	,	PUNCT
dpc-5196	250	10	leslie	leslie	PROPN
dpc-5196	250	11	t.	t.	PROPN
dpc-5196	250	12	omalizumab	omalizumab	NOUN
dpc-5196	250	13	in	in	ADP
dpc-5196	250	14	chronic	chronic	ADJ
dpc-5196	250	15	urticaria	urticaria	NOUN
dpc-5196	250	16	:	:	PUNCT
dpc-5196	250	17	a	a	DET
dpc-5196	250	18	comprehensive	comprehensive	ADJ
dpc-5196	250	19	review	review	NOUN
dpc-5196	250	20	.	.	PUNCT
dpc-5196	251	1	turkderm	turkderm	ADJ
dpc-5196	251	2	.	.	PUNCT
dpc-5196	252	1	2018	2018	NUM
dpc-5196	252	2	;	;	PUNCT
dpc-5196	253	1	52:112	52:112	NUM
dpc-5196	253	2	-	-	SYM
dpc-5196	253	3	119	119	NUM
dpc-5196	253	4	.	.	PUNCT
dpc-5196	253	5	doi	doi	NOUN
dpc-5196	253	6	:	:	PUNCT
dpc-5196	253	7	10.4274	10.4274	NUM
dpc-5196	253	8	/	/	SYM
dpc-5196	253	9	turkderm.26987	turkderm.26987	NOUN
dpc-5196	253	10	.	.	NOUN
dpc-5196	253	11	6	6	NUM
dpc-5196	253	12	.	.	PUNCT
dpc-5196	254	1	syrigos	syrigo	NOUN
dpc-5196	254	2	n	n	CCONJ
dpc-5196	254	3	,	,	PUNCT
dpc-5196	254	4	grapsa	grapsa	VERB
dpc-5196	254	5	d	d	PROPN
dpc-5196	254	6	,	,	PUNCT
dpc-5196	254	7	zande	zande	PROPN
dpc-5196	254	8	m	m	PROPN
dpc-5196	254	9	,	,	PUNCT
dpc-5196	254	10	tziotou	tziotou	PROPN
dpc-5196	254	11	m	m	PROPN
dpc-5196	254	12	,	,	PUNCT
dpc-5196	254	13	syrigou	syrigou	PROPN
dpc-5196	254	14	e.	e.	PROPN
dpc-5196	254	15	treatment	treatment	PROPN
dpc-5196	254	16	response	response	NOUN
dpc-5196	254	17	to	to	ADP
dpc-5196	254	18	omalizumab	omalizumab	NOUN
dpc-5196	254	19	in	in	ADP
dpc-5196	254	20	patients	patient	NOUN
dpc-5196	254	21	with	with	ADP
dpc-5196	254	22	refractory	refractory	NOUN
dpc-5196	254	23	chronic	chronic	ADJ
dpc-5196	254	24	spontaneous	spontaneous	ADJ
dpc-5196	254	25	urticaria	urticaria	NOUN
dpc-5196	254	26	.	.	PUNCT
dpc-5196	255	1	int	int	NOUN
dpc-5196	255	2	j	j	PROPN
dpc-5196	255	3	dermatol	dermatol	NOUN
dpc-5196	255	4	.	.	PUNCT
dpc-5196	256	1	2018	2018	NUM
dpc-5196	256	2	;	;	PUNCT
dpc-5196	257	1	57:417	57:417	NUM
dpc-5196	257	2	-	-	SYM
dpc-5196	257	3	422	422	NUM
dpc-5196	257	4	.	.	PUNCT
dpc-5196	258	1	doi	doi	NOUN
dpc-5196	258	2	:	:	PUNCT
dpc-5196	258	3	10.1111	10.1111	NUM
dpc-5196	258	4	/	/	SYM
dpc-5196	258	5	ijd.13935	ijd.13935	PROPN
dpc-5196	258	6	.	.	PUNCT
dpc-5196	259	1	pmid	pmid	NOUN
dpc-5196	259	2	:	:	PUNCT
dpc-5196	259	3	29399789	29399789	NUM
dpc-5196	259	4	.	.	PUNCT
dpc-5196	260	1	7	7	X
dpc-5196	260	2	.	.	X
dpc-5196	260	3	farrah	farrah	PROPN
dpc-5196	260	4	g	g	PROPN
dpc-5196	260	5	,	,	PUNCT
dpc-5196	260	6	stevenson	stevenson	PROPN
dpc-5196	260	7	b	b	PROPN
dpc-5196	260	8	,	,	PUNCT
dpc-5196	260	9	lie	lie	VERB
dpc-5196	260	10	k	k	PROPN
dpc-5196	260	11	,	,	PUNCT
dpc-5196	260	12	brusch	brusch	PROPN
dpc-5196	260	13	a.	a.	NOUN
dpc-5196	260	14	the	the	DET
dpc-5196	260	15	use	use	NOUN
dpc-5196	260	16	of	of	ADP
dpc-5196	260	17	omalizumab	omalizumab	NOUN
dpc-5196	260	18	for	for	ADP
dpc-5196	260	19	treatment	treatment	NOUN
dpc-5196	260	20	-	-	PUNCT
dpc-5196	260	21	refractory	refractory	NOUN
dpc-5196	260	22	chronic	chronic	ADJ
dpc-5196	260	23	spontaneous	spontaneous	ADJ
dpc-5196	260	24	urticaria	urticaria	NOUN
dpc-5196	260	25	in	in	ADP
dpc-5196	260	26	a	a	DET
dpc-5196	260	27	west	west	ADJ
dpc-5196	260	28	australian	australian	ADJ
dpc-5196	260	29	outpatient	outpatient	NOUN
dpc-5196	260	30	cohort	cohort	NOUN
dpc-5196	260	31	.	.	PUNCT
dpc-5196	261	1	intern	intern	PROPN
dpc-5196	261	2	med	med	PROPN
dpc-5196	261	3	j.	j.	PROPN
dpc-5196	261	4	2019	2019	NUM
dpc-5196	261	5	;	;	PUNCT
dpc-5196	261	6	49	49	NUM
dpc-5196	261	7	:	:	PUNCT
dpc-5196	261	8	526	526	NUM
dpc-5196	261	9	-	-	SYM
dpc-5196	261	10	528	528	NUM
dpc-5196	261	11	.	.	PUNCT
dpc-5196	261	12	 	 	SPACE
dpc-5196	261	13	doi	doi	NOUN
dpc-5196	261	14	:	:	PUNCT
dpc-5196	261	15	10.1111	10.1111	NUM
dpc-5196	261	16	/	/	SYM
dpc-5196	261	17	imj.14245	imj.14245	PROPN
dpc-5196	261	18	.	.	PUNCT
dpc-5196	262	1	pmid	pmid	NOUN
dpc-5196	262	2	:	:	PUNCT
dpc-5196	262	3	30957371	30957371	NUM
dpc-5196	262	4	.	.	PUNCT
dpc-5196	263	1	8	8	X
dpc-5196	263	2	.	.	X
dpc-5196	263	3	chen	chen	PROPN
dpc-5196	263	4	yd	yd	PROPN
dpc-5196	263	5	,	,	PUNCT
dpc-5196	263	6	maurer	maurer	PROPN
dpc-5196	263	7	m	m	PROPN
dpc-5196	263	8	,	,	PUNCT
dpc-5196	263	9	yu	yu	PROPN
dpc-5196	263	10	m	m	PROPN
dpc-5196	263	11	,	,	PUNCT
dpc-5196	263	12	tu	tu	PROPN
dpc-5196	263	13	p	p	X
dpc-5196	263	14	,	,	PUNCT
dpc-5196	263	15	zhao	zhao	PROPN
dpc-5196	263	16	zt	zt	PROPN
dpc-5196	263	17	.	.	PROPN
dpc-5196	263	18	addition	addition	NOUN
dpc-5196	263	19	of	of	ADP
dpc-5196	263	20	omalizumab	omalizumab	NOUN
dpc-5196	263	21	to	to	ADP
dpc-5196	263	22	antihistamine	antihistamine	PROPN
dpc-5196	263	23	treatment	treatment	NOUN
dpc-5196	263	24	in	in	ADP
dpc-5196	263	25	chronic	chronic	ADJ
dpc-5196	263	26	urticaria	urticaria	NOUN
dpc-5196	263	27	:	:	PUNCT
dpc-5196	263	28	a	a	DET
dpc-5196	263	29	real	real	ADJ
dpc-5196	263	30	world	world	NOUN
dpc-5196	263	31	study	study	NOUN
dpc-5196	263	32	in	in	ADP
dpc-5196	263	33	china	china	PROPN
dpc-5196	263	34	.	.	PUNCT
dpc-5196	264	1	ann	ann	PROPN
dpc-5196	264	2	allergy	allergy	PROPN
dpc-5196	264	3	asthma	asthma	PROPN
dpc-5196	264	4	immunol	immunol	PROPN
dpc-5196	264	5	.	.	PUNCT
dpc-5196	265	1	2020	2020	NUM
dpc-5196	265	2	;	;	PUNCT
dpc-5196	265	3	125	125	NUM
dpc-5196	265	4	:	:	PUNCT
dpc-5196	265	5	217	217	NUM
dpc-5196	265	6	-	-	SYM
dpc-5196	265	7	219	219	NUM
dpc-5196	265	8	.	.	PUNCT
dpc-5196	266	1	doi	doi	NOUN
dpc-5196	266	2	:	:	PUNCT
dpc-5196	266	3	10.1016	10.1016	NUM
dpc-5196	266	4	/	/	SYM
dpc-5196	266	5	j.anai.2020.04.026	j.anai.2020.04.026	PROPN
dpc-5196	266	6	.	.	PUNCT
dpc-5196	267	1	pmid	pmid	NOUN
dpc-5196	267	2	:	:	PUNCT
dpc-5196	267	3	32371240	32371240	NUM
dpc-5196	267	4	.	.	PUNCT
dpc-5196	268	1	9	9	X
dpc-5196	268	2	.	.	X
dpc-5196	268	3	sirufo	sirufo	PROPN
dpc-5196	268	4	mm	mm	PROPN
dpc-5196	268	5	,	,	PUNCT
dpc-5196	268	6	bassino	bassino	VERB
dpc-5196	268	7	em	em	PRON
dpc-5196	268	8	,	,	PUNCT
dpc-5196	268	9	de	de	PROPN
dpc-5196	268	10	pietro	pietro	PROPN
dpc-5196	268	11	f	f	PROPN
dpc-5196	268	12	,	,	PUNCT
dpc-5196	268	13	ginaldi	ginaldi	PROPN
dpc-5196	268	14	l	l	PROPN
dpc-5196	268	15	,	,	PUNCT
dpc-5196	268	16	de	de	PROPN
dpc-5196	268	17	martinis	martinis	PROPN
dpc-5196	268	18	m.	m.	NOUN
dpc-5196	268	19	sex	sex	NOUN
dpc-5196	268	20	differences	difference	NOUN
dpc-5196	268	21	in	in	ADP
dpc-5196	268	22	the	the	DET
dpc-5196	268	23	efficacy	efficacy	NOUN
dpc-5196	268	24	of	of	ADP
dpc-5196	268	25	omalizumab	omalizumab	NOUN
dpc-5196	268	26	in	in	ADP
dpc-5196	268	27	the	the	DET
dpc-5196	268	28	treatment	treatment	NOUN
dpc-5196	268	29	of	of	ADP
dpc-5196	268	30	chronic	chronic	ADJ
dpc-5196	268	31	spontaneous	spontaneous	ADJ
dpc-5196	268	32	urticaria	urticaria	NOUN
dpc-5196	268	33	.	.	PUNCT
dpc-5196	269	1	int	int	PROPN
dpc-5196	269	2	j	j	PROPN
dpc-5196	269	3	immunopathol	immunopathol	PROPN
dpc-5196	269	4	pharmacol	pharmacol	PROPN
dpc-5196	269	5	.	.	PROPN
dpc-5196	269	6	2021	2021	NUM
dpc-5196	269	7	;	;	PUNCT
dpc-5196	269	8	35	35	NUM
dpc-5196	269	9	:	:	SYM
dpc-5196	269	10	20587384211065870	20587384211065870	NUM
dpc-5196	269	11	.	.	PUNCT
dpc-5196	270	1	doi	doi	NOUN
dpc-5196	270	2	:	:	PUNCT
dpc-5196	270	3	10.1177	10.1177	NUM
dpc-5196	270	4	/20587384211065870	/20587384211065870	NOUN
dpc-5196	270	5	.	.	PUNCT
dpc-5196	271	1	pmid	pmid	NOUN
dpc-5196	271	2	:	:	PUNCT
dpc-5196	271	3	35170369	35170369	NUM
dpc-5196	271	4	.	.	PUNCT
dpc-5196	272	1	10	10	NUM
dpc-5196	272	2	.	.	PUNCT
dpc-5196	272	3	wertenteil	wertenteil	PROPN
dpc-5196	272	4	s	s	PROPN
dpc-5196	272	5	,	,	PUNCT
dpc-5196	272	6	strunk	strunk	NOUN
dpc-5196	272	7	a	a	NOUN
dpc-5196	272	8	,	,	PUNCT
dpc-5196	272	9	garg	garg	PROPN
dpc-5196	272	10	a.	a.	NOUN
dpc-5196	272	11	prevalence	prevalence	NOUN
dpc-5196	272	12	estimates	estimate	NOUN
dpc-5196	272	13	for	for	ADP
dpc-5196	272	14	chronic	chronic	ADJ
dpc-5196	272	15	urticaria	urticaria	NOUN
dpc-5196	272	16	in	in	ADP
dpc-5196	272	17	the	the	DET
dpc-5196	272	18	united	united	PROPN
dpc-5196	272	19	states	states	PROPN
dpc-5196	272	20	:	:	PUNCT
dpc-5196	272	21	a	a	PRON
dpc-5196	272	22	sexand	sexand	PROPN
dpc-5196	272	23	age	age	NOUN
dpc-5196	272	24	-	-	PUNCT
dpc-5196	272	25	adjusted	adjust	VERB